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Abstract 
The base excision DNA repair (BER) enzyme alkyladenine glycosylase (AAG) can 
drive DNA damage-induced cell death in specific cell types in mice and can induce 
frameshift mutagenesis and microsatellite instability in yeast and in human cells. It 
was hypothesised that humans with overactive AAG, or who encounter higher 
levels of alkylating agents in the form of pollution, diet or chemotherapy, or suffer 
an ischaemic reperfusion event such as a stroke, may incur increased tissue 
damage through this mechanism. An inhibitor of AAG is required to further study 
this mechanism and form a potential lead for future drug discovery. 
In previous work, to discover an inhibitor, a published X-ray co-crystal structure of 
AAG was used in a virtual screen of two million compounds for potential binding 
activity. Of the top 49 virtual hits, one real hit triazole-thione-based inhibitor 
(UNIS00021) with an IC50 of ~60 µM was identified in a biochemical assay.  In this 
thesis, efforts to design and synthesise analogues of UNIS00021 with improved 
potency against AAG are described. 
Successful divergent syntheses were developed which provided access to: 1.  
analogues varying at the alkyl group of the amide (six different amides); 2. 
analogues with a free amine in place of the amide and with variation of the length 
of the alkyl linkage group (five different amines); and 3. analogues bearing a C5-
methyl group instead of thiol/thione at the core (one cyclohexylamide triazole). 
Work was also begun on the synthesis of analogues varying the N4-CH2-aryl group 
but was not completed due to time constraints. 
Two main types of microplate biochemical assay were investigated for assessment 
of the candidate inhibitors’ potencies against AAG using: 1. a surface-bound 
fluorescein-conjugated substrate DNA-oligomer; and 2. a free substrate oligomer 
and LCMS. Despite much experimentation, these assays continued to show 
inconsistent and irreproducible inhibition curves so it was not possible to make 
conclusions about the candidate inhibitors’ potencies. 
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1. Introduction 
1.1 General Introduction and Project Aim 
Alkyladenine glycosylase (AAG) is one of the monofunctional glycosylase 
enzymes responsible for initiating the base excision DNA repair (BER) pathway. 
AAG protects against alkylative and oxidative DNA damage which can interfere 
with DNA replication and transcription and would otherwise lead to mutagenesis 
and cytotoxicity.1 AAG initiates BER by flipping substrate damaged nucleotides out 
of the DNA double-helix (through bond rotations about the phosphodiester-
deoxyribose group) and into its active site where it facilitates hydrolytic cleavage 
of the N-glycosidic bond to release the damaged nucleobase.2  Downstream 
enzymes replace the resulting abasic site with the correct nucleotide.  The BER 
pathway and AAG’s structure and mechanism will be described in detail in 
Sections 1.2.2 and 1.3, respectively. 
However, AAG has been shown to drive DNA damage-induced cell death in certain 
tissue types in mice, for example leading to alkylation-induced retinal 
degeneration,3 and cell/tissue damage in the cerebellum, spleen, thymus, liver, 
brain and kidney.4,5 AAG has also been implicated in tissue damage during 
experimentally induced ischaemia/reperfusion in mice, a procedure that can be 
used to simulate stroke.5  Finally, AAG overexpression has been associated with 
increased risk for lung cancer in humans.6  These detrimental activities of AAG will 
be discussed in detail in Section 1.3.2. 
Given the above, small molecule inhibitors of AAG would be beneficial for use as 
tool molecules for the investigation of DNA damage-induced cell death mediated 
by AAG and its role in disease. Also, such inhibitors could be used as drug 
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discovery leads for ‘chemoprotectives’ for patients undergoing alkylation-based 
chemotherapy or as a rapid treatment for stroke. 
Known inhibitors include DNA oligomers containing either an ethenocytidine 
nucleotide or an abasic pyrrolidine nucleotide inhibit AAG in vitro with a 50% 
inhibitory concentration (IC50) of 39 nM and a Kd of 21 ± 3 pM, respectively.7,8 
However,  these inhibitors are 13 nucleotides in length and too polar to work in cell 
and animal models or be suitable as drug leads in vivo.  During the research 
reported in this dissertation, the polyhydroxy natural product flavonoid morin was 
also identified as an inhibitor with IC50 of 2.6 uM.9 
The aim of this project was to design and synthesise small molecule inhibitors of 
AAG which are potent (IC50 < 100 nM), selective for AAG, cell permeable and not 
rapidly metabolised. Inhibitor discovery was based on the hit triazole-thione 
UNIS00021 (Figure 1.1) which was discovered using a high throughput virtual 
screen of ~2 million lead-like (250 ≤ MW < 350, logP < 3.5) compounds.10 
Biochemical assay showed it to have an IC50 of ~68 µM against AAG. Inhibitors 
with improved potency and properties were therefore sought through the synthesis 
and testing of analogues which vary at the triazolothione core, the benzyl group 
and the amide, as will be discussed in detail in Section 1.6.  
  
Figure 1.1: UNIS00021  
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1.2 DNA Damage and Repair 
Genomic DNA is constantly attacked by endogenous and exogenous DNA 
damaging agents and most damage occurs in the form of lesions to the DNA 
bases.11 Due to environmental factors and metabolic processes inside the cell, the 
DNA damage is estimated to occur at a rate of 1 000 to 1 000 000 molecular lesions 
per cell per day.12 Such damage can generate errors in the transcription of DNA 
and, following that, mistranslation of proteins that are necessary for signalling and 
cellular function. In addition, if damaged DNA is not repaired prior to cellular 
replication, genomic mutations can be carried over to the following generations of 
cells. That may lead to cell death or, in the case of a number of mutations in tumor 
suppressor genes and oncogenes, cancer. 
1.2.1 Causes of DNA damage 
DNA damage can result from exposure to reactive oxygen species (ROS), reactive 
nitrogen species (RNS), lipid peroxidation (LPO) products and other reactive 
alkylating agents.13  
ROS are usually formed from metabolic and other biochemical reactions in all living 
cells.  If ROS production exceeds the body’s natural antioxidant defence 
mechanisms, oxidative stress occurs which leads to the damage of DNA, lipids, 
and proteins.14  ROS include hydrogen peroxide (H2O2), superoxide (O2-·), and 
hydroxyl radicals (OH·) which damage DNA directly by oxidising the bases or 
breaking the DNA backbone.13  Endogenous RNS include nitric oxide and 
peroxynitrite.15   
An indirect cause of DNA damage by ROS involves peroxidation of lipids to give 
LPO products which lead to the generation of etheno DNA adducts – nucleobases 
which possess extra five membered rings. Malondialdehyde (MDA) 1 and trans-4-
hydroxy-2-nonenal (HNE) 2 are examples of  LPO reactive aldehyde products that 
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generate etheno adducts such as 1,N2-etheno-2’-deoxyguanosine (1,N2-ɛdGuo),  
ethenoadenine (ɛA) and ethenocytidine (ɛC) (Figure 1.2).16 
 
Figure 1.2: Structures of two of LPO-derived reactive aldehydes and their induced etheno 
adducts.17 
The mechanism by which HNE can ethenylate DNA bases is shown for the 
example of ɛA in Scheme 1.1.16 
 
Scheme 1.1: Proposed mechanism for the formation of ɛA by HNE.17  
Other alkylating agents react with exocyclic oxygen (O) and exo- and endocyclic 
ring nitrogen (N) atoms of DNA bases.18  S-Adenosylmethionine (AdoMet or SAM) 
4 is an example of weak endogenous methylating agent whose reactivity stems 
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from the positive charge on the sulfur atom making the methyl group electrophilic. 
It has been shown to induce mutations in DNA mainly through generating 3-
methyladenine (3MeA) and 7-methylguanine (7MeG) (Figure 1.3).19  
 
Figure 1.3: S-Adenosyl-L-Methionine with two of its mutated base products 
Exogenous alkylating agents are found in low concentrations in air, food, and water 
and can be from natural food plant metabolism, drugs or pollution. .One example 
are N-nitroso compounds formed in tobacco smoke.  Among these compounds the 
most effective are 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) 5, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 6, and N’-nitrosonornicotine 
(NNN) 7 and it has been reported that they give rise to the DNA alkylations by 
generating O6-methylguanine (O6-MeG), 7-meG, and O4-methylthymine (O4-MeT) 
shown in Scheme 1.2.20 
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Scheme 1.2: Tobacco compounds NNK and NNAL which give rise to the DNA base alkylations 
shown (box).21 
DNA damage is purposefully induced during many types of cancer chemotherapy.  
The drugs involved are mostly chloroethylating agents (e.g. lomustine, carmustin, 
and fotemustine) or methylating agents (e.g. temozolomide and streptozotocin).21 
For example, temozolomide (TMZ) 8 is an alkylating agent prodrug which delivers 
a methyl group to purine bases of DNA.  It has been reported that temozolomide 
first binds noncovalently in the major groove of DNA.  It then undergoes ring-
opening and decarboxylation to give the bioactive agent 5-(3-methyltriazen-1-yl)-
imidazole-4-carboxamide (MTIC) 9 (Scheme 1.3).22  Fragmentation of this 
liberates 5-amino-4-imidazolecarboxamide (AIC) 10 and methyldiazonium cation 
11.  DNA methylation by the reactive methyldiazonium intermediate 11 is facilitated 
by the basic microenvironment of guanine-rich sequences.22  
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Scheme 1.3: Base-catalysed decomposition of temozolomide to MTIC then methyldiazonium ion 
in water.22 
Different factors contribute to the damage profile induced by a given alkylating 
agent.  One is the number of reactive sites in the alkylating agent.  Those with one 
reactive group are called monofunctional alkylating agents, (e.g. Dacarbazine 12, 
Temozolomide 8, and Procarbazine 13) while those with two are bifunctional 
alkylating agents (e.g. Altretamine 14, Mitomycin C 15, and Thiotepa 16), as shown 
in Figure 1.4, and can cross-link DNA.18 
In addition, the type of chemical reactivity of the alkylating agents affects its 
damage profile – whether the mechanism proceeds with more SN1 or SN2 
character influences the alkylation of DNA bases.  SN1-like alkylating agents, which 
tend to react via cationic intermediates such as methyldiazonium ions, can target 
both ring nitrogen atoms and exocyclic oxygen atoms in DNA bases due to their 
hard electrophilic nature and preference for reaction with atoms bearing more 
electron density.23   SN2 alkylating agents preferentially target softer ring nitrogen 
atoms.  Many of the anticancer drugs are monofunctional SN1-like methylating 
agents such us, dacarbazine 12, and procarbazine 13.18  
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Figure 1.4: Examples of monofunctional and bifunctional chemotherapeutic alkylating agents.18 
1.2.2 Base Excision Repair (BER) 
DNA base damage includes deaminated cytosine, deaminated adenine, 5-
methylcytosine and oxidation and alkylation products of the four bases.  However, 
most of these lesioned base units do not go on to harm the cell since they are 
repaired by endogenous pathways such as the base excision repair (BER) 
pathway. The BER pathway can be reconstructed in vitro with a glycosylase, AP 
endonuclease, polymerase β, and a ligase. The steps involved are shown in 
Scheme 1.4 and described below.11 
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Scheme 1.4: The base excision repair (BER) pathway of the monofunctional DNA glycosylases 
The process starts with recognition and hydrolysis of the damaged base from the 
deoxyribose-phosphate backbone by initiator enzymes known as DNA 
glycosylases, such as alkyladenine DNA glycosylase (AAG).  The initiator 
enzymes can be divided into two mechanistic subclasses: the monofunctional 
glycosylases and the bifunctional glycosylases.12  
Monofunctional DNA glycosylases only catalyse the hydrolysis of the N-glycosidic 
bonds of damaged residues, and do not cleave the phosphodiester bonds.22 This 
is achieved by flipping the damaged base out of the double helix (through bond 
rotations about the deoxyribose-phosphate backbone) and intercalating an 
aromatic amino acid into the resulting space left in the DNA.  With the damaged 
 10 
base now undergoing several intermolecular interactions in its active site, its 
leaving group ability is increased and the enzyme catalyses hydrolysis of its N-
glycosidic bond using an activated water molecule as a nucleophile which attacks 
the anomeric carbon atom.24,25 This leaves an apurinic/apyrimidinic (AP) site which 
must be repaired by downstream enzymes. The first of these is 
apurinic/apyrimidinic endonuclease 1 (APE1) which hydrolyses the phosphate P-
O bond at 5’ to the AP site generating a single stranded DNA break (SSB) which 
will leave a 3’-OH group and a 5’-deoxyribose-phosphate moiety (5’-dRP) at the 
termini next to the nucleotide gap. The abasic 5’-dRP is then removed by the next 
enzyme in the pathway, polymerase β (Pol β), to leave a complete nucleotide gap 
on which Pol β acts to replicate the correct replacement nucleotide (matching the 
opposite DNA strand) onto the 3’-OH terminus.  After this step, a break in the 
polymer still remains between the 3’-OH of the new nucleotide and the 5’-
phosphate terminus.  This is joined to make the required phosphodiester group by 
the enzyme DNA ligase. 
Alternatively, bifunctional DNA glycosylases do not use an active site water 
molecule to hydrolyse the damaged base but an N-terminal proline or lysine side 
chain amine moiety which results in an imine (Schiff base) between the anomeric 
carbon and the enzyme (Scheme 1.5).26  These enzymes then also possess AP 
lyase activity which eliminates the 3’-phosphate group from the damaged 
nucleotide to leave an α,β-unsaturated imine which undergoes hydrolysis to the 
α,β-unsaturated aldehyde. Downstream enzyme APE1 recognises these as 
substrates and hydrolyses the phosphate P-O bond at 5’ to the AP site to leave a 
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nucleotide gap. The remaining steps are the same as for monofunctional DNA 
glycosylases.  
 
Scheme 1.5: The base excision repair (BER) pathway initiated by bifunctional DNA 
glycosylases.26 
BER can then proceed through either short-patch (SP-BER) or long-patch (LP-
BER) processes. In SP-BER a single nucleotide is introduced by polymerase β 
and then the DNA nick is sealed by the enzyme ligase IIIα. In the LP-BER 
polymerase α/ε introduces two to eight nucleotides past the abasic site. Then the 
DNA nick is sealed by DNA ligase I after the removal of the DNA overhang by 
FEN1 endonuclease.12 
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1.3 Alkyladenine Glycosylase (AAG) 
1.3.1 AAG Structure and Mechanism 
The project described in this thesis is concerned with the monofunctional DNA 
BER glycosylase alkyladenine DNA glycosylase (AAG27), also known as 
methylpurine-DNA glycosylase (MPG), and alkyl N-purine glycosylase (ANPG).28 
It is able to recognise and excise several different alkylated bases including 3-
methyladenine (3MeA) and 7-methylguanine (7MeG) which can be caused by 
alkylating agents such as methyl methanesulfonate (MMS) (Figure 1.5). It also 
recognises damaged bases caused directly or indirectly (through LPO) by reactive 
oxygen and nitrogen species (RONS) such as 1,N6-ethenoadenine (εA), 
deaminated adenine (hypoxanthine, Hx), and deaminated guanine 
(xanthine).29,30,31 
 
Figure 1.5: Structures of normal purine bases and modified versions excised by AAG.2 
Several crystal structures of AAG in complex with DNA oligomers containing 
lesions have been published.1  Figure 1.6 shows that (PDB: 1EWN) of E125Q 
mutant AAG bound to a DNA oligomer containing εA, one of AAG’s substrates.32  
The mutation is for the glutamate residue which normally holds and deprotonates 
the active site nucleophilic water molecule and so glycosylase activity is removed.  
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Interestingly, in the same study, it was also found that purified active AAG protein 
is inhibited by MgCl2, which was contained in the crystallisation buffer. Thus, a 
crystal structure of wild-type AAG in complex with an εA-containing DNA oligomer 
could be solved.  The reason for inhibition by MgCl2 is unknown and no electron 
density for a Mg2+ ion was observed in the crystal structure.  
 
Figure 1.6: Crystal structure of AAG with DNA containing ethenoadenine lesion (PDB: 1EWN) 
and ligand interactions33 [drawn using PyMOL] 
Based on this and other X-ray crystal structures, a mechanism by which AAG 
catalyses the hydrolysis of the base from the nucleotide and differentiates between 
between normal adenine and guanine and the damaged bases has been 
proposed.8  AAG flips the damaged base, in this case εA, to the outside of the DNA 
through rotations about the phosphodiester backbone.  The εA base fills a pocket 
in the active site where it π-stacks on top of Tyr-127 and makes an edge-to-face 
π-stacking interaction with Tyr-159 above.  It also stacks against His-136 and 
makes a hydrogen bond between N6 of εA and His-136.  Meanwhile, Tyr-162 
Tyr-162 (not shown) 
intercalates position 
previously occupied 
by the damaged base. 
‘Flipped out’ damaged 
base (εA). 
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intercalates into the DNA duplex between the bases that were flanking εA to fill the 
empty site in the DNA.  Lau. et. al. generated a mutant AAG where Tyr-162 was 
replaced with alanine (Y162A mutant) and showed it to have minimal glycosylase 
activity and to only weakly bind to ɛA-DNA and pyr-DNA (an inhibitory oligomer 
containing an abasic pyrrolidine nucleotide mimetic, discussed later) in vitro, 
showing the importance of this intercalation mechanism. Furthermore, cells 
expressing the Y162A mutant were observed to show higher sensitivity to MMS 
than the wild-type.32  
AAG cleaves the N-glycosylic bond between the εA base and the deoxyribose 
sugar through acid/base catalysis and a nucleophilic water molecule.34 This water 
molecule is held in place by hydrogen bonds with residues Val-262 and Arg-182 
and is deprotonated by Glu-125 to facilitate attack of the anomeric position and 
glycosylic bond cleavage (Figure 1.7).32 The crystal structure of the εA complex 
(PDB: 1EWN) also showed that N7 of εA was in contact with another water 
molecule and the same is observed if hypoxanthine (Hx) is modelled onto the same 
crystal structure as the damaged base.8 This water molecule is thought to 
protonate the base and the protonated form is then stabilized by a hydrogen bond 
between N7H+ of εA and the backbone carbonyl oxygen atom of Ala-134. 
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Figure 1.7: Mechanism in the AAG active site with ɛA [reproduced from reference 33]. 
The lesioned bases that are recognised by AAG do not appear to have common 
structural features. Some of them, such as 3MeA and 7MeG, are positively 
charged which could be selectively recognised by a tight-binding interation with an 
aromatic side chain of the AAG active site, and they are already good leaving 
groups that weaken the glycosylic bond.32 However, other lesioned bases are 
neutral such as Hx and ɛA and they are still recognised and cleaved by AAG.  Lau. 
et. al. proposed some reasons for AAG’s specificity towards its substrate damaged 
bases based on the shape and electrostatic properties of the binding pocket of the 
enzyme.32 Comparing ɛA with adenine in the AAG active site, a hydrogen bond is 
donated from the backbone amide of His-136 to the etheno N6 nitrogen of ɛA in 
the AAG crystal structure (Figure 1.8) and it has a large aromatic surface that is 
snugly accommodated into the active site. Yet, in adenine (A) the 6-amino group 
cannot accept a hydrogen bond so easily due to delocalisation of the lone pair.  
Hypoxanthine, another of AAG’s substrates, is able to make the same hydrogen 
bond using its O-atom.  In the case of guanine (G), which could also make the 
hydrogen bond, there is a steric clash between its 2-amino group and the Asn-169 
side chain which disfavors its binding.2,32  Although the alkylated base, and AAG 
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substrate, 7-methylguanine also has a 2-amino group, it is positively charged 
which increases its interaction with Tyr-127 and His-136 by cation-π interaction 
and that would be enough to outweigh the steric clash with Asn-169.32  
 
Figure 1.8: AAG catalytic specificity towards damage bases based on the shape and electrostatic 
properties of the binding pocket of the enzyme.2 
1.3.2 Reasons to inhibit AAG  
1.3.2.1 Alkylation-Induced Retinal Degeneration 
Growing research suggests that increased levels of certain DNA repair enzymes 
can result in an imbalance of intermediates between the enzymatic steps in the 
BER pathway and that can negatively affect cellular growth.6,35,36 It was found that 
the accumulation of BER intermediates such as the AP sites and single strand 
breaks (SSB) is cytotoxic.37,38 These two repair intermediates can block 
transcription and replication which can lead to cell death.37  
In the retina there are two types of neuronal photoreceptor cells which are 
responsible for perception of light and colour; they are called rods and cones. It 
has been found that retinal degeneration via photoreceptor cell death leads to 
blindness and is a hallmark of a group of diseases together referred to as retinitis 
pigmentosa (RP).39 Oxidative stress and oxidation-dependent DNA damage are 
thought to play roles in RP-associated photoreceptor apoptosis. It has been shown 
that exposure to excessive light stimulates the shedding of rod outer segments 
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which are subsequently phagocytosed by retinal pigment epithelium (RPE) cells in 
a process that generates an excess of reactive oxygen and nitrogen species 
(RONS).40,41  In addition, studies have shown that treatment of rodents with the 
SN1 DNA alkylating agent methyl nitrosourea (MNU) causes retinal degeneration. 
MNU reacts with both oxygen and nitrogen atoms in DNA to form O6-
methylguanine (O6MeG), 7MeG, and 3MeA.42  
In 2009 Meira et al. showed that retina photoreceptor cell degeneration was also 
observed in mice treated with the SN2 alkylating agent, methyl methanesulfonate 
(MMS).3 They showed that there was a dramatic reduction in the number of 
photoreceptors in the outer nuclear layer of the retina of wild-type (Aag+/+) mice 
treated with MMS. On the other hand, mice with the Aag gene knocked out (Aag-/-) 
treated with MMS did not show a reduction of photoreceptors and a heterozygous 
group (Aag+/-) suffered intermediate levels of retinal degeneration. Therefore, it 
was concluded that alkylation-induced retinal cell death is proportional to the gene 
copy number of Aag.  It is now hypothesised that the action of AAG on alkylated 
bases leads to an accumulation of abasic sites and SSB with which the 
downstream enzymes cannot keep up and which eventually drive photoreceptors 
to death. The single strand breaks resulting from action of downstream enzyme 
APE1 are known to activate poly(ADP-ribose) polymerase 1 (Parp1) whose action 
can lead to the depletion of ATP and NAD+ and resultant cell death.4 
Based on these studies, it is hypothesised that individuals with overactive AAG or 
those undergoing alkylation-based chemotherapy may be susceptible to retinal 
degeneration and an inhibitor of AAG could slow the production of abasic sites and 
single strand breaks thus reducing retinal degeneration.  
1.3.2.2 Ischaemic Stroke 
Ischemia/reperfusion (I/R)-induced tissue inflammation results from blockage of 
the blood supply to a tissue followed by release of the blockage and reperfusion of 
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the tissue with blood.  It leads to a wide range of human diseases such as, 
myocardial infarction, hepatic and renal failure and stroke. I/R causes the 
production of large amounts of reactive oxygen and nitrogen species (RONS) that 
can lead to direct and indirect DNA damage which is a substrate for DNA repair by 
BER.5  
It was found that the absence of Uracil and Ogg1 DNA glycosylases lead to an 
increase in brain damage induced by I/R which indicate that BER initiated by these 
enzymes protects against I/R-induced tissue damage.43,44 In contrast, 
Ebrahimkhani et. al. found that BER initiated by AAG increased the I/R-induced 
tissue damage in brain, liver and kidney in mice. For instance, it was found that in 
wild type (WT) mice, a protocol where a 90-min liver ischemia was followed by 24 
h reperfusion resulted in hepatic injury that was much more severe than that found 
in Aag-/- liver.5 The authors correlate this increased toxicity with the accumulation 
of BER abasic sites in WT liver DNA.  In Aag-/- liver DNA, the number of abasic 
sites induced was found to be reduced by half. 45,46   The group also found that 
there was a high level of Parp1 activation combined with greater depletion of NAD+ 
and ATP which can lead to cell death, as described previously. Yet, in Aag-/- livers, 
which were treated similarly, there was a decrease in the activation of Parp1 which 
indicate that Aag-initiated BER promotes BER intermediate generation, Parp-1 
activation, tissue injury and inflammation in liver following I/R.5 
1.3.2.3 Alkylation-Induced Degeneration of Specific Tissue Types  
It was found that bone marrow (BM) cells are deficient in recognising and repairing 
DNA alkylation damage which makes them sensitive to alkylating agent 
cytotoxicity.47  However, a study by Roth and Samson showed unexpected 
alkylation resistance of Aag-/- BM cells compared to WT BM cells when using 
alkylating agents such as MMS and TMZ and ex vivo BM survival assays.48  
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Another study by Calvo et al. found that AAG also drives alkylation-induced cell 
damage in the rapidly proliferating tissues of the spleen and thymus as well as 
cells in the cerebellum. Alkylation-induced toxicity was apparent in wild-type mice 
but completely suppressed in Aag-/- mice.4 
Coquerelle et. al. showed that Chinese hamster ovary (CHO) cells overexpressing 
AAG are more sensitive to alkylating agents MMS and Dimethyl Sulfate (DMS) 
than normal ovary cells expressing low AAG activity.49  In addition, these cells 
showed more double-strand breaks and greater inhibition of DNA replication 
compared to normal cells.49  
Repair of mitochondrial DNA (mtDNA) by AAG has also been investigated.  Fishel. 
et al. engineered mitochondrial targeting AAG and showed that its overexpression 
increases cell death of breast cancer cells when treated with MMS50.  van Loon 
and Samson showed that wild type AAG naturally localises to mitochondria as a 
result of association with mitochondrial single standed binding protein (mtSSB).50-
52 Fishel. et. al. hypothesised that the overexpression of AAG in mitochondria leads 
to an imbalance in the BER pathway resulting in an accumulation of AP sites, or 
single-strand and double-strand breaks causing cell death.50  
1.3.2.4 Other toxicity correlating to AAG overactivity 
A study related to AAG activity in lung cancer patients by Crosbie et al. showed it 
is not related to sex or smoking status but patients with high levels of AAG had a 
three fold increased probability of lung cancer compared to patients with lower Aag 
levels.6 The association between AAG overexpression and increased breast 
cancer cell sensitivity to alkylation was also reported.53  It is postulated that this is 
due to the imbalance in the BER pathway creating many abasic sites, overloading 
the proteins involved in the downstream steps and causing cytotoxic single and 
double strand break formation.53  
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1.3.3 Possible Side Effects of AAG Inhibition 
Inhibiting the AAG enzyme could result in detrimental side effects. For instance, 
Engelward et al. showed that AAG in mouse protects embryonic stem (ES) cells 
against MeOSO2(CH2)2-lexitropsin (MeOSO2Et-Lex), alkylating agent used for 
cancer chemotherapy, which is an SN2 alkylating agent that forms almost 
exclusively 3MeA lesions.54,55 They found that Aag null cells are more sensitive 
than WT and heterozygous cells to this methylating agent due to their inability to 
repair 3MeA which leads to cell death by blocking DNA replication.55 Also, they 
found the same result using two other cancer chemotherapy agents: mitomycin C 
and chloroethylnitrosourea.55 The same group showed that Aag-/- mouse ES cells 
are more sensitive than WT cells to chromosome damage.56  However, they also 
found that Aag null ES cells divided normally although these cells show no 
detectable repair of 3MeA in vitro. They relate this result to one of three possible 
reasons: to a low level of formation of 3MeA causing no detectable change in 
growth rate; the replication process can bypass endogenous levels of 3MeA 
lesions; or other possible pathways that remove the 3MeA produced 
endogenously.55 Meira et al. reported that AAG deficiency in mouse increases 
inflammation-associated colon tumorigenesis.57 They found that Aag-/- mouse 
colon was more sensitive compared to Aag+/+ mouse after treating them with 
carcinogen agents azoxymethane (AOM) and dextran sulfate sodium (DSS). They 
showed that 8-oxoG, ɛA, and ɛC induced by inflammation increased dramatically 
in the colonic epithelium of Aag-/- mice in response to DSS.57  
From all these reported results, we conclude that inhibiting AAG might protect 
several tissue types from cell death in the case of ischemic reperfusion or alkylative 
chemotherapy.  However, such an inhibitor could be detrimental to developing 
embryos and could have tumorigenic effects in those suffering from inflammation 
of the colon. 
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1.4 Published Inhibitors of AAG 
1.4.1 Pyrrolidine-Based Inhibitor 
A double stranded 25 nucleotide DNA oligomer containing an abasic pyrrolidine 
nucleotide 17 has been reported to be a very potent inhibitor (Figure 1.9) of 
Escherichia coli 3-methyladenine DNA glycosylase II (AlkA).7 
 
Figure 1.9: The pyrrolidine nucleotide-containing DNA oligomer inhibitor (left, 17) and the 
proposed transition state for enzyme mediated glycosidic bond cleavage which it mimics 
In their study the authors proposed that the protonated pyrrolidine moiety mimics 
the positive charge developed in the transition state of the glycosidic bond 
cleavage reaction in DNA glycosylase active sites.28 Their experimental results 
showed that all DNA glycosylases, except uracil DNA glycosylase, interact with 
oligomer 17, including AAG which had a dissociation constant (for a pyrrolidine 
opposite thymine duplex oligomer, pyr:T) of 23 ± 4 pM.28 This high potency of 
pyrrolidine containing DNA was also proven by measuring the release of 
methylated bases from [3H] dimethyl sulfate-treated calf thymus DNA by the DNA 
glycosylase enzymes in its presence. The pyrrolidine-duplex showed almost 
complete inhibition compared to a normal A-T duplex. 
In 1998 Lau. et al. reported the crystal structure (PDB: 1F6O) of the AAG enzyme 
in complex with pyr:T oligomer 17.58 This showed the pyrrolidine rotated outwards 
from the duplex and into the AAG active site while AAG’s Tyr-162 intercalates into 
the empty space left in the DNA to stabilize the DNA distortion.  A hydrogen 
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bonding network is found between the nucleophilic water molecule in the AAG 
active site, pyrrolidine, Glu-125, Arg-182, and the main chain carbonyl of Val-262.58 
Comparing this with the crystal structure of AAG complexed with the εA-containing 
oligomer, described in Section 1.3.1, it is seen that the conformation of the protein 
is the same, including the pocket for binding the base despite the absence of a 
base in the pyrrolidine-oligomer 17. However, there is a slight rotation of the 
pyrrolidine ring away from the corresponding position of the εA-deoxyribose ring in 
its crystal structure and this is thought to be to allow hydrogen bonding between 
N4 of the pyrrolidine and the nucleophilic water molecule.32 However, when these 
crystal structures are compared with one of AAG in complex with another inhibitory 
oligomer containing the smaller base ethenocytidine (εC, see below)8,33 then the 
pyrrolidine group is in the same position as that deoxyribose ring (Figure 1.10) 
indicating the possibility that it is the larger εA which pushes the deoxyribose back.  
 
Figure 1.10: Superposition of the active sites of the E125Q/ɛA-DNA (blue), E125Q /ɛC-DNA 
(pink), and E125Q/pyr-DNA (green) X-ray crystal structures.  
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1.4.2 3,N4-Ethenocytosine (εC)-containing DNA oligomer 
Although AAG is able to excise a variety of lesions, there are still many which it 
fails to remove including 3-methyluracil, 3-ethyluracil, 3-methylcytosine, 3-
methylthymine59, and εC.60 
Interestingly, it has been found that an εC-containing oligomer forms a stable, 
abortive complex with AAG and inhibits AAG activity in human cells.61 Such 
abortive complexes sequester AAG and can lead to the accumulation of more DNA 
damage.  Lingaraju et al. compared the binding affinity of AAG to the εA:T duplex 
oligomer using 25 and 13-mers to that to the εC:G 13-mer. It was found that AAG 
binds to the εC:G 13-mer duplex (Kd=21± 3 nM) with ~2-fold higher affinity  than to 
the εA:T 13-mer duplex  (Kd= 46 ± 6 nM) and that binding strength increased with 
increasing duplex length.8 Also, it was found that both the truncated AAG used for 
crystallography and full length AAG are inhibited by the εC:G 13-mer, according to 
a gel-based assay. Lingaraju et al. measured the IC50 of the εC:G 13-mer duplex 
using competition DNA glycosylase assay and it was calculated to be 39 nM which 
was ~4-fold stronger than the εA:T 13-mer duplex (IC50= 163 nM).8 
The crystal structure solved by the group showed that the εC base lesion is 
stabilised in the same AAG active site pocket that binds the εA by hydrogen bonds 
and van der Waals interactions. The way that AAG recognises the εC is similar to 
the way it does so for εA and that is achieved by a hydrogen bond donated from 
the main chain amide of His-136 to the N9 of εC or N12 of εA (Figure 1.11). 
However, there is an additional hydrogen bond between the carboxamide nitrogen 
of the side chain of Asn-169 and the O2 of  εC which is thought to increase the 
affinity of AAG for εC. That was proved by replacing the normal Asn-169 with 
leucine or alanine in N169L and N169A mutant forms of AAG and showing a ~2-4 
fold reduced affinity for the εC:G 25-mer compared to the wild type AAG.  The 
reason εC does not act as a substrate of AAG could be due to the failure of AAG 
to activate the it as a leaving group by protonation due to the presence of a carbon 
 24 
atom (C5) in εC where a basic nitrogen atom (N7) is present in εA (Figure 1.11). 
This was also proven in their experiment comparing the substrate hypoxanthine 
(Hx) with non-substrate 7-deaza-Hx where the corresponding basic N-atom has 
been changed into a carbon atom: AAG failed to cleave the 7-deaza-Hx.8 
 
Figure 1.11: Comparison of binding and excision of εA (left), in the AAG active site, with binding 
and non-excision of εC (right) and the structure of 7-deaza-Hx and Hx (box).   
Based on this, Chu et al. at the University of Surrey synthesised the single 
ethenocytidine nucleoside along with three phosphate derivatives to test their 
activity as small molecule inhibitors of AAG when not part of a larger oligomer. 
However, there was no inhibition up to 1 mM concentration which indicates the 
importance of the extended DNA strands in the inhibitory oligomer for action as an 
inhibitor.10  
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1.4.3 Morin 
In 2015, while the research described in this thesis was taking place, the naturally 
occurring polyphenol morin was reported by the Dixon group to be an inhibitor of 
AAG with an IC50 of 2.6 µM.62 In their report, a gel-based assay with εA-containing 
duplex oligonucleotides as substrate was used against a library of small molecules 
and morin was identified as a hit.  They also calculated the IC50 of morin in live 
cells and cell extracts to be ~100 and 300 µM, respectively. An important counter-
assay in this work showed that morin does not bind to DNA thus eliminating that 
as a possible mechanism of inhibition. 
The authors’ molecular docking of morin into the AAG crystal structure (PDB: 
1EWN) revealed that the amino residues which interact with morin are His-136, 
Ala-134, and Val-262. They also showed that there is an interaction between the 
5’-OH in the A ring of morin and Ala-134 and His-136 while the 2’-OH in the B ring 
of morin interacts with Val-262.  
This docking was repeated for this dissertation using MOE (Figure 1.12) and 
compared with Dixon’s.  The new result showed that  Ala-134 and Val-262 were 
not close enough to the 5’-OH on the A ring or the 2’-OH on the B ring, respectively, 
to make strong hydrogen bonds. Interestingly the docking showed a hydrogen 
bond between the nucleophilic water molecule in the Aag active site and the 
carbonyl group in the C ring which might contribute to inhibition by morin.  
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Figure 1.12: Docked morin (UNIS00084) in Aag crystal structure (PDB: 1EWN) and the 
interaction between morin and Aag amino acids in the active site. 
1.5 Virtual Screen for Novel Inhibitors of AAG 
In the absence of a small molecule lead in 2012, a virtual screen was set up using 
the published crystal structure of AAG bound to the inhibitory εC-containing 
oligomer (PDB: 3UBY).10 The digital structures of two million compounds were 
downloaded from the ZINC ‘lead-like, commercially available’ library which has 
been filtered to only include compounds with molecular weights of 250-350 Da, 
clogP ≤3.5 and rotatable bond count ≤ 7.63 The screen was carried out using the 
molecular modelling software MOE which generated the lowest energy 
conformation of each compound, docked it into the AAG structure and predicted a 
binding energy against which the compounds were ranked. The top 3000 
molecules were re-screened using a more thorough docking mode and these were 
again ranked according to binding energy and visually inspected for binding to the 
nucleophilic water molecule and synthetic tractability. Forty-nine of these were 
purchased and tested for actual inhibition of AAG in a fluorescence-based 
biochemical assay. Of these only one showed real inhibitory activity of AAG; 
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UNIS00021 whose IC50 was 60 µM (Figure 1.13 and Figure 1.14). In addition, it 
was shown to be a reversible inhibitor using a jump dilution bioassay10 which 
involved incubation with AAG for 15 or 30 minutes followed by 100-fold dilution 
and monitoring of AAG activity by fluorescence over 60 min.10 
 
Figure 1.13: UNIS00021 
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 Figure 1.14: UNIS00021 IC50 curve, % inhibition values calculated from apparent AAG activity 
obtained by interpolation of absorbance values into the AAG standard curve.  
UNIS00021 has a central triazole-thione, which can act as a hydrogen bond donor 
and acceptor, and also an amide bond connected to a cyclohexyl group. Amide 
bonds play an important role in medicinal chemistry - about 25% of known drugs 
contain an amide group64 and that is because amides are neutral, stable, have 
both hydrogen-bond acceptor and hydrogen-bond donor sites and are relatively 
easy to synthesise.  
Figure 1.15 and Figure 1.16 show the predicted docking of UNIS00021 in crystal 
structure 3UBY, with εC-containing DNA oligomer removed, using MOE.  Figure 
1.15 is overlayed with εA-containing oligomer-AAG crystal structrure 1EWN for 
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comparison.  It is thought that the hydrogen bond between the amide N-H and 
AAG’s nucleophilic water molecule is of utmost importance because this water 
molecule is held in the active site by three hydrogen bonds with Val-262, Arg-182 
and Gln-125 so it would be unfavourable to displace it with an inhibitor, but 
favourable to bond to it as is predicted for UNIS00021.  Also of note is the phenyl 
ring of UNIS00021 which is inside the pocket normally occupied by an alkylated 
base. There is pi-pi stacking between the phenyl ring and Tyr-127. In addition, 
most of the cyclohexyl group is outside the pocket and in the solvent, so it may be 
that changing that group to a smaller analogue such as isopropyl will maintain 
potency but decrease molecular weight which will permit future additions to the 
molecule. Besides that, the amide N-H of Val-264 acts as a hydrogen bond donor 
to one of the nitrogen atoms of the core and there is an interaction between His-
136 and the thione group. 
 
Figure 1.15: Overlay of ԑA-oligo (pink)/AAG X-ray33 crystal structure (PDB: 1EWN) and 
UNIS00021 (blue) docked into crystal structure from ԑC-oligo/AAG (PDB: 3UBY, DNA removed). 
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Figure 1.16: MOE predicted binding mode of UNIS00021 in the AAG active site. Hydrogen 
bonding between the H2O molecule and UNIS00021’s amide is predicted. 
The aim of this project is to synthesise analogues of UNIS00021 to establish which 
groups are necessary for potent binding and which can be modified to improve 
potency, solubility, cell membrane permeability, target selectivity and stability. 
1.6 The Hit Inhibitor (UNIS00021) and Proposed 
Analogues  
Based on the docking result of UNIS00021 into the AAG crystal structure as 
described above it was planned to design four synthetic routes to four types of 
analogue which would establish informative structure-activity relationships (Figure 
1.17). It was planned to start by synthesising UNIS00021 and analogues with 
smaller alkyl groups on the amide including: isopropyl, cyclopropyl, and methyl. 
This would help to establish whether any alkyl group is necessary considering most 
of the cyclohexyl group in UNIS00021 is predicted to be exposed to the solvent.  
The second synthesis route is to remove the carbonyl in the linkage amide in order 
to have just the amine. Synthesising the cyclohexylamine analogue of UNIS00021 
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might increase the strength of hydrogen bonding with the nucleophilic water 
molecule because the amine would be protonated and hold a positive charge. 
Another important feature of UNIS00021 is the thione moiety in the triazole-thione 
core which could be susceptible to oxidation or electrophilic attack. Therefore, it 
was planned to test replacement of the thione with a different moiety such as a 
hydrogen atom or a methyl group. Finally, the docking showed the benzyl group 
inside the enzyme’s base-binding pocket but it is not big enough to fill it. 
Consequently it was planned to synthesise analogues of UNIS00021 with bigger 
aryl groups to occupy most of the AAG pocket and pick up extra interactions. 
 
Figure 1.17: Possible points for variation in analogues UNIS00021 
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1.7 Chemistry of UNIS00021 and Proposed Analogues 
1.7.1 Triazole-thione Chemistry 
Triazoles are five-membered ring aromatic compounds containing three nitrogen 
atoms. There are two isomeric forms of triazole: 1,2,3-triazole 18 and 1,2,4-triazole 
19 (Figure 1.18).65 
 
Figure 1.18: Triazole isomers 
1,2,3-Triazole itself is a colourless solid with a low melting point (23-25 °C) and a 
boiling point of 203 °C, whereas 1,2,4-triazole is a colourless crystalline solid with 
a much higher melting point (119-121 °C).66 Both exist in tautomeric equilibria: 
1,2,4-triazole can be described either as 1,2,4-1H-triazole which means it is a N1-
substituted triazole, or by 1,2,4-4H-triazole which describes a N4-substituted 
triazole.65 
The chemistry of 1,2,4-triazoles and their derivatives has been researched 
extensively over the last few decades.67-69 This is mainly due to their important 
pharmacological activities; 1,2,4-triazole compounds with antifungal70 and 
antiviral71 activities have been discovered. Examples of antifungal drugs that 
contain the 1,2,4-triazole group are Fluconazole 20,72 and Ravuconazole 21 
(Figure 1.19).72  
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Figure 1.19: Antifungal drugs with 1,2,4-triazole groups that inhibit the biosynthesis of ergosterol, 
a major steroid in fungal membranes 
1,2,4-Triazole-thiones can exist in two further, major tautomeric forms; thiol (left, 
Scheme 1.6) and thione (right, Scheme 1.6).68,73 
  
Scheme 1.6: Tautomeric forms of 1,2,4-triazoline thiol (left) and 1,2,4-triazole thiole (left) 
1.7.2 Triazole-thione Synthesis 
A generally used method to synthesise 4-amino-triazole-5-thione involves the 
reaction of hydrazine with an appropriate electrophile, such as the ester, to give 
the hydrazide . This is followed by reaction with carbon disulfide then hydrazine 
hydrate (the mechanism for this reaction is given in 74,75  For example, El-Khawass 
et al. synthesised 1-(4-amino-4H-1,2,4-triazole-5-yl)methyl-1H-benzotriazole (24) 
according to Scheme 1.7.74 
 
Scheme 1.7: Synthesis of 1-(4-amino-4H-1,2,4-triazole-5-yl)methyl-1H-benzotriazoles 
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O’Callaghan reported in 1974 that 4-alkyl-5-cyanomethylthiosemicarbazide 
derivatives (25) can be cyclised in the presence of hydrazine (as base) to yield 4-
alkyl-5-cyanomethyl-1,2,4-triazoline-3-thiones (UNIS00073) at room temperature 
(Scheme 1.8). The proposed mechanism is given in Scheme 1.9.75 
 
Scheme 1.8: Cyclisation of thiosemicarbazide at RT using hydazine hydrate as base 
 
Scheme 1.9: Mechanism of cyclisation of thiosemicarbazide using hydrazine hydrate at RT 
Research by Colanceska-Ragenovic  et al. has shown that thiosemicarbazides 26 
can also be cyclised to 1,2,4-triazoline thiones 27 by sodium hydroxide but not by 
acid.76 In acidic media, 1,3,4-thiadiazole 28 derivatives were obtainedas shown in 
Scheme 1.10 and Scheme 1.11.77 However, a study by Siwek and Paneth showed 
that the direction of cyclisation depends also on the nature of substituents and not 
just on the acidic or alkaline media.78  
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Scheme 1.10: Cyclisation of thiosemicarbazide by base (NaOH) or acid (H2SO4) 
 
Scheme 1.11: Mechanism of acid-mediated cyclisation of thiosemicarbazide into 1,3,4-
thiadiazole.77 
Many publications show that thiosemicarbazide can be cyclised into triazole-thione 
in alkaline medium by heating the reaction at reflux.  Table 1.1 summarises some 
products, reaction conditions and yields.  All reactions were heated at reflux and 
worked up by adjusting the pH to 5-6 and removing the resulting precipitate by 
filtration.  
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Product Conc. /M Time Yield Ref. 
 
2 2 h 70% 79 
 
0.5 2h 80% 80 
 
2 4 h - 81 
 
 
2 2 h 79% 77 
 
2 4 h 89% 76 
 
2 2 h 85% 82 
 
2 30 min 62% 83 
Table 1.1: Published cyclisations of 1,2,4-triazoline thione using NaOH 
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2. Synthesis of Amide Alkyl Group 
Analogues 
2.1 Introduction and proposed synthesis 
It was important to start this project by synthesising the hit compound UNIS00021, 
to corroborate the inhibitory activity of the purchased compound, and to vary the 
alkyl group to smaller groups to maintain its potency but reduce its molecular 
weight since the docking result showed that most of the alkyl group was outside of 
the AAG binding pocket. 
Based on the literature described in Scheme 1.2, in order to synthesise analogues 
of UNIS00021 the following route was proposed (Scheme 2.1). 
 
Scheme 2.1: Proposed synthesis of UNIS00021 and analogues with different amide alkyl groups 
There is literature precedence for the conversion of esters 29 into hydrazides 30 
(Scheme 2.2) at room temperature.84  
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Scheme 2.2: Conversion of cyanoacetate 30 to cyanoacetohydrazide84 
Of relevance to the second step of the planned synthesis, O’Callaghan reported 
the preparation of 1-cyanoacetyl-4-methylthiosemicarbazide (31) by reacting 
cyanoacetylhydrazine 30 with methyl isothiocyanate (Scheme 2.3).75 
 
Scheme 2.3: Synthesis of cyanoacetyl-4-methylthiosemicarbazide by reacting 
cyanoacetylhydrazine  with methyl isothiocyanate 
Many syntheses of differently substituted thiosemicarbazides and their cyclisation 
to form 1,2,4-triazoles and 1,3,4-thiadazoles have been published. O’Callaghan 
showed that, on treatment with NaOH at 20 °C,  thiosemicarbazide 25 (Scheme 
2.4) does not give triazole UNIS00073 but instead pyrazoline 32 by cyclisation onto 
the nitrile instead of the hydrazide carbonyl group, presumably due to steric 
factors. However, treatment of 25 with hydrazine hydrate instead of NaOH at 20 
°C  afforded the triazole-thione UNIS00073.75 
 
Scheme 2.4: Cyclisation of thiosemicarbazide into pyrazoline at r.t. 
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In order to convert nitrile UNIS00073 to the carboxylic acid UNIS00064, it can be 
hydrolysed using strongly acidic conditions, especially sulfuric or hydrochloric acid. 
Addition of water to the protonated nitrile gives the primary amide, and hydrolysis 
of this amide gives carboxylic acid plus ammonia.85  
For the final step of the proposed synthesis, an amide bond must be formed.  
Amides result from the combination of a carboxylic acid and an amine, but these 
starting materials do not react at room temperature, only at high temperatures (˃ 
200 °C) with the elimination of water.86 This high temperature is incompatible with 
the presence of other functionalities,87 therefore, it is important first to activate the 
carboxylic acid (in which the –OH of the acid is converted into a good leaving 
group) prior to treatment with the amine.22  Coupling reagents are used to activate 
carboxylic acids, such as dicyclohexylcarbodiimide (DCC), 
diisopropylcarbodiimide (DIC), and 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) (Scheme 2.5).22,88  
 
Scheme 2.5: Amide coupling 
2.2 Step 1: Synthesis of 2-Cyanoacetohydrazine (30) 
Cyanoacetohydrazide 30 was prepared according to the published procedure89 in 
79% yield. The crude product was purified by recrystallization from ethanol. 
Analysis by 1H, and 13C NMR showed the compound existed as a mixture of 
atropisomers due to limited rotation about the amide bond (Scheme 2.6).  This 
was evidenced in the 13C NMR spectra by the presence of two peaks for the 1-C, 
2-C and in the 1H NMR spectrum by two peaks for N-H and N-H2. 
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Scheme 2.6: Atropisomers of cyanoacetohydrazide 
2.3 Step 2: Synthesis of Thiosemicarbazide 25  
The preparation of thiosemicarbazide 25 followed the procedure reported by 
Colanceska-Ragenovic et al.76 which involved heating hydrazide 30 with benzyl 
isothiocyanate in ethanol at reflux for 2 h (Scheme 2.7) and (Scheme 2.8). The 
product was purified by recrystallization from ethanol to give 83% yield of pure 
product. The LCMS of this compound showed one peak with a mass spectrum 
matching a [M-H] - ion at m/z 247. The structure of the compound was established 
by IR, 1H-NMR, 13C-NMR and CHN analysis. In the IR spectrum characteristic 
absorption bands were observed: 2265 cm-1 corresponding to the CN group, 1700 
cm-1 corresponding to an amide C=O group, 1172 corresponding to the C=S group 
and 3124-3348 cm-1 corresponding to NH groups. Important peaks in the 1H-NMR 
spectrum in DMSO-d6 included three low field singlets at 8.63-10.17 ppm 
representing the protons of the three N-H groups, and two singlets at 4.74 and 
3.66 ppm assigned to the CH2 groups connected to the benzene ring and CN 
group, respectively. The 13C-NMR spectrum was in accordance, interestingly 
exhibiting a characteristic -NH-(C=S)NH- signal at 181.9 ppm. 
 
Scheme 2.7: Preparation of thiosemicarbazide 25 
 
 40 
 
Scheme 2.8: Mechanism of thiosemicarbazide synthesis 
2.4 Step 3: Cyclisation to give triazole-thione 
Synthesis of triazole-thioneacetonitrile 26 was carried out under the conditions 
reported by O’Callaghan as described in Chapter 1 using hydrazine hydrate at 
room temperature for 48 h.75 Although these conditions afforded the triazole-
thione, the yield after silica gel chromatography was only 22% because of other 
unidentified by-products. Therefore, the reaction was carried out at different 
temperatures and time (Table 2.1) in order to optimise the yeld. Heating the 
reaction did not improve the yield significantly since some unidentified by-products 
started to appear as detected by LCMS. There was an increase in the yield by 
increasing the time at room temperature. 
Scale (mg) Conditions Time (h) Yield % 
100 RT 48 22 
500 Reflux 1 Could not be isolated 
2000 a  50 °C 8 37 
500 RT 64 48 
a The reaction was then left at r.t. for 26 h 
Table 2.1: Cyclisation of thiosemicarbazide to 1,2,4-triazoline thione using H2N-NH2.H2O 
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Another concern might have been that the isolated product was pyrazoline 32, 
formed via cyclisation onto the nitrile instead of the hydrazide carbonyl, and not 
the triazole-thione UNIS00073. However, this was discounted using HMBC NMR, 
which detects correlations between carbon and hydrogen atoms which are 2-4 
bonds apart.  In the pyrazoline, the CH2- of the benzyl group is 6 bonds from carbon 
‘e’ so no correlation would be seen by HMBC. Yet, in the actual HMBC there was 
a correlation between CH2- of the benzyl group and carbon ‘e’  which are three 
bonds distant in the triazole-thione UNIS00073 (Scheme 2.9). 
 
Scheme 2.9: Comparison between compound triazole-thione and pyrazoline using HMBC 
The alternative published cyclisation method was to use NaOH following the 
conditions in Table 1.1 in Chapter 1. However, none of compounds reported in the 
literature contained an acetonitrile group so it was not known if these conditions 
would work in this case so a test experiment was made. The work up for these 
reactions involved the addition of 2M HCl to adjust the pH to 5-6 and then 
extraction with DCM. However examination of the organic layer by LCMS showed 
no product peak and there was a small peak for the starting material. In a different 
attempt the pH in the work up was adjusted to 3 and (DCM/MeOH, 9:1) was used 
for the extraction. Surprisingly, in the LCMS there was one peak with m/z 248 in 
negative mode which indicated that the thiosemicarbazide had cyclised but in 
addition the –CN group had hydrolysed into –COOH (Scheme 2.10). 
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Scheme 2.10: Hydrolysis of nitrile into acid 
After extracting the compound  from the aqueous layer using  DCM/MeOH (9:1) 
the structure of the compound was established by its IR, 1H-NMR and 13C-NMR 
spectra and these results were compared with the nitrile compound UNIS00073. 
Although the IR spectrum of nitrile UNIS00073 shows a peak at 2265 cm-1, it is too 
small to prove conclusively that nitrile functionality is present.  Comparison of the 
13C NMR spectra revealed a quaternary carbon atom at 114.6 ppm for nitrile 
UNIS00073 but a peak at 167.7 ppm for acid UNIS00064 (Figure 2.1). The CH2 
adjacent to the acid was also deshielded (32.0 ppm) compared to that adjacent to 
the nitrile (15.9 ppm).  Also, the 1H-NMR spectra showed a singlet peak for one 
proton at 13.88 ppm for the acid UNIS00064 but not for the nitrile UNIS00073 
(Figure 2.2).  
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Figure 2.1: 13C NMR (500 MHz, DMSO-d6) of acid  UNIS00064 and nitrile UNIS00073 
While these compounds may exist in thione-thiol tautomeric equilibria, the IR 
spectra of both compounds showed no absorption bands around 2600-2550 cm-1 
which would be indicative of the thiol form. The IR absorption due to the C=S group 
in both compounds appears at 1307-1348 cm-1.76 
Although using NaOH gave directly the acid which was needed for the amide 
coupling, the yield was only 15%. Therefore an alternative method was used to 
cyclise the thiosemicarbazide into the 1,2,4-triazole nitrile UNIS00073. It has been 
reported that heating thiosemicarbazide at reflux in aqueous NaHCO3 cyclised it 
into the corresponding 1,2,4- triazole-thione.90  Use of these conditions cyclised 25 
and, again, hydrolysed the nitrile into the acid UNIS00064 in 14 h in 86% yield. 
This represented an efficient one-step synthesis of the desired acid from 
thiosemicarbazide 25. 
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In a different attempt this reaction was carried out at the lower temperature of 60 
oC for 24 h and gave rise to the cyclisation product with intact nitrile UNIS00073 in 
80% yield. The LCMS of this compound gave a [M-H] - ion peak at m/z 229 and its 
IR, 1H-NMR and 13C-NMR matched the nitrile compound which was obtained from 
the hydrazine hydrate mediated cyclisation. In this case, the work up  involved 
adding 2M HCl to reach pH 5, rather than 3, since no carboxylate group was 
present requiring protonation. The nitrile UNIS00073 precipitated after addition of 
the acid and no further purification was necessary. 
 
Figure 2.2: 1H NMR (500 MHz, DMSO-d6) of acid UNIS00064  
2.5 Step 4a: Amide coupling 
Amides were synthesised from acid UNIS00064 and the appropriate amine using 
EDC as a coupling reagent.88  In the first attempt, isopropyl amine was used to 
give 25% yield of triazole-thione acetamide UNIS00067.  Although the literature 
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reported that a similar reaction to synthesis the amide 35 was carried out for 6 h 
using the amine 33 and the acid 34 compounds as shown in Scheme 2.11 at room 
temperature,91 both reactions took 26 h and still the yield was low.  In an attempt 
to optimise the reaction it was heated at 42 °C for 6 h and the yield was improved 
to 50%. The structure of the compound was established by IR, 1H-NMR, and 13C-
NMR. In the IR spectrum the characteristic absorption bands were observed: 3287 
cm-1 corresponding to N-H of the amide group, 1627 cm-1 corresponding to C=O 
of the amide group, and 1348 corresponding to the C=S group. The 1H-NMR 
spectrum showed a doublet integrating to six protons at 1.1 ppm for the two methyl 
groups of the isopropyl amide and a septet integrating to one proton at 3.86 ppm 
for the -CH of the isopropyl amide.  
 
Scheme 2.11: Literature amide coupling reaction.91  
Different amides were made by reacting acid UNIS00064 with the corresponding 
amine in the presence of EDC as the coupling reagent at room temperature (Table 
2.2). The structures of these amides were established by their IR, LCMS, 1H-NMR, 
and 13C-NMR spectra. The IR spectra of these compounds all showed the 
characteristic absorption bands: 3266-3292 cm-1 corresponding to N-H of the 
amide, 1627-1642 cm-1 corresponding to C=O of the amide, and 1348-1363 
corresponding to the C=S group. There was no absorption for the N-H group for 
both UNIS00071 and UNIS00070 since, being tertiary amides, they did not have 
N-H groups. In the 13C-NMR spectra characteristic peaks included: 166-169 ppm 
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corresponding to C=O of the amide group and 148-149 ppm corresponding to -
N=C-CH2-C=O. 
UNIS code Amide Temp. Time Yield 
UNIS00067 
 
RT 
42 °C 
26 h 
6 h 
28% 
50% 
UNIS00021 
 
RT 21 h 20% 
UNIS00068 
 
RT 28 h 47% 
UNIS00069 
 
RT 24 h 52% 
UNIS00070 
 
RT 29 h 40% 
UNIS00071 
 
21 h at RT then 3 h at 42 °C 26% 
Table 2.2: Experimental conditions and yields for alkyl amide analogues of UNIS00021 
Examining the molecular weight of UNIS00067 using LCMS gave a [M-H]- ion peak 
with m/z 291 rather than 289 and it was noted that this was observed after leaving 
it in CD3OD for a long time. Similarly, but for UNIS00021, the peak for CH2-C=O in 
the 13C-NMR was not found after leaving it in CD3OD for some time but the peak 
had appeared when the spectrum was taken immediately after dissolution (red 
circle in Figure 2.3).  Also, LCMS of that compound gave a [M-H]- ion peak at m/z 
331 rather than 329.  These observations could be explained as resulting from 
exchange of the CH2-C=O protons for deuterons in CD3OD as shown in Scheme 
2.12. 
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Figure 2.3: 13C NMR (500 MHz, MeOD) of UNIS00021 before and after proton-deuterium 
exchange 
 
Scheme 2.12: Exchange of CH2-C=O protons for deuterons in CD3OD 
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2.6 Step 4b: Synthesis of primary amide 
Several reactions were trialled to synthesise the primary amide UNIS00074 from 
triazole-thione acetonitrile UNIS00073. The first used sodium borohydride in a 
mixture of ethanol and water at 80 °C, as published by Praveen who has proposed 
that NaBH4 abstracts protons from water to give hydroxide ions, which promote 
the hydration of nitriles (Scheme 2.13).92 
 
Scheme 2.13: Possible reaction pathway for base (NaBH4) promoted nitrile hydration reaction92 
Praveen mentioned that the reaction was carried out at 80 °C for between 5 and 
12 hours and that excellent yields were obtained for the hydration of 4-
cyanopyridine, 2-thiophenecarbonitrile, 3-cyanoindole and 5-cyanophthalide 
without affecting the heterocyclic ring system. However, carrying out this reaction 
on nitrile UNIS00073 for 21 hours gave no product, only the starting material was 
recorded by LCMS. 
Benzonitrile gave 94% yield of benzamide when refluxed for 20 min in tert-butyl 
alcohol containing powdered potassium hydroxide.93 Nevertheless, tert-butyl 
alcohol and powdered potassium hydroxide did not convert nitrile UNIS00073 to 
the corresponding primary amide, instead LCMS showed a peak for the hydrolysed 
product, acid UNIS00064 and a peak for the starting material.  
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There is literature precedent for the use of  sodium percarbonate 
(Na2CO3.3/2H2O2) to convert heteroaromatic nitriles and aromatic nitriles lacking 
ortho substituents into the corresponding amides.94 Using this reagent in a mixture 
of acetone and water at 50 °C for 1 h, the authors found that benzyl cyanide was 
converted into benzamide in 95% yield. These conditions were applied to triazole-
thioneacetonitrile UNIS00073 and a small peak for the primary amide appeared in 
the LCMS but about 90% of the starting material was recovered using column 
chromatography. 
Miyazawa et al. established a method to prepare primary amides from nitriles using 
hydroxylamine derivatives.95 The reaction was carried out in an inert atmosphere 
at reflux using DCM as solvent and 3 equiv. of the hydroxylamine derivative. Yet, 
the hydration of most nitriles such us heterocyclic nitriles and aliphatic nitriles 
progressed in low yield after long reaction times. In 2011, Xiao-yun Ma noticed that 
using water as a solvent in the presence of N,N-diethylhydroxylamine, transformed 
3-chloro-4-arylpicolinonitrile into 3-chloro-4-arylpicolinomide in quantitative yield at 
room temperature after 6 h.96 He proposed the radical mechanism shown in 
Scheme 2.14 and reported that in the case of aliphatic nitriles the hydration 
process was similar to that of aromatic nitriles and occurred in good to excellent 
yield. For instance, the conversion of benzonitrile to benzamide took 5 hours at 
reflux and occurred in 92% yield. 
 
Scheme 2.14: Proposed mechanism for nitrile hydration using N,N-diethylhydroxylamine96 
Using this method for the conversion of nitrile UNIS00073, a peak for the primary 
amide was observed by LCMS but it was difficult to separate and purify it. On the 
other hand, another peak was observed by the LCMS with [M-H]- m/z of 319.4, 
which was isolated in 10% yield. Analysis by NMR showed it to be α-amino amide 
UNIS00072 and a suggested mechanism for its formation is given in Scheme 2.15. 
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Scheme 2.15: Proposed mechanism for the formation of UNIS00072 
Another publication reported that hydration of the nitrile could be achieved by acid 
or base catalysis. Jarugu et al. showed that a variety of aromatic, aliphatic and 
allylic mono- to -tetra-nitrile compounds could be converted into their 
corresponding amides in a single step using a TFA- or an AcOH-H2SO4 reagent 
system. The reactions of most of these compounds were done at room 
temperature for 4-8 h, followed by quenching of the reaction mixture with ice-cold 
water. The conversion to the amide is formally by addition of water, yet the 
transformation is accomplished in an indirect way. It is the trapping at the imidate 
stage by the acetate which prevents full hydrolysis to the acid (Scheme 2.16). 
 
Scheme 2.16: Proposed mechanism of conversion of nitriles to amides using TFA-H2SO4.85  
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Applying these condition to nitrile UNIS00073 for 2 h gave the primary amide which 
was purified successfully using a reverse phase column to give 50% yield (Scheme 
2.17). 
 
Scheme 2.17: One-pot synthesis of UNIS00074 
2.7 Summary and Conclusion 
A robust synthetic method to vary the alkyl group of the amide in UNIS00021 in 
order to decrease the molecular weight of the inhibitor was established. The core 
1,2,4-triazole-thione can be produced by cyclisation of a thiosemicarbazide. The 
thiosemicarbazide was synthesised in 83% yield by refluxing hydrazide 25 with 
benzylisothiocyanate in ethanol for two hours. Cyclisation of this into the triazole-
thione required optimisation: using hydrazine hydrate at room temperature for 48 
h gave a low yield and other by-products after purification using column 
chromatography. Hence, NaOH was used to cyclise the thiosemicarbazide at 
reflux and this actually gave the desired acid product UNIS00064, through nitrile 
hydrolysis, instead of the expected nitrile UNIS00073. Although, this method saved 
one step, the yield was low at 15%. On the other hand, using 1 M of NaHCO3 at 
reflux to cyclise 25 gave the acid product in 86% yield and surprisingly gave the 
nitrile product UNIS00073 in 80% yield if the reaction was carried out at 60 °C. 
After discovering how to synthesise acid UNIS00064 in good yield the amide 
couplings using EDC and the appropriate amines were carried out. Various product 
amides were purified using column chromatography and characterised by NMR, 
LCMS and IR. However, the primary amide was not produced by this method but 
by the hydration of nitrile UNIS00073. The best two  methods for this reaction were 
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to use either water as a solvent in the presence of N,N-diethylhydroxylamine for 5 
hours or TFA-H2SO4 at room temperature for 4 hours. Using the first method the 
primary amide was obtained but it was difficult to purify and instead another by-
product was identified as UNIS00072. On the other hand, the second method gave 
the product in 50% yield and purification was achieved using reverse phase 
column chromatography.  
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3. Synthesis of Analogues Varying at 
the Linkage Group 
3.1 Introduction  
It is of interest whether the central amide of UNIS00021 can be replaced with an 
amine group. Based on the docking result of UNIS00021 into the AAG crystal 
structure PDB: 3UBY, with DNA oligomer removed, the amide forms a hydrogen 
bond with the active site nucleophilic water molecule, itself held by 2-3 hydrogen 
bonds with active site residues.  An amine in this position would most likely be 
protonated and could therefore form a very strong hydrogen bond with the strongly 
bound water molecule.  
To predict the activity of UNIS00021 analogues that lack the amide linkage and 
replaced with an amine,  UNIS00077 was docked into the AAG crystal structure 
3UBY as shown in Figure 3.1. In this, the nucleophilic water molecule in the active 
site makes a hydrogen bond to the amine of UNIS00077.  This should be stronger 
if the amine is protonated than hydrogen bonding to an amide as in UNIS00021.  
At 3.4 Å, there is also possibly an interaction between this amine and the carbonyl 
of Val-262 which was not there when UNIS00021 was docked into the same AAG 
crystal structure.   
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Figure 3.1: Overlay of ԑA-oligo X-ray8 structure (PDB: 1EWN) and UNIS00077 docked into X-ray 
structure from ԑC-oligo (PDB: 3UBY) with DNA removed. 
In this chapter It is planned to design the synthesis by varying the linkage using 
n=1and n=2.  The primary amines can be converted then into different substituted 
amines using reductive amination. These analogues will help to check the 
necessity of the carbonyl and whether the protonated amines will add any extra 
hydrogen bonding. Also, it was planned to check if varying the length of the linkage 
group will increase the potency of the amine analogues.In this chapter the 
synthesis of UNIS00077 (Figure 3.2) and four other analogues varying at the 
linkage moiety or the amine R group will be discussed.  
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Figure 3.2: Analogue of UNIS00021 varying at the linkage group 
3.2 Attempted synthesis via reduction of nitrile 
UNIS00073 
3.2.1 Background 
Lithium aluminium hydride has been used as a reducing agent to convert nitriles 
into amines for a long time.  The mechanism for this reaction, proposed by Weldon 
G.,97 is shown in Scheme 3.1.97-99 For example, Mori et al. used LiAlH4  in dry THF 
to convert the nitrile group in compound 36 into an amine 37 in 74% yield (Scheme 
3.2).100 
 
Scheme 3.1: Mechanism for reduction of a nitrile group using LiAlH4 
 
Scheme 3.2: Reduction of a nitrile group into an amine using LiAlH4 
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Also, Robert reported that the activity of LiAlH4 can be improved by the addition of 
the Lewis acid aluminium chloride.101 He hypothesised that when 1 equiv. of each 
of these reagents is used it causes the formation of aluminium hydride and lithium 
chloride and then further reaction might take place to form aluminium 
chlorohydride, AlH2Cl.101 Robert found that combining these two reagents, rather 
than just using LiAlH4, in the reduction of diphenylacetonitirile in dry ether 
increased the yield from 46% to 91%. However, all their starting materials 
contained either phenyl, benzyl, or aliphatic groups; none of them bore a triazole. 
A search using SciFinder revealed no reports of LiAlH4 being used in the presence 
of a  triazole-thione.  Milder NaBH4 has been used to reduce a more reactive 
pyridinium side group in the presence of a triazole-thione but the yield was low.  
NaBH4 has also been used with triazole-thiones to produce tris(triazole-thione) 
boron complexes.102 Based on this literature it was decided to first test access to 
the desired amine analogues of UNIS00021 via reduction of the nitrile group of 
triazole-thione acetonitrile UNIS00073 using LiAlH4 only. 
3.2.2 Results and Discussion 
The reduction of triazole-thione acetonitrile UNIS00073 using LiAlH4 was carried 
out following the procedure reported by Mori et al. Three equivalents of LiAlH4 were 
added to the starting material at 0 °C using dry THF as the solvent. The reaction 
was warmed to room temperature for 1.5 h. It was worked-up using Fieser’s 
method, that avoids aluminium hydroxide gel/emulsion formation, by adding first 
0.1 ml water, then 0.2 ml of 2 M NaOH, and finally 0.3 ml water.103 However, the 
LCMS of the filtrate did not show any peaks correlating to the expected product 
([M-H]- ion at m/z 234) and instead there was a peak for the starting material ([M-
H]- at m/z 229), and two other peaks with mass spectra matching a [M-H]- ion with 
m/z 231, and with 232. It was difficult to purify and isolate these components and 
attempts to use reverse phase column chromatography was not successful.  
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Next, the procedure using using LiAlH4 in combination with Lewis acid aluminium 
chloride, described above, was trialled.101 1.3 Equiv. of each was combined and 
added dropwise to the starting material.  After 1.5 h reaction the LCMS showed a 
small peak corresponding to the starting material and a mixture of other unknown 
peaks and it did not show the corresponding primary amine.  It is hypothesised 
that this potent mixture also reduced the triazole-thione and led to several further 
reactions of the products. 
It has been found that using Raney Ni / N2H4.HCO2H could transform nitriles to 
primary amines with a good yield.104,105 It was reported that hydrazinium 
monoformate in the presence of Raney Ni (Scheme 3.3) acts as a hydrogen donor 
and reduced a wide variety of nitro and nitrile compounds to the corresponding 
amines in less than ten minutes.104 However, none of the reported starting 
materials contained a triazole-thione.104 It was also reported that hydrazinium 
monoformate is soluble in solvents like methanol, ethanol, THF, DMF and 
glycols.104   
 
Scheme 3.3: Reduction of nitrile using Raney Ni and hydrazinium monoformate.(R=alkyl or aryl 
residue substituted with –OH, OR, -CO2H, -CO2R, -CONH2, or -NHCOOCH3.) 
The method was applied to nitrile UNIS00073.  The hydrazinium monoformate was 
prepared by slowly neutralizing hydrazine hydrate with 96% formic acid in an ice 
water bath before adding Raney nickel in ethanol and nitrile UNIS00073.  TLC 
revealed just the starting material even after 24 hours at room temperature and 
this was corroborated by LCMS. In another attempt the amount of hydrazinium 
monoformate was increased to 10 equiv. and  the reaction was left for 5 hours at 
room temperature. However, the LCMS again revealed just the starting material 
so the method was abandoned.  
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3.2.3 Conclusion 
All attempts to produce a primary amine from 1,2,4-triazole-thione acetonitrile 
UNIS00073 using reducing agents LiAlH4, LiAlH4-AlCl3 and Raney 
nickel/N2H4.HCO2H were unsuccessful with starting material or over-reduced 
products being detected in most cases.  It was therefore decided to design an 
alternative synthetic route to triazole-thione alkylamines such as UNIS00077. 
3.3 Synthesis via Boc-amino alkyl hydrazides 
3.3.1 Background 
To permit divergent synthesis of several substituted secondary amines, the 
triazole-thione alkyl-primary amine was required which could be used in reductive 
aminations. To mitigate side-reactions of the amine during synthesis of the triazole-
thione, it should be protected and the Boc group was chosen. There are relatively 
few literature and patent reports of syntheses of triazole-thione alkyl(Boc)amines. 
For example Cowen et. al. reported the synthesis of  triazole-thione substituted 
alkyl(Boc)amines 39 via cyclising thiosemicarbazide that contain the protected 
amine 38 with ammonia at a temperature ranged between 65 °C to room 
temperature (Scheme 3.4).106  
 
Scheme 3.4: Synthesising triazole-thione substituted alkyl(Boc)amines via cyclising 
thiosemicarbazide106 
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Similarly Michaela et. al. synthesised the triazole-thione alkyl(Boc)amines 44 by 
using the corresponding acid hydrazides 41 in a reaction with benzylisothiocyanate 
to give the thiosemicarbazide 42 required for cyclisation in 2% NaOH at reflux to 
give the triazole-thione 43 (Scheme 3.5).107 
 
Scheme 3.5: Synthesis of triazole-thione alkyl(Boc)amines 44 via thiosemicarbazide 
cyclisation.107 
Henichart et. al. also reported the synthesis of triazole-thione having 
dialkylaminoethyl substituent at the 3 position and benzyl in the the fourth position 
in 85-88% yield by cyclising the corresponding thiosemicarbazide.108 
Based on the literature and successful synthesis of triazole-thiones described in 
Chapter 2, the retrosynthetic analysis shown in Scheme 3.6 was performed which 
allows variation of the length of the linker group and seven reactions starting from 
amino acids 45.   
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Scheme 3.6: Retrosynthetic plan for analogues of UNIS00021 varying at the linkage group 
The proposed forward synthesis is shown in Scheme 3.7. 
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Scheme 3.7: Proposed synthesis of the amine analogues of UNIS00021 
The synthesis proceeds via the amino acid esters 46 (n=2) which can be easily 
prepared through activation with thionyl chloride in the presence of methanol. This 
reaction has been widely used in the literature in yields ranging from 79 to 
100%.109-112  
The next step involves protection of the amine group in 46.  Boc is one of the most 
widely used protecting groups in organic chemistry to protect primary or secondary 
amines as well as amino acids in peptides chemistry. It is ideal to protect amines 
during the synthesis of multi-functional targets113 because of its resistance towards 
nucleophilic and basic attack.114 Many publications describe Boc amine protection 
in the presence of a base such as triethylamine (TEA) in excellent yields.115-118 
Synthesis of the subsequent hydrazides 49 (n=1) and 50 (n=2) can be achieved 
by reacting the protected amine compound 47 (n=1) and 48 (n=2) with hydrazine 
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hydrate in water at reflux for 2 h,119 or for 16 hours using methanol as the 
solvent.115  
Addition of the hydrazide to benzylisothiocyanate should give the 
thiosemicarbazide 51 (n=1) and 52 (n=2) as was successful for 
cyanoacetohydrazide 30 as described in Chapter 2.75,76,120   
O’Callaghan used hydrazine as the base to cyclise 4-alkyl-5-
cyanomethylthiosemicarbazides into the corresponding triazole-thiones.75 Other 
reported methods used (0.5 -2 M) NaOH as the base (see Table 1.1 in Chapter 
2). However, the results from this project, described in Chapter 2, found 1 M 
NaHCO3 at 60 °C sufficient to give the 1,2,4-triazolothione acetonitrile UNIS00073. 
The Boc protecting group can next be easily removed by treatment of the 1,2,4-
triazole-thione UNIS00080 (n=1) and UNIS00075 (n=2) with an acid before 
proceeding to the next step.107,121  
This step should be followed by alkylating the primary amine to form the secondary 
amines 57. Usually, the formation of such secondary amines is achieved by 
treatment of primary amines with alkyl halides in the Hofmann alkylation.122  
However, the problem with this type of reaction is overlakylation which is due to 
the increased nucleophicity of the product amines.123 Overalkylation can give rise 
to mixtures of primary, secondary, tertiary amines, and quaternary ammonium 
salts (Scheme 3.8).   
 
Scheme 3.8: Overalkylation of primary amines in the Hofmann alkylation.122  
 The free 1,2,4-triazol-thione alkylamines UNIS00081 and UNIS00076 can also be 
converted into the target secondary amines by reductive amination which is the 
solution to overalkylation problem.  In this, the nucleophilic amine attacks the 
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electrophilic carbonyl to form the intermediate carbinol amine 58 which dehydrates 
to form an iminium ion (Scheme 3.9).124 These are then reduced to the alkylated 
amine product by the reducing agent.125 
 
Scheme 3.9: Reductive amination through the formation of carbinol amine124 
This reaction can be carried out in one pot by using a milder reducing agent which 
has selectivity for iminium ions over the starting aldehyde or ketone.  Sodium 
cyanoborohydride (NaBH3CN) is one such reducing agent.113,126 Intrestingly 
NaBH3CN reduced aldehydes and ketones effectively at pH 3-4 wherease at pH 
6-8 the only the imines are protonated and so are reduced faster than aldehydes 
or ketones.126,127  However, this can produce toxic by-products such as NaCN and 
HCN during the workup,124 and can contaminate the product with cyanide.128 
Gordon and Duncan reported the milder reducing reagent sodium 
triacetoxyborohydride (NaBH(OAc)3). The electronwithdrawing and the steric 
effects of the three acetoxy groups are responsible for its mild reducing 
properties.The pH used with this reagent is ~ 3 in the presence of acetic acid.129-
131 For example, Ahmed F. et. al. used it in their reductive amination reactions of 
aldehydes and ketones with a variety of aliphatic and aromatic amines and they 
repoted yield between 35-99 %124 They found that it reacts faster with a better 
yields and with fewer byproducts compared to the NaCNBH3.124 The reactions of 
this reagent in DCE as a solvent is faster than those carried out in THF. 124  
The first analogue of UNIS00021 should bear a cyclohexylamine.  Use of this 
substrate using the method above has been reported by Louis L. et. al. in the 
synthesis of pyrrolotriazinone 60 (Scheme 3.10).132  
 64 
 
Scheme 3.10: Use of NaBH(OAc)3 for reductive amination using cyclohexanone.132  
It is also of interest to synthesise the monomethyl amine analogue UNIS00079 to 
measure the activity against AAG with the smallest alkyl group.  
One reported method to methylate the amine was to used a mixture of CO2 and 
H2 in a ruthenium-catalyzed process (Scheme 3.11).133,134 The CO2 acts as the C1 
source and H2 as the reducing agent . However, the disadvantages of this method 
are that it need high pressure (20-70 bar) and temperature ( >140 oC).134  
 
Scheme 3.11: Catalytic methylation of amines using CO2 and molecular H2.133 
A simpler method was reported by LeBleu et. al. in which a direct N-
monomethylation of primary amines was achived using methyl 
trifluoromethansulfonate (MeOTf) or dimethylsulfate (Me2SO4), as the electrophilic 
source of methyl, in the presence of hexafluoroisopropanol (HFIP).135 HFIP is 
thought to prevent overmethylation by selective deactivation of secondary and 
tertiary amines through hydrogen bonding. The influence of the hydrogen bond 
donor ability of fluorinated alcohol solvents such as HFIP was examined 
experimentally by LeBleu et al. who proposed that the reaction between a primary 
amine and MeX should not be affected by HFIP, but the nucleophilicity of the 
resulting secondary and tertiary amines, with higher energy N lone pairs, would be 
offset by hydrogen bonding to it and so prevent overmethylation. This proposed 
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idea was confirmed by their result of reacting benzylamine (1 mmol) with MeI (1.5 
eq.) but the yield after 24 hours was just 8%. However, the monomethyl adduct 
was the only product. The conversion was improved to 79% by performing the 
reaction at 60 °C but the monomethylamine was accompanied by tertiary amine 
(20%) and the quaternary ammonium salt (3%).  This was solved by using more 
powerful methylating agents Me2SO4 or MeOTf, which have hydrogen bond 
acceptors, and the conversion improved to 76-81% with 57-68% selectivity 
towards secondary amine.135 
3.3.2 Results and Discussion 
3.3.2.1 Step 1: Synthesis of β-alanine methyl ester (46 (n=2)) 
The preparation of β-alanine methyl ester 46 followed the procedure reported by 
Colak et al., described above.112  Thionyl chloride was added dropwise at 0 °C to 
the starting material in methanol. The reaction was stopped after eight hours by 
adding cold diethylether to precipitate the substituted amino acid ester products 
(Scheme 3.12) in the form of a salt, in good yield (88%). The 1H-NMR showed a 
peak at 3.7 ppm which integrated to three and the 13C-NMR showed a peak at 52.3 
- both representing the new methoxy group. The structure of the compound was 
established by IR, 1H-NMR, 13C-NMR and GC-MS. 
 
Scheme 3.12: Preparation of β-Alanine Methyl Ester synthesis 
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3.3.2.2 Step 2: Synthesis of N-(tert-butoxycarbonyl)-β-alanine methyl 
ester (48 (n=2)) 
N-(tert-Butoxycarbonyl)-β-alanine methyl ester 48 (n=2) was formed by reacting 
the HCl salt of amino ester  46  with di-tert-butyl dicarbonate (Boc2O).115 The 
product 48 was isolated in 96% yield after removing the triethyl ammonium 
hydrochloride salt by filtration (Scheme 3.13). The 1H-NMR showed a singlet peak 
integrate to nine for the tert-butyl group and 13C-NMR revealed a new carbonyl 
peak at 155.9 ppm assigned to the carbonyl group of Boc and a peak at 79.5 ppm 
for the (-C-(Me)3). 
 
Scheme 3.13: Preparation of protecting β-Alanine Methyl Ester using ditert-butyl carbamate 
3.3.2.3 Step 3: Synthesis of N-Boc-aminoalkyl hydrazides with n=1 and 
n=2 
For triazole-thione alkylamines with n=2, Boc-β-alanine hydrazide was required 
and was synthesised according to S. Poojari et al.  from Boc-β-alanine ester 47 
and was isolated after aqueous work-up in 67% yield (Scheme 3.14).115 For 
triazole-thione alkylamines with n=1, the required starting material, N-Boc-alanine 
ester 47 is commercially available and was reacted with hydrazine hydrate using 
the same procedure to give hydrazide 49 in 76% yield (Scheme 3.14).   
Analysis by 1H, and 13C NMR for both products showed that there was no longer 
a peak for the methoxy group.  Also, 1H-NMR  in DMSO-d6 showed a low field 
singlet at 8.90 ppm (integrating to 1) corresponding to the –NH-NH2 and another 
singlet at 6.7 ppm corresponding to the Boc-NH-. 
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Scheme 3.14: Preperation of  N-Boc-aminoalkyl hydrazides using hydrazine monohydrate  
3.3.2.4 Step 4: Thiosemicarbazide synthesis 
The preparation of thiosemicarbazide 51 (n=1) and 52 (n=2) was carried out 
following the procedure reported by Colanceska-Ragenovic et al. and used in 
Chapter 2 76 Owing to impurities observed in the LCMS of the crude products, they 
were purified by column chromatography, a procedure which was not necessary 
with the ester products produced in Chapter 2.  After this, the reaction yield was 
92% for the thiosemicarbazide with n=2 (Scheme 3.15). Whereas the reaction 
yield with n=1 was 75% and 12% was the triazole-thione UNIS00080 as by product 
(Scheme 3.16). The 1H-NMR spectrum in DMSO-d6 showed a new low field 
singlet at 8.40 ppm representing the protons of the new N-H from the benzyl 
isothiocyanate. A 5H multiplet in the aromatic region at 7.22-7.29 ppm confirmed 
the new phenyl group to be present and 13C-NMR spectrum showed a signal 
corresponding to the (C=S) group  at 182 ppm in the same environment as in 
spectrum of compound 25 in Chapter 2.   
 
Scheme 3.15: preparation of thiosemicarbazides 52 
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Scheme 3.16: preparation of thiosemicarbazides 51 
3.3.2.5 Step 5: Cyclisation of thiosemicarbazides into triazole-thiones 
The cyclisation of  thiosemicarbazides 51 and 52 was carried out using the same 
conditions used to synthesis UNIS00073 in Chapter 2 which involved heating in 1 
M aqueous NaHCO3 at reflux (Scheme 3.17). Both starting thiosemicarbazides 
cyclised into the desired triazole-thiones.  LCMS showed just one peak with m/z 
333 matching [M-H]- for n=2 and 319 for n=1.  Purification was not required after 
work-up and the yields were 79% for n=2 and 80% for n=1.  The 13C-NMR spectra 
exhibited a signal at 151.3 ppm corresponding to the (-N=C-) group for both 
products. The signal for (-C=S) moved from 182 ppm in the starting material to 168 
ppm. This was also assigned by HMBC and HSQC.The formation of the triazole-
thione, as opposed to amino-thiadiazole, was evidenced by IR absorption which 
showed absorbance of only one carbonyl group at 1666,-C=S at 1356, and –NH-
Boc at 3265 cm-1  for both products. 
 
Scheme 3.17: Preparation of triazole-thione UNIS00080 and UNIS00075 
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3.3.2.6 Step 6: Deprotection of the amino group 
The most used method that has been reported for N-Boc deprotection is 
application of mildly acidic conditions136 such as HCl in EtOAc, trifluoroacetic acid 
(TFA) in DCM, H2SO4 in tert–BuOAc, or aqueous phosphoric acid in THF.137,138  
The first method that was tested was TFA in DCM (1:1).  This was added to the 
Boc-amine UNIS00075 and left at room temperature for 2 h.121  The LCMS of the 
crude product showed a peak with a mass spectrum matching a [M-H]- ion at m/z 
233 and other unknown impurities. The reaction was stopped by adding saturated 
NaHCO3 and extracted with DCM. That was followed by reverse phase column 
since the TLC and LCMS showed that the product was very polar. However, 
impurities remained. In a repeat of the reaction 1 M NaHCO3 was added to make 
the solution pH~8 and then it was extracted with DCM/MeOH (9:1) to give the 
product in 40% yield.  The TLC of this showed one spot but the 1H- and 13C NMR 
still showed impurities.  This problem is associated with use of TFA to remove Boc 
groups and has been reported previously along with the fact that the yields after 
aqueous extraction can be poor.139   
A different reported deprotection method employs HCl in dioxane or MeOH/EtOAc 
at room temperature.140,141  HCl/EtOAc (1:1) was trialled as the solvent142 with Boc-
amine UNIS00075, however, the starting material did not dissolve in the HCl acid 
mixture even after leaving it for 2 h at room temperature. The TLC showed just 
starting material so it was decided to heat the reaction at reflux. After one hour at 
reflux there was no starting material by TLC and there was a new spot. At that 
point the solvent was evaporated to dryness to give the product as a white powder 
in 86% yield (Scheme 3.18).  The LCMS of the isolated product n=1 showed a 
peak at 1.23 retention time with a mass spectrum matching a [M-H] + ion at m/z 
235.  
Since the product was in the salt form and not the free amine which was required 
for the next step (reductive amination), it was decided to repeat the reaction but 
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quench it using NaHCO3 to pH~8 followed by extraction with DCM/MeOH (9:1). In 
this, although the extraction process was carried out ten times and NaCl was 
added to the aqueous layer, the yield was only 11%.  It was therefore decided to 
try to use UNIS00076 (n=2) in the salt form for the reductive amination step (see 
next Section). 
The same conditions were used to deprotect the shorter Boc-alkylamine 
UNIS00080 in 92% yield (Scheme 3.18).  
 
Scheme 3.18: Deprotection of the amino group in triazole-thione UNIS00081 and UNIS00076 
The structure of the two compounds were established by IR, 1H-NMR, 13C-NMR. 
In the IR spectrum characteristic absorption bands for NH2, were observed at 3028 
cm-1. In the IR spectrum characteristic absorption there was no band observed for 
the removed Boc carbonyl group. The 1H-NMR spectrum showed the 
disappearence of the singlet of the tert-butyl group.  
3.3.2.7 Step 7a: Reductive amination 
The reductive amination reaction, described in Section 3.3.1, involves reacting the 
appropriate aldehyde or ketone with the amine and NaBH(OAc)3 in the presence 
of acetic acid.132 This procedure was followed with cyclohexanone and 1,2,4- 
triazole-thione ethylamine UNIS00076 (n=2).  A 24 h reaction time was required 
for full conversion of the starting material then, after aqueous work-up and flash 
silica column chromatography the product was obtained in 63%. The yield would 
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have been higher but some product remained trapped in the aqueous layer as 
detected by LCMS.  
Using this method, the four triazole-thione alkylamines shown in Scheme 3.19 
were synthesised, all in moderate yield. The structures of these amines were 
confirmed by LCMS, IR, and NMR.  The IR spectra all showed the characteristic 
absorption bands: 3228-3233 cm-1 corresponding to N-H of the amine and 1350-
1362 corresponding to the C=S group. 
 
Scheme 3.19: Reductive amination reaction using NaBH(OAc)3 in the presence of acetic acid. 
3.3.2.8 Step 7b: Monomethylation of triazole-thione alkylamines  
The method that was used to monomethylate the triazole-thione alkylamines was 
that reported by LeBleu et. al. using HFIP and Me2SO4.135  In the first attempt using  
triazole-thione methylamine UNIS00081 (n=1) and 1.5 equiv. of Me2SO4 (Scheme 
3.20), the mixture formed a non-stirrable sludge so an extra 3 equiv. HFIP was 
added.  Regardless, after 1 h, TLC showed just starting material.  Addition of DCM 
to better bring the mixture into solution also led only to the detection of starting 
material by LCMS.   
 
Scheme 3.20: Attempted synthesis of methylamine triazole-thione 61 
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It was thought that this reaction failed because amine UNIS00081 was in the salt 
(protonated) form and therefore non-nucleophilic. Hence, it was decided to add 
one equiv. of anhydrous Na2CO3 to deprotonate the amine into the same reaction. 
However, this did not dissolve and again, after 2 h LCMS still showed only starting 
material. At that point it was decided to add one equivalent of 1 M aqueous 
NaHCO3. After 30 min, LCMS showed a peak with a mass spectrum matching a 
[M-H]- ion at m/z 233 for the desired product. The reaction was stopped after 24 
hours by adding 2 M HCl until the mixture reached pH~7 and extracting with 
DCM/MeOH (9:1). However, after purification using flash silica column 
chromatography, the desired secondary amine was not isolated.  Instead, LCMS 
of the isolated product showed it to be a mixture of tertiary amine and quaternary 
ammonium salt which were not present before the work up based on the LCMS. It 
was hypothesised that overmethylation occurred during the extraction process in 
which Me2SO4 was still present and HFIP partitioning into a different layer to the 
amines so it was rendered less effective at inhibiting the nucleophilicity of the 
secondary amine.  
The reaction was repeated, albeit with longer chain amine UNIS00076 due to 
availability, including the 1 M aqueous NaHCO3 as a base. Once Me2SO4 was 
added the mixture turned from a milky solution into a transparent solution. After 5 
h, LCMS showed a peak with a mass spectrum matching a [M-H]- ion of the desired 
product at m/z 247 and there was no peak of the starting material. This time the 
crude material was purified directly using a reverse phase column , thus avoiding 
addition of 2 M HCl and the extraction process in which the remaining Me2SO4 can 
overmethylate the product.  Interestingly, the 1H-NMR of the isolated compound 
showed the product but also Me2SO4 as a major contaminant which revealed that 
quenching the reaction with acid was necessary to trap the remaining Me2SO4 in 
the aqueous layer.  
In a final attempt to synthesise UNIS00079 the reaction was stopped first by adding 
2 M HCl to achieve a pH~2-3 and then extracting with DCM three times to remove 
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all of the Me2SO4 from the aqueus layer but leaving the protonated product amine 
there.  Next, the aqueous layer was basified using 1 M NaHCO3 to pH~8 and this 
was extracted with DCM/MeOH (9:1) three times. The combined organic layers 
were purified using reverse phase silica column chromatography to give the 
desired secondary amine in 78% yield with no Me2SO4 detectable in1H-NMR 
(Scheme 3.21).  The 1H-NMR in MeOD showed a 3H singlet peak at 2.79 ppm 
representing the new methyl group. 
 
Scheme 3.21: Synthesis of the 1,2,4-triazole-thione ethyl methylamine (UNIS00079)  
3.4 Summary and Conclusion 
The synthesis of analogues of UNIS00021, with a free amine in place of the amide, 
by reduction of 1,2,4-triazole-thione nitrile UNIS00073 using LiAlH4 and other 
reducing agents and over-reduced products was not successful and probably over-
reduced products were obtained.Instead, a robust synthetic method which also 
allowed variation of the length of the alkyl linkage group was developed.  Similar 
to the amides synthetic method (Chapter 2), the 1,2,4-triazole-thione core can be 
produced by cyclisation of thiosemicarbazides which were synthesised with n=1 
and n=2 in 75% and 92%, respectively, by refluxing hydrazides 50 and 49 with 
benzylisothiocyanate in ethanol for 2 h. As for the amides described in Chapter 2, 
heating these thiosemicarbazides in 1 M of NaHCO3 induced cyclisation to give 
the 1,2,4-triazole-thione protected amines in 79-80% yields. After removing the 
Boc group using HCl/EtOAc (1:1), because TFA gave too many impurities, 
reductive amination using  NaBH(OAc)3 in the presence of acetic acid was carried 
out. Cyclohexyl and isopropyl amines, each with two lengths of linkage, were 
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produced and fully characterised. The methyl amine triazolothione with n=1 was 
synthesised in 78% yield using Me2SO4 as the electrophile with HFIP additive in 1 
M aqueous NaHCO3.  The use of aqueous base with the known HFIP methodology 
to produce only monomethylated secondary amines has not previously been 
reported. 
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4. The Synthesis of UNIS00021 
Analogues Varying at the Core 
4.1 Introduction 
One of the important features of triazole-thiones is that they can exist in two major 
tautomeric forms: the thione and the thiol.73 Thiols are one of the most reactive 
groups found in cells and are susceptible to electrophilic attack and oxidation to 
form stable disulfides.143 UNIS00021 in the thiol form could react with electrophilic 
biomolecules or cysteine residues and cause off-target effects, although its 
nucleophilicity and oxidation potential should be attenuated by the conjugated N-
atoms in the ring.144 It is not known which tautomeric form binds to AAG and each 
has different hydrogen bonding patterns in which thion can act as the hydrogen 
bond acceptor (HBA) and the NH of the core act as the hydrogen bond donor 
(HBD)  and show in Scheme 4.1 .   
 
Scheme 4.1: Two possible thione/thiol tautomeric form of UNIS00021 
Nevertheless, it was important to synthesise the triazole core lacking the thiol to 
potentially remove reactivity complications and investigate the role of the 
thiol/thione and hydrogen bonding of the ring so the analogues shown in Figure 
4.1 were desired.  These consist of methyltriazole UNIS00088, with a methyl group 
in place of the thiol, and triazole 62 lacking any group (except a proton) in its place.  
The activities of these compounds should provide insights into both the role of the 
sulfur atom and the active tautomeric form.  If methyltriazole is of comparable 
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activity to UNIS00021 it would suggest that the thiol tautomer is the active one, or 
that NH of the thione tautomer is not hydrogen bonding, and that the methyl rests 
in a hydrophobic area originally filled by the S-atom.  If triazole 62 maintains 
activity, it might suggest that the S-atom is superfluous and again, N-H is not 
required for a significant interaction. 
 
Figure 4.1: Target analogues of UNIS00021 varying at the core 
The absence of a thiol or thione in UNIS00088 (compared to UNIS00021) means 
that the N-atoms of the triazole ring can act as hydrogen bond acceptors but not 
donors. Figure 4.2 shows the predicted binding of UNIS00088 in AAG’s active site 
using MOE docking. Similar to the UNIS00021 docking, the catalytic water 
molecule of AAG, held by Val262, Arg182, and Glu125, hydrogen bonds with the 
amide N-H of inhibitor.  In addition,  for UNIS00088 the phenyl ring appears inside 
AAG’s nucleobase-binding pocket forming a pi-pi stacking interaction with Tyr127. 
The docking result did not show any interaction between the methyl group 
UNIS00088 and His136 which was noticed between the thiol/thione of UNIS00021 
His136 in MOE predicted binding (Chapter 1 Figure 1.16).  
In this chapter the synthesis of UNIS00088 and attempts towards triazole 62 will 
be discussed. 
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Figure 4.2: Overlay of ԑA-oligo X-ray structure (PDB: 1EWN)8 and UNIS00088 docked into X-ray 
structure from ԑC-oligo (PDB: 3UBY) with DNA removed. 
4.2 Proposed Syntheses and Background Literature 
3,4,5-Trisubstituted 1,2,4-triazoles 69 are usually synthesised by cyclisation of N-
acylamidrazones 67 which can be accessed in a variety of ways and are often 
reaction intermediates which are not isolated.67  They have been synthesised 
through coupling of hydrazides with a range of activated amides including 
cloromethylene amides 63145, imidates 64146,  thioamides 65147 , and thioamidates 
66148 as shown in Scheme 4.2. This reaction can also proceed via the N-
acylhydrazonate 68 which can be cyclised into the target 1,2,4-triazoles by reacting 
it with an amine.149,150 However, there is little information available in the literature 
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on which intermediate, N-acylamidrazones 67 or N-acylhydrazonate 68, will be 
formed and why. However, it was noticed from the reported literature reactions that 
if the activated amide is an imidate 64 with X=OMe, R2= H then the N-atom is 
displaced, not the alkoxy group and so proceeds via the hydrazonoate and a new 
amine can be added for the cyclisation.  
 
Scheme 4.2: Synthesis of 3,4,5-trisubstituted 1,2,4-triazoles via activated amide intermediates.151 
For example, Brook et al. synthesised the 5-unsubstituted triazole 73 by using 
formic acid hydrazide in a reaction with imidate 71 to give the hydrazonoate 72 
required for cyclisation with benzylamine to give the triazole 73 (Scheme 4.3). It is 
worthy of note, due to use in this project, that the imidate 71 was formed by reacting 
[2-nitro-4-(trifluoromethyl)phenyl]acetonitrile 70 with the anhydrous HCl solution 
produced by reacting AcCl with methanol.  
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Scheme 4.3: The synthesis of a 3,4-disubstituted 1,2,4-triazole using an imidate precursor150  
In another example for the formation of N-acylhydrazonate 69 instead of N-
acylamidrazones 67, Ashton et al. reported the synthesis of 3-alkyl-5-aryl-(or 
heteroaryl)-4-(arylmethyl)-4H-triazoles such as 76. Here, the imidate hydrochloride 
74 was reacted with 2-furoic acid hydrazide 75 to give furanoyl hydrazonoate 76 
which was converted to the triazole 78 upon heating with 4-nitrobenzylamine 
77(Scheme 4.4).149  
 
Scheme 4.4: Synthesis of 3-alkyl-5-aryl(or heteroaryl)-4-(aryl methyl)-4H-triazoles149 
On the other side, Olson S. et al. synthesised adamantyl triazole 82 via 
acylamidrazones 67 in 80% yield by condensing the imidate imino ether 80 of 
caprolactam 79 with admantyl-1-carbohydrazide 81 in toluene.152 The imidate 80 
was formed by reaction with Meerwein’s salt as shown in Scheme 4.5.  
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Scheme 4.5: Synthesis of adamantyl triazole via an imidate152 
In this project, using this methodology, there are two possible disconnections of 
desired product 83 (Scheme 4.6).  The first (red) requires the starting hydrazide 
to be attached to the acetoester (86) and the triazole C5-atom to come from the 
activated amide 85 whereas  the second (blue) requires the starting hydrazide to 
be attached to include the C5-atom (88) and the activated amide to incorporate the 
acetoester (89).  
 
Scheme 4.6: Two possible disconnections of 1,2,4-triazole ester 83 
4.3 One pot synthesis via activation of future triazole 
C5-containing amide 
The one-pot synthesis is one of the effective synthetic method to synthesis the 
3,4,5-trisubstituted1,2,4-triazoles using the idea of activating the amide with 
chlorinating agent. Many research groups have reported the formation of such 
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heterocycles via the substitution of the activated amide derivatives with 
hydrazides.145, 153, 154, 67,146 
Lindström and Johansson reported a one-pot synthesis of 3-aryl-5-methyl-4-
substituted 1,2,4-triazoles 93 involving activation of N-substituted acetamides (90) 
to form imidoyl chlorides 91 using oxalyl chloride as the activating reagent.145 The 
imidoyl chlorides reacted readily with aryl hydrazides 92 to form stable 
intermediates which could be easily cyclised to the triazole by heating in the 
presence of base as shown in Scheme 4.7 and Scheme 4.8. Yields of 32-87% 
were reported for most examples, however, the importance of an electron-donating 
group on the aryl group of the acetamide to activate it for reaction with oxalyl 
chloride was noted. For example, when N-phenyl acetamide and N-4-nitrophenyl 
acetamide were used there was no gas evolution (CO2 and CO from reaction with 
oxalyl chloride) and 1,2-dibenzoylhydrazine was the major isolated product when 
benzhydrazide was added to this mixture. Interestingly, one of their examples had 
a methyl group at C5 of the triazole, but none of their examples had a benzyl or 
acetoester in the 4- or 3-positions of the 1,2,4-triazole as required in the 
UNIS00021 analogues. 
 
Scheme 4.7: Synthesis of 3-aryl-5-methyl 4-substituted [1,2,4] triazoles145 
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Scheme 4.8: Proposed mechanism of the one-pot synthesis of 3-aryl-5-methyl 4-substituted 
[1,2,4] triazoles 93 
It was hoped that benzyl amides would be sufficiently electron rich to react with 
oxalyl chloride and so this method was applied to the desired 1,2,4-triazole ester 
with a methyl group at C5 (Scheme 4.9).  In the first instance, this required 
synthesis of hydrazide acetoester 96. 
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Scheme 4.9: A designed route synthesis of 1,2,4-triazole acid 102 and 103 
4.3.1 Step 1: Synthesis of hydrazide acetoester (96) 
Park et al. synthesised acethydrazide-d3 by reacting acetyl chloride-d3  with 
hydrazine at 0 °C.155 This procedure was followed in an attempt to synthesise 
hydrazide acetoester 96 by reacting methyl malonyl chloride (1 equivalent) with 
hydrazine (2 equivalents). After two hours the LCMS in the positive  mode showed 
a peak with mass spectra showing m/z 232.9 but no sign for the product mass. 
The reaction was quenched at that point by diluting it with ethanol and extracted 
with ethylacetate. The crude product was purified using flash column 
chromatography but the only product isolated was shown to be dimer 104 
(Scheme 4.10) by LCMS ([M+H]+ 232.9 and IR where no –NH2 stretch between 
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3550-3200 cm-1 was seen.  Unfortunately, there was no signal for NH in 1H NMR 
even in DMSO-d6. 
 
Scheme 4.10: The formation of ethoxycarbonylacetohydrazide dimer from reaction of malonyl 
chloride with hydrazine at 0 °C 
It was hypothesised that the dimer formed because the addition of the methyl 
malonyl chloride was done at 0 °C and so there was enough time for it to 
accumulate in the presence of the desired product and react with it.  It was 
therefore decided to add the methyl malonyl chloride into the hydrazine at room 
temperature. However, the LCMS again showed the same peak correlate to the 
dimer [M+H]+ 232.9 and there was no sign of the product.  
Metwally et al. reported the synthesis of hydrazide acetoester 106 in 34% yield by 
reacting hydrazine with diethyl malonate (105) at room temperature for 24 h 
(Scheme 4.11).156 This procedure was followed exactly.  After stopping the 
reaction by filtration, it was purified by trituration with diethyl ether to give the 
product in 38% yield. The first filtration before trituration was malonohydrazide 
(107) which was isolated as a byproduct in 24% yield.  LCMS of the purified 106 
revealed one peak with a mass spectrum matching a [M+H]+ ion at m/z 147. This 
reaction was repeated several times with the same conditions and the yield ranged 
between 33-46%. 
 
Scheme 4.11: Synthesis of hydrazide acetoester 106 
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4.3.2 Step 2a: One-pot conversion into 5-methyl triazole 
UNIS00085 
Following the procedure described above, N-benzyl acetamide was used so that 
after subsequent steps, a methyl group would be incorporated on C5 of the target 
1,2,4-triazole.  Thus, oxalyl chloride was added to a mixture of benzyl acetamide 
and 2,6-lutidine as base followed by addition of hydrazide acetoester 106 after 40 
minutes. After 3 h, LCMS showed one peak at 0.49 minutes retention time with a 
mass spectrum matching a [M+H]+ ion of the desired intermediate acyl amidrazone 
108 with m/z 278.  
After evaporating the solvent, saturated NaHCO3 was added and the mixture 
heated at reflux for 3 h to facilitate the cyclodehydration. Unfortunately, LCMS 
showed no peak corresponding to the desired triazole. Analysing the extracted 
organic product after 3 h by 1H-NMR showed a quartet and triplet at 4.1 and 1.2 
representing the ethyl ester group which did not integrate correctly compared to 
the benzyl group as shown in Scheme 4.3.  
 
Figure 4.3: The result of the cyclisation step of the intermediate 34 in 0.5 M NaHCO3 
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Interestingly, it was noticed that heating the acyl amidrazone at reflux with 
saturated NaHCO3 for 24 hours gave an LCMS peak at 2.6 minutes retention time 
with a mass spectrum matching a [M+H]+ ion at m/z 232 for the acid version of 
triazole UNIS00085.  After 48 h this reaction was quenched using 2 M HCl to 
pH~5.5–6 and was extracted with DCM/MeOH 9:1 but nothing was present by 
TLC. However, by 1H-NMR the isolated organic product (Figure 4.4, b) did not 
show the expected acid since there was no signal for the -CH2-COOH, and there 
appeared to be two peaks for –CH2-Ph and two peaks for methyl groups. 
Furthermore, examining the same 1H-NMR after some time (~two months, c) 
showed a change in the peaks of the benzene signals. Also, it now showed single 
peaks corresponding to the –CH2-Ph and methyl groups and no sign of a peak for  
-CH2-COOH. As will be discussed in section 4.7.3, the acid was found to be 
unstable, decarboxylating to dimethyl triazole UNIS00086, and this is what is 
thought to have partially occurred in this reaction.   
 
Figure 4.4: 1H-NMR spectrum showing instability of the triazole acid 103  
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The reaction was repeated but with heating at reflux in toluene only to promote the 
cyclodehydration, thus avoiding aqueous NaHCO3 which could cause hydrolysis 
and contribute to by-product formation (Scheme 4.12). Suprisingly, after one hour 
at reflux the LCMS showed a peak at 4 minutes retention time with a mass 
spectrum matching a [M+H]+ ion with m/z 260 corresponding to the product. 
However, the intermediate was not fully soluble in toluene causing most of it to 
form a black, sticky sludge at the bottom of the flask. It was decided to leave the 
reaction longer so the sticky sludge of starting material might dissolve and go into 
the solution. Yet, after six hours of reflux there was still black sludge and so it was 
decided to stop the reaction at that point. The product was isolated in just 5% yield 
by filtering the crude and evaporating all the solvents (Scheme 4.12). Interestingly, 
the 1H-NMR in CD3OD revealed the product with the correct integration for the 
ester and benzyl groups. The 13C-NMR spectrum showed three quaternary carbon 
atoms at 169.1, 154.5, and 151.0 ppm representing the (C=O), (CH3-C=N), and –
CH2-C=N-) respectively.  
 
Scheme 4.12: Cyclodehydration of intermediate acyl amidrazone 108 into 1,2,4-triazole 
acetoester UNIS00085 
Based on this result different solvents were tested to improve the yield of the 
cyclisation at reflux either for 24 h or 43 h and all were followed by LCMS (Table 
4.1). The best solvent to use was a mixture of CH3CN and toluene (2.5:1). 
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% area by LCMS (24 h)a (43 h)a 
Solvents 
Intermediate 
acyl amidrazone 
108 Product 
Intermediate 
acyl amidrazone 
108 Product 
DMF/toluene (1:1) 
50 50 - - 
CH3CN 
98 2 - - 
CH3CN/toluene (2.5:1) 
40 60 28 72 
Tolueneb 
2 98b (5%)d - - 
Acetic acid 
100 0 100 0 
saturated NaHCO3c 
61 0 - - 
H2O/toluene (1:1) 
45 55 - - 
Isopropanol 
100 0 - - 
Isopropanol/toluene 
(1:1) 
41 59 35 65 
Pyridine 
100 0 - - 
CH3CN/toluene (1:2) 
42 58 (49%)d - - 
a % of total LCMS UV chromatogram peaks by area 
b Most of the intermediate formed black sticky sludge at the bottom of the round bottom flask 
which give a false representation of the reaction mixture 
c 40% represent a new peak with a mass spectrum m/z 232 
d isolated yield after purification 
 
Table 4.1: Testing the cyclisation using different solvent followed by LCMS  
This cyclisation of the intermediate using a mixture of CH3CN and toluene (2.5:1) 
at reflux was followed by 1H-NMR to check the time that needed to stop it by 
checking the crude of the reaction after 24 h and 48 h as shown in Figure 4.5. It 
was interesting to observe the formation of the benzyl group in the crude reaction 
compared to the intermediate spectrum after 24 h and also the change in the shape 
of the coupling of the ester group.  
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This time the reaction was stopped by cooling it in a cold water bath and then 
filtering off the 2,6-lutidine salt (as evidenced by NMR shown in Figure 4.6). After 
purification by repeated column chromatography the final yield of pure triazole 
acetoester UNIS00085 was 49%. The rest of the product contained other 
impurities from which separation was too difficult.  
 
Figure 4.5: The 1H-NMR spectrum of the intermediate 108 compared to the cyclised 1,2,4-
triazole ester UNIS00085 after 24 h and 48 h in toluene/CH3CN at reflux. 
Another two attempts were made to improve the yield and this time the reactions 
were scaled up to 2 and 3 g.  However, the yield remained around 50-53% and 
multiple column chromatography was necessary.     
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Figure 4.6: The 1H-NMR spectrum of 2,6-lutidine salt 
4.3.3 Step 2b: Attempted one-pot conversion into 5-H triazole 
(110) 
This one-pot reaction was also tested with benzyl formamide to to put a proton at 
C5 of 1,2,4-triazole ester instead of a methyl group (Scheme 4.9). The same 
conditions were applied, however this time the mass of the intermediate acyl 
amidrazone 109 (molecular weight 263) was not detected by LCMS. The mixture 
was heated at reflux in CH3CN/toluene (2.5:1) anyway and after 20 h the 1H-NMR 
spectrum of the crude was compared with that of the ‘intermediate’ which revealed 
no difference between them. The reaction was left for 44 h but the 1H-NMR still 
showed no difference. The reaction was stopped and purified using flash column 
chromatography. Examining the isolated product by 1H-NMR (DMSO-d6) revealed 
a compound with structure similar to the intermediate acyl amidrazone 109 
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(Scheme 4.13) but with several anomalies in the NMR spectra (which included 
COSY, HSQC and HMBC for assignments). 
 
Scheme 4.13: Failed attempted cyclodehydration of intermediate acyl amidrazone 109 into 1,2,4-
triazole acetoester 110 
There were two singlets at 10.6 and 10.2 ppm both integrating to one and a triplet 
at 9.4 ppm which also integrated to one all of which represent three –NHs. This 
was further evidenced by treating the same 1H-NMR sample with D2O and seeing 
all three resonances disappear. Moreover, the –CH2 in the benzyl group was a 
doublet before the D2O shake and turned to a singlet after the treatment. This 
indicates a proton is present on the benzylic nitrogen atom which couples to the 
benzylic CH2; it is unlikely that the compound is in its protonated form because it 
passed silica chromatography and the benzylic CH2 is seen at 4.34 ppm.  The 13C 
NMR spectrum displayed four low field carbon resonances at 167, 164, 159 and 
158 ppm, which indicate the two carbonyl signals, and two more sp2-carbon atoms 
bound to electronegative atoms, of which there is only one (C=N) in intermediate 
109.  Despite these observations, the structure of the compound could not be 
identified. 
4.4 Synthesis via acyl hydrazonoates 
Based on the survey of the literature described in the introduction it was decided 
to design an alternative route to synthesize the 5-H triazole (113). The route was 
designed to access the 5-H triazole 100 via the N-acylhydrazonate 112 as shown 
in  (Scheme 4.14).  
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Scheme 4.14:  Proposed retrosynthesis of UNIS00021 analogues lacking a thione 
The synthesis proceeds via the imidate 111157,158 which can be easily synthesised 
through addition of methanol to methyl cyanoacetate 29 in the presence of 
anhydrous HCl which can be generated by reacting acetyl chloride with methanol 
at 0 oC.   For example, preparation of compound 111 was reported by Uneo et al 
with 77% yield (Scheme 4.15).158  
 
Scheme 4.15: Synthesis of methyl 3-imino-3-methoxypropanoate hydrochloride 
The methylhydrazonoate 112 is formed by reaction of imidate 111 with formic or 
acetic hydrazide at room temperature. This intermediate can then be reacted with 
benzylamine and cyclised into the 1,2,4-triazole ester 100. The 1,2,4-triazole ester 
100 can be converted into the target analogues using direct amidation or ester 
hydrolysis followed by amide coupling of the resulting carboxylic acid.159  
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4.4.1 Step 1: Synthesis of imidate (111) 
As described above, synthesis of the imidate salt 111 involves reaction of the 
appropriate nitrile with the required alcohol in the presence of HCl.157,158,160  
However, this procedure requires the use of HCl lecture bottles and their 
associated hazards. Instead, HCl gas can be generated using either concentrated 
H2SO4 and NaCl salt161 or by adding acetyl chloride to alcohol as reported by 
Brooks et al.150 Both methods were trialled in this project. 
The synthesis of 111 was carried out following the procedure reported by Brooks 
et al (Scheme 4.3) in which HCl gas was generated by adding acetyl chloride into 
anhydrous methanol at 0 °C. The methanol was dried using molecular sieves 
which were activated by heating under high vacuum and kept under nitrogen gas.  
After generation of the HCl solution, methyl cyanoacetate 29 was added and the 
reaction was kept at 0 °C overnight. In the first and second attempts NMR analysis 
of the filtrate revealed dimethyl malonate 114, and ammonium chloride salt.  The 
dimethyl malonate was hypothesised to result from overhydrolysis of the starting 
material which could result from a second addition of methanol followed by loss of 
MeCl, as shown in Scheme 4.16, or more simply from the presence of water in the 
reaction mixture. The ammonium chloride salt obtained from the reaction appeared 
as a triplet in the proton NMR spectrum at a chemical shift of ~7.5 ppm (in DMSO-
d6) which agreed with that of a purchased sample (Figure 4.7). 
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Scheme 4.16: Possible mechanism for overhydrolysis of methyl cyanoacetate 114 
 
 
Figure 4.7: Formation of NH4Cl from the imidate synthesis 
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In the third attempt the reaction was repeated using the same conditions but using 
purchased anhydrous methanol supplied in a bottle with a septum. However, NMR 
showed a new product 115 resulting from self-condensation of the desired product 
(Scheme 4.17). The 1H NMR spectrum in DMSO showed two methyl group proton 
resonances at 3.60 (6H, s, -CO-OMe), and 3.59 (3 H, s,  -OMe). The 1H NMR 
spectrum in DMSO-d6 showed two methyl group proton resonances at 3.60 (6H, 
s, -CO-OMe), and 3.59 (3 H, s,  -OMe). The 13C NMR spectrum showed the 
presence of three low field carbon resonances at 168.4 (-N=C-OMe), 167.2 (-CH2-
C=NH), and 167.0 (-CO-OMe). The structure of this compound was almost fully 
assigned using HMBC and HSQC as shown in Figure 4.8 but, unfortunately, the 
correlation between –C=NH and its next neighbouring –CH2- was not seen 
although this could be due to overlap with the HMBC peaks for -COOMe.  
 
Scheme 4.17: Self-condensation of product imidate 
 
Figure 4.8: HMBC correlations of self-condensation product 115  
As an alternative, HCl gas was generated by adding concentrated H2SO4 to 
sodium chloride and using a series of bubblers (one containing concentrated 
H2SO4) to remove moisture before entry into the reaction vessel and also to 
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quench excess HCl (saturated sodium carbonate solution) on exit from the reaction 
vessel (Figure 4.9).161  
 
Figure 4.9: Apparatus for generation of HCl gas using concentrated H2SO4 and sodium chloride 
(left) and bubbling into reaction mixture (right) 
The reaction temperature was kept at 0 °C overnight as described in the 
literature.158 Unfortunately, using this method, only starting material was recovered 
as shown by NMR (Figure 4.10), perhaps indicating insufficient HCl dissolved into 
the reaction solution or insufficient temperature. 
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Figure 4.10: Recovering starting material by using H2SO4 and brine salt to generate HCl gas 
Synthesis of the analogous ethyl imidate 117 has been reported by Michael et al 
using ethyl cyanoacetate, ethanol and anhydrous HCl gas but their reaction was 
warmed from 0 °C to room temperature and stirred for 20 h to give the product in 
99% yield.162 Following these temperature conditions and also using ethyl 
cyanoacetate as the starting material, but acetyl chloride and dry ethanol to form 
HCl, the desired product was obtained as a powder (Scheme 4.18).  
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Scheme 4.18: Synthesis of ethyl 3-ethoxy-3-iminopropanoate 
It was purified by trituration with diethyl ether to give 60% yield of the product. 
LCMS analysis of this compound showed one peak with a mass spectrum 
matching a [M+H] + ion at m/z 160. The structure of the compound was established 
by IR, 1H-NMR, 13C-NMR and compared with the literature. The IR spectrum was 
key to characterising the product, showing peaks at 1741 and 1615 cm-1 
representing the C=O and C=N, respectively.  
The same temperature profile (0 °C addition then RT for 20 h) was applied to the 
original reaction using methyl cyanoacetate, methanol and HCl generated by 
acetyl chloride and dry methanol but no solid was formed.  Instead an oily product 
was obtained after evaporating and triturating with diethyl ether. The 1H-NMR 
spectrum revealed this oil to contain neither product nor starting material. 
However, a white precipitate had been observed in the reaction after three hours. 
Therefore, it was supposed that the reaction needed less time than the ethyl 
cyanoacetate to generate the product and longer time led to by-products instead. 
The same reaction was repeated at room temperature for four hours and the work 
up was similar to the previous reaction. The methyl imidate salt was obtained as a 
white powder in 75% yield.  
The LCMS of this compound showed one peak with a mass spectrum matching 
product cation at m/z 132. The structure of the compound was established by IR, 
1H-NMR, 13C-NMR and compared with the literature. Two singlets at 4.34 and 3.76 
ppm were found corresponding to the two –CH3 of the methoxy groups. The IR 
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spectrum was again key to characterising the product, showing peaks at 1732 and 
1614 cm-1representing the C=O and C=N bonds, respectively. 
In conclusion, the synthesis of imidate 111 required careful control of temperature 
and time with successful reaction requiring warming to room temperature but for a 
limited time so as not to lead to by-products.  Limited investigation of this showed 
optimum time to be dependent on the alcohol used (methanol or ethanol). 
4.4.2 Step 2: Synthesis of Acylhydrazonoates 
The synthesis of the methyl and ethyl hydrazonoates requires substitution of the 
imidate with formic hydrazide at room temperature as reported by Brook et. al.  
Following this procedure formic hydrazide was added to imidate 117, which was 
stored at room temperature, at room temperature (Scheme 4.19). Unfortunately, 
in two attempts, only starting material could be isolated in 84% yield.  
 
Scheme 4.19: Synthesis of ethylhydrozonate 118 
Interestingly, in these two attempts it was noticed that leaving the starting material 
at room temperature caused it to decompose into a product that was no longer 
soluble in CDCl3. It was thought that the reaction did not work for that reason.  It 
was therefore decided to synthesise 111 and 117 from scratch but keep them at -
20 °C under nitrogen gas.  
The new, carefully-stored 117 was reacted with formic hydrazide following the 
same conditions. The reaction was monitored by TLC until starting material was 
no longer present (4 h).  It was quenched by adding saturated NaHCO3 solution, 
 100 
as described in the literature, and extracted with DCM/MeOH (9:1) several times. 
Once again, no product could be isolated but only the neutral form of imidate 117, 
in 84% yield, as shown by a change in the chemical shifts of the two –CH2 of the 
ethyl.  
      Ashton et al. synthesised furanoyl hydrazonoate 76 by preparing a solution of 2-
furic acid hydrazide 75 in dry EtOH and adding it dropwise into a solution of the 
imidate hydrochloride in dry EtOH at -10 °C followed by holding it at 5 °C for three 
days to give the product in 58% yield (Scheme 4.4). 
Following this procedure using imidate 117, after three days the LCMS showed 
two broad peaks adjacent to each other, each with a mass spectrum matching a 
[M+H]+ ion at m/z 203-03-17-3rd day 9am.  At that point the reaction was stopped 
and the crude mixture was purified using flash column chromatography 
(DCM/MeOH 9:1) following the procedure by Ashton et al.  However, it was 
challenging to separate the two spots shown by TLC and the 1H-NMR spectrum 
showed that it was still a mixture of either the starting material and the product or 
product and something else. Also, the 13C-NMR spectrum showed an excess of 
peaks (Figure 4.11) 
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Figure 4.11: NMR spectrum showing the resulting mixture from reacting 117 with formic 
hydrazide 
It was thought the acetylhydrazonoate 119, which would later be converted to the 
desired 5-methyltriazole analogue UNIS00085, may be less reactive and prone to 
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by-product formation than formic hydrazonoate 118 so acetylhydrazide was 
subjected to the same reaction conditions (Scheme 4.20).  
 
Scheme 4.20: Synthesis of ethylhydrazonoate 119 
The LCMS of the crude mixture showed two broad peaks adjacent to each other 
whose mass spectra correlated to the product with a m/z 217 matching a [M+H]+.  
There was also another unknown peak at 0.47 min retention time that increased in 
area as the reaction progressed (Figure 4.12).  
 
Figure 4.12: LCMS of crude mixture resulting from reaction of 117 with acethydrazide at 5 °C for 
4 d 
 
The reaction was stopped after four days by filtering off the NH4Cl salt followed by 
flash column chromatography (DCM/MeOH 9:1). The 1H-NMR of desired 
hydrazonoate 119 should show two peaks for each of the –CH2 groups and two for 
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each of the –CH3 groups of the ethoxy groups. However, the isolated product 
revealed three –CH2 peaks and three –CH3 peaks as shown in Figure 4.13. Also, 
the 13C-NMR spectrum showed a large number of peaks which could not be  
correlated with the 1H-NMR peaks. It was hypothesised that the product existed as 
a mixture of atropisomers and/or tautomers (Scheme 4.21). It was too challenging 
to prove this using HSQC and HMBC so instead it was thought to see if the NMR 
peaks would coalesce as the NMR temperature was increased (r.t., 40, 60, 70, 
90 ̊C) in DMSO and the rate of interconversion between atropisomers approached 
the NMR timescale. Unfortunately, there was no large change observed in this 
experiment (Figure 4.14).  Another thought was to separate the atropisomers by 
reverse phase column chromatography, based on the LCMS result. However, this 
attempt failed and both peaks came off together. Therefore, it was assumed that 
the isolated mixture was the product and it was used directly in the next step. 
  
 
Figure 4.13: 1H-NMR of the product mixture resulting from reacting 117 with acetylhydrazide 
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Scheme 4.21: Possible atropisomers and tautomers of 119 
 
Figure 4.14: 1H-NMR of 119 at different temperatures (r.t., 40, 60, 70, 90, and 127 ̊C)  
In a different attempt the reactions were repeated using the formic hydrazide and 
acetylhydrazide but this time the reaction was warmed from -10 oC to room 
temperature to try to improve the yield of the product. Surprisingly, the LCMS of 
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the crude after 10 hours showed just the two broad peaks of the products without 
impurities.  
In order to quench any remaining hydrazide it was preferred to use the sodium 
bicarbonate again. Intrestingly, using just 0.1 M sodium bicarbonate gave a better 
result without the need to carry out column chromatography and the yield was 
improved to 90%. 
4.4.3 Step 3: Amination and cyclisation of N-acylamidrazone 
to form 1,2,4-triazole 
As described in Section 4.2, amination and cyclisation of acylhydrazonoates 118 
and 119 can be achieved by reacting them with benzylamine at room temperature 
for three days.150 This procedure was followed using ethyl acetylhydrazonoate 119 
in ethanol as solvent (Scheme 4.22).  
 
Scheme 4.22: Attempted amination and cyclisation of 119 into 1,2,4-triazole UNIS00085 
Unfortunately, there was no sign of the product mass by LCMS of the reaction 
mixture but GCMS and 1H-NMR spectroscopy revealed the presence of benzyl 
acetamide suggesting transamidation of the starting material by benzylamine. 
After three days the reaction was quenched by adding 0.1 M HCl and extracting 
with DCM/MeOH (9:1). The isolated product after flash column chromatography 
(DCM/EtOAc 4:6) was shown to be the neutral form of the imidate 117 by 1H-NMR 
(Figure 4.15),  
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The same reaction conditions were applied to the ethyl formylhydrazonoate 118 
(Scheme 4.23).  GCMS of the crude product mixture revealed the formation of 
benzyl formamide, again suggesting transamidation of the starting material. 
 
Scheme 4.23: Attempted amination and cyclisation of ethyl formylhydrazonoate 118 into 1,2,4-
triazole 110 
 
Figure 4.15: The isolated product of reacting benzyl amine with 117 
It was thought that the problem could have arisen from use of the protic solvent 
ethanol as proton transfers are involved in the transamidation mechanism. 
Therefore, it was decided to repeat the reaction of ethyl formylhydrazonoate 118 
in aprotic solvent (THF, DMF, and CHCl3) and in a protic solvent (EtOH). Following 
-CH2-CH3 
-CH2-CH3 
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the reactions by LCMS it was observed with all solvents that the starting material 
was converted into a new peak similar to that which was found previously at 0.81 
minutes retention time. It was therefore decided to heat the reactions at 50 °C for 
six more hours but no change was observed. The 1H-NMR spectrum of the isolated 
peak again revealed the free imidate. It was a challenge to isolate the benzyl 
formamide. However, the presence of benzyl formamide was proved by 
comparison with the 1H-NMR of purchased benzylformaldehyde and by its addition 
into the crude reaction (Figure 4.16).  
 
Figure 4.16: 1H-NMR spectrum of the crude reaction mixture, from reaction of 20 with 
benzylamine, spiked with purchased benzylformaldehyde showing a large increase in size of 
peaks at 8.14 (-CHO), 7.29 (-Ph), and 4.39 (-CH2-Ph) ppm 
In summary, the proposed synthetic route to triazole analogues of UNIS00021 
could not be completed. The challenges were the difficulty in characterising the 
acyl hydrazonoates 118 and 119 and aminating/cyclising them into 1,2,4-triazoles. 
In all attempts the benzylformamide or benzylacetamide was formed indicating 
transamidation of the starting material instead of condensation. 
 108 
4.5 One pot synthesis via activation of acetoester 
amide 
4.5.1 Introduction and background literature 
As mentioned in Section 4.2, N-acylamidrazones 67 are cyclisation precursors to 
triazoles and can be prepared from chloroimidates 63. These, in turn, can be 
prepared by activating amides with a dehydrating/chlorinating agent such as oxalyl 
chloride.163 
William et al. have developed a practical one-pot synthesis to access multiple 
3,4,5-trisubstituted 1,2,4-triazoles by activating secondary amides with 
trifluoromethanesulfonic anhydride (Tf2O).151 The reaction began with the amide 
and Tf2O at 0 °C in either DCE or DCM in the presence of 2-fluoropyridine (2-FPyr) 
as a base for 10 minutes.  2-FPyr was necessary to deprotonate the amide. That 
was followed by addition of the hydrazide followed by heating at 110 °C for one 
hour under microwave (µW) irradiation to promote the cyclodehydration (Scheme 
4.24 and Scheme 4.25). One of the example products in the paper, triazole 120, 
included N4-benzyl substitution and another, triazole 121, included C3-CH2-CO2Et, 
both of which are present in precursors to the desired triazole analogues of 
UNIS00021. However, no examples were unsubstituted at the C5 position 
(Scheme 4.24). 
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Scheme 4.24: One-pot synthesis of 3,4,5-trisubstituted 1,2,4-triazoles using  
trifluoromethanesulfonic anhydride and 2-fluoropyridine164 
 
Scheme 4.25: Proposed mechanism of the one-pot synthesis of triazole acetoester  
 Based on the above literature a synthetic route was proposed to synthesise 
triazole acetamides 100, unsubstituted at the C5 position, and discover whether 
the Tf2O-mediated condensation/cyclisation described above is applicable when 
only a proton is present on the C5 atom.  The route is shown in Scheme 4.26 and 
begins with synthesis of N-benzyl malonamic acid methyl ester 123 from methyl 
malonyl chloride.165 This is followed by one-pot activation using Tf2O, substitution 
with formic hydrazide and cyclodehydration to give 1,2,4-triazole ester 100 which 
can then be converted into the target analogues 125 using direct amidation or ester 
hydrolysis followed by amide coupling of the resulting acid.  
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Scheme 4.26: Proposed synthetic route to C5-unsubstituted triazoles 125 
4.5.2 Step 1: Synthesis of N-benzyl malonamic acid methyl 
ester (123) 
The synthesis of amide 123 was carried out following the procedure reported by 
Alessandra (Scheme 4.27).165 After work-up and purification by flash column 
chromatography, the product was isolated in 34% yield.  Before trying to improve 
this yield, the material was tested in the planned one-pot synthesis to test its 
viability (next section).  The 1H-NMR spectrum in CDCl3 exhibited a doublet at 4.50 
ppm representing the protons of the –CH2 of the benzyl group.  IR, 1H-NMR and 
13C-NMR data all correlated with that in the literature.  
 
Scheme 4.27: Synthesis of N-benzyl malonamic acid methyl ester 123 
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4.5.3 Step 2: Attempted one-pot conversion into triazole (100) 
Following the procedure reported by William et al., Tf2O was added to a mixture of 
amide 123 and 2-FPyr in DCE at 0 °C. After ten minutes, the formic hydrazide was 
added and the reaction was heated in the microwave at 140 °C for two hours. The 
reaction was stopped by adding saturated NaHCO3 and purified using flash column 
chromatography. Unfortunately, LCMS of the only isolated product showed no sign 
for the mass of the product and the 1H-NMR spectrum showed a great many peaks 
which could not be used to identify any products.   
4.6 Attempted direct amidation of 1,2,4-triazole   
acetoester UNIS00085 
There are many reported methods for direct amidation of esters using efficient 
inorganic catalytic systems such as (Zr(OtBu)4-HOAt)166, and also organic 
catalysts such us DBU167, triazabicyclo[4.4.0]dec-5-ene168, and N-heterocyclic 
carbenes.169 
Price et al. reported a mild, high yielding direct amidation of alkyl cyanoacetates in 
the presence 0.25 equivalents of DBU without the need to activate the cyanoacetic 
acid or use temperatures higher than 40 °C (Scheme 4.28).167  They hypothesised 
that DBU acts as a nucleophilic (Lewis base) catalyst in which DBU displaces the 
alkoxy moiety and activates the carbonyl for attack by the amine as shown in 
Scheme 4.29  However in all their examples the α-cyano group was present so 
this may be necessary for the reaction to take place. 
 
Scheme 4.28: Direct amidation using DBU167 
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Scheme 4.29: Proposed catalytic cycle of direct amidation in the presence of DBU167 
This method was used in an attempt to convert 1,2,4-triazole acetoester 
UNIS00085 to isopropylamide UNIS00089 (Scheme 4.30) using n-BuOH as 
solvent. After 15 h, LCMS analysis showed a very small peak at 3.6 minutes 
retention time with a mass spectrum showing a product [M+H]+ ion at m/z 273 
along with a major peak at 4.1 minutes retention time with a mass spectrum 
showing m/z 288. After 21 h the reaction was acidified, worked-up and purified 
using flash column chromatography to give the product of n-BuOH 
transesterification. 
    
Scheme 4.30: Failed synthesis of UNIS00089 using DBU-catalyzed amidation of UNIS00085 
Price et al. also reported the use of 2-methyltetrahydrofuran as solvent so the 
reaction was repeated using this solvent but with all other conditions the same. 
After 24 h the UV chromatogram in LCMS analysis of the crude showed a peak for 
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the product but with just 25% conversion based on the integral chromatogram. The 
same result was obtained after heating at reflux for 14 h.  
It has been reported elsewhere that ester aminolysis can be catalysed with anionic 
nucleophiles, in particular the anion of 1,2,4-triazole generated when it is treated 
with DBU.170  It was mentioned in this paper that the aminolysis of unactivated 
esters in the presence of DBU alone does not work even at elevated temperatures 
under solvent-free conditions and that the addition of 1,2,4-triazole resulted in a 
dramatic rate acceleration. This corresponds to the experience with acetoester 
UNIS00085 described above and suggests an α-cyano group is necessary for 
successful use of the method reported by Kristin et al.   
The anionic nucleophile direct amidation of UNIS00085, described above, was 
applied following the authors’ protocol which involved solvent free conditions. 
However, the reaction became very dry and it was decided to add 2-
methyltetrahydrofuran as solvent.  Only starting material was detected by LCMS 
after 24 h reaction so direct amidation was abandoned in favour of hydrolysis and 
amide coupling (next section). 
4.7 Hydrolysis of 1,2,4-triazole acetoester UNIS00085 
4.7.1 Attempted hydrolysis with 1 M NaOH 
The synthesis of 1,2,4-triazole acetamides can also potentially be done by 
hydrolysing the 1,2,4-triazole acetoester and carrying out an amide coupling. Most 
similar to acetoester UNIS00085 in the literature is the example reported by Soares 
et al. involving the hydrolysis of imidazole-thione ester 127 into the imidazole acid 
128 using 1 M NaOH in MeOH at room temperature in a yield of 72%. 
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Scheme 4.31: Hydrolysis of imidazole ester 127.171 
This procedure was applied to 1,2,4-triazole acetoester UNIS00085. After two 
hours, LCMS showed nearly complete conversion to the product. The reaction was 
quenched using 2 M HCl to pH~2 and extracted with DCM/MeOH (9:1). However, 
very little organic compound was extracted and the rest was trapped in the 
aqueous layer confirmed by LCMS which showed [M+H]+ ion with m/z 232. 
Unfortunately, the 1H-NMR spectrum of the isolated product in DMSO-d6 (Figure 
4.17, a) did not correspond to the desired acid, and repeated 1H-NMR of the 
sample after leaving it at room temperature for some time (~4 d) showed instability 
of the compound (Figure 4.17, b).  The decomposition product spectrum matched 
that of the product described in section 4.2.1 resulting from heating acyl 
amidrazone 108 at reflux with saturated NaHCO3 ( Figure 4.17, c) which was 
identified as dimethyltriazole UNIS00086 resulting from spontaneous 
decarboxylation. 
Figure 4.17: The 1H-NMR spectrum of hydrolysing UNIS00085 with 1M NaOH   
4.7.2 Hydrolysis with LiOH 
An alternative reported ester hydrolysis uses LiOH in THF.172 It was thought that 
the lithium ions may coordinate to, and activate, the ester in preference to the 
triazole of triazole acetoester UNIS00085 and so it was applied using 3 equiv. of 
LiOH.H2O at room temperature (Scheme 4.32). 
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Scheme 4.32: The hydrolysis of  UNIS00085 using LiOH in THF 
After 3 h, LCMS analysis showed only starting material so 1ml of water was added 
and after 30 min, LCMS showed the product and there was no sign of the starting 
material. The reaction was stopped by adding 2 M HCl to pH~2 and extracting with 
DCM/MeOH (9:1) to the product as a sticky oil in 34% yield. The low yield was 
attributed to the difficulty of extract the compound from the aqueous layer so 
several trials were performed to improve this by: 1. adding saturated NaCl in the 
extraction step; 2. carrying out reverse phase chromatography on the mixture after 
addition of HCl; and 3. freeze-drying the mixture after HCl addition followed by 
trituration with DCM/MeOH (9:1).  Regardless, the yield remained 15-34%.     
4.7.3 Decomposition of 1,2,4-triazole acetic acid (103) 
It was noticed that the peak representing -CH2-COOH of acid 103 in the 1H-NMR 
was not found after leaving the sample in DMSO-d6 for some time and the methyl 
group of the triazole no longer integrated to three but instead to six. Similarly the 
peaks for -CH2-COOH and –COOH in the 13C-NMR were not found. Also, the mass 
spectrum [M+H]+ ion of this sample changed to be at m/z 188. It was suspected 
that decarboxylation of the acid occurred at room temperature to give the dimethyl 
triazole (UNIS00086). To prove this hypothesis a newly synthesised acid sample 
was analysed by 1H-NMR in DMSO-d6 every two hours for 24 hours.  This showed 
the appearance, and increase in area over time, of a new peak for the dimethyl 
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group (Figure 4.18). Based on this result, it was concluded that the acid should be 
used directly for the next step or be kept at -20 oC. 
 
Figure 4.18: Graph and NMR spectra showing spontaneous decarboxylation of 1,2,4-triazole 
acetic acid 103 into dimethyl triazole over time 
4.8 Amide coupling 
As reported previously in Chapter 2, formation of the amide bond requires 
activation of the carboxylic acid using a coupling reagent such us EDC, DCC, or 
DIC.88 One of the challenges in applying coupling reactions to triazole acetic acid 
103 was the amount available was either small or it was combined with LiCl salt (if 
the extraction with DCM/MeOH was done after freeze drying of the reaction 
CH3  (acid) 
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mixture). Following the same conditions used in chapter 2, cyclohexylamine and 
EDC were used with 1,2,4-triazole acetic acid 103 to give 50% yield of the desired 
cyclohexylamide UNIS00088 after 24 h. In this attempt heating was avoided to 
prevent decarboxylation.  
 
Scheme 4.33: Preparation of cyclohexylamide UNIS00088 using triazole acetic acid 103 and 
EDC 
It was decided to synthesise the isopropyl amide using the same coupling reagent 
and conditions. In the first attempt it was a challenge to purify the product. Although 
the crude material was purified twice using the flash column chromatography and 
preparative TLC the 1H-NMR spectrum still showed a mixture of the product and 
starting material. In a different attempt the crude product was purified using 
preparative TLC but the 1H-NMR spectrum did not show the desired product but 
the methyl ester triazole UNIS00087 instead.  This was evidenced by a 3H singlet 
at 3.63 ppm as well as a mass spectrum which showed a [M+H]+ ion at m/z 246 . 
It was hypothesised that the presence of methanol in the starting material which 
was purified by extraction with DCM/MeOH (9:1) led to this product in preference 
to the sterically hindered isopropylamine.  
The reaction was repeated with a dry starting material using the same conditions. 
Unfortunately, after purification methyl ester UNIS00087 was again isolated in 16% 
yield and just 1% yield of the desired isopropylamide triazole (UNIS00089) was 
obtained. The structure of UNIS00089 was established by IR, 1H-NMR, and 13C-
NMR. The 1H-NMR spectrum showed a doublet integrating to six protons at 1.01 
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ppm for the two methyl groups of the isopropyl amide and a septet  integrating to 
one proton at 3.76 ppm for the -CH of the isopropyl amide. 
It was next thought that the formation of methyl ester UNIS00087 could have arisen 
from the use of EDC as the HCl salt as it may protonate the isopropylamine of 
which 1.2 equiv .was used. Therefore, in an attempt to improve the yield 
trimethylamine was added to the reaction along with EDC at 0 oC followed by 
warming to rt for 24 h. However, the isolated product from this reaction was the 
dimethyl triazole resulting from decarboxylation even though the starting material 
had been kept at -20 °C after synthesis and prior to use. 
In a parallel work (descriped in Chapter 5) the triazole-thione acetic acid 
UNIS00091 was purified using dowex resin to give the acid in quantitative yield 
without the presence of the salt as described in Chapter 5. This method was 
applied to triazole acetic acid 103 and allowed it to be isolated in quantitative yield.  
This was followed by amide coupling reaction using EDC as the coupling reagent 
but this time in the presence of HOBT and DIPEA.173 After purification by flash 
chromatography followed by reverse flash chromatography, the desired isopropyl 
amide UNIS00089 was isolated in 60% yield (Scheme 4.34).   
 
Scheme 4.34: Preparation of isopropylamide UNIS00089 using triazole acetic acid 103 and EDC 
and HOBt 
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4.9 Conclusion 
The synthesis of an analogue of hit triazole-thione UNIS00021 bearing a C5-methyl 
group instead of thiol/thione was achieved using a one-pot synthesis involving 
activation of benzyl acetylamide, using oxalyl chloride, to form an imidoyl chloride 
which was reacted hydrazide acetoester to give an intermediate acyl amidrazone 
which could be cyclodehydrated to give a triazole acetoester.  This was 
successfully hydrolysed to the acid using LiOH in THF/water where use of NaOH 
in water had instead hydrolysed the core triazole. The resulting acid undergoes 
decarboxylation at room temperature so must be used straightaway or stored at 
low temperature.  It could be coupled with cyclohexylamine or isopropylamine 
using EDC as the coupling agent to give the desired analogues for future testing 
as inhibitors of AAG. 
The same route could not be used to synthesise the C5-H analogue due to a failure 
in cyclising the intermediate acyl amidrazone 109. Attempts to access this 
compound with alternative methods including: 1. Tf2O activation of N-benzyl 
malonamic acid methyl ester (123) and reaction with formic hydrazide; and 2. 
Synthesis of hydrazonoates followed by amination and cyclisation with 
benzylamine; also failed so this compound was not obtained. 
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5. Synthesis of UNIS00021 Analogues 
Bearing N
4
 Substituents Alternative 
to Benzyl 
5.1 Introduction  
The docking result of UNIS00021 into the Aag crystal structure using MOE showed 
the phenyl ring occupies the pocket which normally accepts the damaged base of 
substrate DNA (Figure 1.15 and Figure 1.16, Chapter 1).  In this pocket, a parallel 
displaced pi-pi stacking interaction is made between the phenyl ring and Tyr127.  
However, this phenyl ring does not fill the whole pocket compared to the 
ethenoadenine- or ethenocytidine-containing oligomers. Therefore, it was 
important to synthesise analogues of UNIS00021 bearing different aryl groups to 
assess the possibility of finding additional and/or stronger binding interactions in 
this pocket.  
In this chapter the attempted development of a divergent synthesis towards 
analogues of UNIS00021 varying at the N4-substituent will be discussed.  This 
would allow preparation of a range of analogues in one step from a common 
precursor. 
5.2 Proposed Synthesis and Background Literature 
Molander and Maxwell have reported the use of potassium organotrifluoroborates 
in palladium-catalyzed cross-coupling reactions with aryl halides.174  They report 
high yields with low catalyst loadings and broad reaction scopes. The potassium 
organotrifluoroborates have been used widely due to their air and moisture stability 
and also their greater nucleophicity.175 Of relevance to the synthesis of analogues 
of UNIS00021, Molander et. al. have produced amidomethyl- and tertiary 
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aminomethyl-trifluoroborates and used them in Suzuki-Miyaura cross-coupling 
reactions with aryl halides (Scheme 5.1) and Scheme 5.2. 176, 177 
 
Scheme 5.1: Aminomethylations via cross-coupling of potassium organotrifluoroborates with aryl 
bromides.177 
 
Scheme 5.2: Amidomethylations via cross-coupling of potassium organotrifluoroborates with aryl 
chlorides.176 
Based on these successes, the same group also reported the synthesis of a 
potassium Boc-protected aminomethyltrifluoroborate 129 and its use in Suzuki-
Miyaura cross-coupling reactions with various aryl and heteroaryl chlorides 
(Scheme 5.3). The trifluoroborate 130 was prepared in a one-pot process over 
four steps in 75% yield as shown in Scheme 5.4. 
 
Scheme 5.3: Suzuki-Miyaura cross-coupling reactions using potassium Boc-protected 
aminomethyltrifluoroborate178 
 
Scheme 5.4: The preparation of the potassium Boc-protected aminomethyltrifluoroborate 
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It was hypothesised that Molander’s methods could be applied to analogues of 
UNIS00021 by synthesizing a precursor in which a potassium 
aminomethyltrifluoroborate takes the place of UNIS00021’s phenyl ring allowing it 
to be later subjected to Suzuki-Miyaura cross-coupling reactions to afford a range 
of arylmethyl triazole-thiones. Therefore, the retrosynthesis shown below 
(Scheme 5.5) was devised.  It was planned to synthesise the 3,5-disubstituted 
cyclohexylamide triazole-thione UNIS00092 first and add the potassium 
methyltrifluoroborate group last. This was to avoid the need to synthesise the 
amide after Suzuki-Miyaura cross-coupling reaction of each analogue.  Also, 
potassium organotrifluoroborate salts can be prone to hydrolysis so it would be 
difficult to carry it through the earlier steps of the synthesis, especially ester 
hydrolysis.  
 
Scheme 5.5: Retrosynthesis of analoges of UNIS00021 varying at the N4 benzyl group 
Based on the retrosynthetic analysis, a six step synthetic route was proposed 
(Scheme 5.6). 
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Scheme 5.6: Proposed synthesis of analoges of UNIS00021 varying at the N4 benzyl group  
The synthesis proceeds via base-mediated cyclisation of acyl thiosemicarbazide 
133 which can be synthesised through the addition of ethyl-3-chloro-3-
oxopropionate 131 to the thiosemicarbazide 132.179 The 1,2,4-triazole-thione ester 
UNIS00090 is prepared by reacting 133 with strong base, either aqueous sodium 
hydroxide solution or sodium ethoxide in ethanol.179,180 
Alternatively,  Elnagdi et al reported the synthesis of the 1,2,4-triazole-thione 
UNIS00090, in 32% yield, through reaction of thiosemicarbazide 132 with imidate  
117, which was synthesised in Chapter four in 70%, (Scheme 5.7).181 This yield is 
low and there is no spectral data found for UNIS00090 in this reported method.  
 
Scheme 5.7: The synthesis of 1,2,4-triazolinethiones ester UNIS00090.181 
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Noel et al. also reported the formation of 1,2,4-triazole-thione acetic acid 
UNIS00091 by heating 1-aminobarbituric acid 137 at reflux in aqueous acid 
(Scheme 5.8).182  
 
Scheme 5.8: Synthesis of 1,2,4-triazole-thiones acetic acid UNIS00091182 
In all the reported methods the 1H-NMR spectrum of the –NH of the 1,2,4-triazole-
thione core was not reported and different tautomeric forms were drawn in the 
schemes; all possibilities are shown in Scheme 5.9 
 
Scheme 5.9: Possible tautomeric forms of 1,2,4-triazole-thione ester UNIS00090 5 
In order to convert ester UNIS00090 to the carboxylic acid UNIS00091, it can be 
hydrolysed using basic conditions, such as NaOH or NaHCO3. Of closest 
relevance to the synthesis of UNIS00091, although not bearing the thione group, 
Nara et al. hydrolysed ethyl 1H-1,2,4-triazol-3-ylacetate (138) using 4 M aqueous 
sodium hydroxide solution in a mixture of water, methanol and THF at reflux for 2 
h. 
 
Scheme 5.10: Hydrolysis of the 1,2,4-triazole ester 138 into 1,2,4-triazole acid 139 4   
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The synthesis of the 1,2,4- triazole-thione cyclohexylamide UNIS00092 could be 
achieved by activating the acid UNIS00091 using a coupling reagent such as EDC 
prior to treatment with amine as done previously to synthesise UNIS00021 
analogues in previous chapters. However, these amides were obtained in low 
yields and that was hypothesised to be due to the absence of a base such as Et3N 
or DIPEA while purchased EDC is in the acid form which may protonate and 
deactivate the substrate amine.  It has also been reported that the use of EDC in 
the presence of HOBt and a base such as DIPEA promotes amide couplings in 
excellent yields.173,183 Alternative amide coupling reagents are also available, such 
as HATU, an example of whose use includes coupling of pyrrole carboxylic acid 
(140) with isopropylamine (Scheme 5.11).184  
 
Scheme 5.11: Amide coupling of pyrrole carboxylic acid with isopropylamine using HATU 
coupling reagent            
The aminomethyltrifluoroborate 1,2,4-triazole-thione 134 will be formed by reacting 
the triazolothione amide UNIS00092 with potassium (bromomethyl) trifluoroborate, 
commercially available,185 in the presence of a base to deprotonate the target NH 
of the 1,2,4-triazole-thione core.  Selectivity between the various acidic protons on 
the core is an issue at this point but there is precedence for selectivity for N4:  
Kumudha et al. alkylated the same position with ethyl chloroacetate using K2CO3 
as a base in 72% yield (Scheme 5.12).186  
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Scheme 5.12: Alkylation of the 5-substituted-1,2,4-triazole-thione using potassium carbonate as 
base 
The aminomethyltrifluoroborate 1,2,4-triazole-thione 134 can then subjected to 
Molander’s conditions for Suzuki-Miyaura cross-coupling reactions with different 
aryl halids.185                 
5.3 Results and Discussion 
5.3.1 Step 1: Synthesis of 1,2,4-triazole-thione acetoester 
UNIS00090 
The synthesis of ethyl 2-[(carbamothioylamino)carbamoyl]acetate 133 was 
performed in one step according to the existing literature procedure.179 After 2 h at 
reflux, the reaction was stopped by filtering off the precipitate, and recrystallizing 
from ethanol. The product was isolated in poor yield (23%) (Scheme 5.13) and 
most of the thiosemicarbazide remained unreacted as shown by LCMS.  
 
Scheme 5.13: Acylation of thiosemicarbazide.  
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Cameron et al. synthesised 133 by adding ethyl malonyl chloride dropwise  into a 
mixture of thiosemicarbazide and anhydrous pyridine as solvent at  -5 °C and then 
warming to room temperature.180  This method was carried out instead, but again, 
after 24 h 99% thiosemicarabazide was recovered from the filtrate.   
It was decided then to add just one equivalent of pyridine to a mixture of ethyl 
malonyl chloride and thiosemicarbazide in CH3CN and it was left at reflux for 2 h. 
However, this time the yield was even lower (13%). 
As described in the introduction to this chapter, Elnagdi et al. reported that reaction 
of thiosemicarbazide with imidate  117  yielded a mixture of 1,2,4-triazole-thione 
UNIS00090 in 32% yield and amino-1,3,4-thiadiazole in 49% yield.181  Since 
imidate 117 was synthesised previously in good yield, as described in Chapter 4, 
it was decided to try this method. The reaction was first performed in CHCl3 at 0 
°C and, after 2 h and silica chromatography the desired 1,2,4-triazole-thione 
UNIS00090 or isomer amino-1,3,4-thiadiazole 136 (by LCMS) was isolated in 55% 
yield (Scheme 5.14).  The remainder was was a mixture of thiosemicarbazide and 
triethylamine salt.  This reaction was repeated with three different solvents: CHCl3, 
CH3CN, and EtOH and the best yield obtained was 60% using EtOH. 
 
Scheme 5.14: The synthesis of UNIS00090 using the imidate 117 and thiosemicarbazide 
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It was a challenge to assign the structure of the isolated product as that of the 
desired 1,2,4-triazole-thione UNIS00090 and not amino-1,3,4-thiadiazole 136 
since as shown in Scheme 5.15 both could possibly show an HMBC correlation 
(2-4 bond distance) could show a correlation between the NH- of ‘a’ and 
quarternary carbon ‘e’. 
 
Scheme 5.15: HMBC correlation between carbon ‘e’ and the  triazole or thiadiazole core protons  
However, IR spectrum could be used to differentiate between the three groups 
(C=S, -S-H, C-S-C).  Based on the literature the C-S-C stretching vibration 
frequency is around 690-725 cm-1 and the NH2 stretching frequency is 3080-3300 
cm-1.187,188  On the other hand, C=S in unsubstituted 1,2,4-triazole-thione has a 
stretching frequency of 1200 cm-1 and the S-H and C-S  IR absorption frequencies 
in 3-mercapto-1,2,4-triazole are at 2565 and 944 cm-1 respectively.189,190 
Unfortunately, all these absorption frequencies could be seen in the IR spectrum 
of the isolated product and it was difficult to assign the actual structure (Figure 
5.1).  
Kiseleva et al. mentioned that refluxing thiosemicarbazide 133 in AcOH affords not 
the 1,2,4-triazole-thione UNIS00090 but amino-1,3,4-thiadiazole 136 and that the 
amino group nitrogen is less reactive than sulfur during cyclisation under these 
conditions.191 However, they only reported melting points of their products (158-
160 °C for amino-1,3,4-thiadiazole and 192-194 °C for 1,2,4-triazole-thione) and 
there were no proton NMR or IR in their paper with which to compare.191 The 
melting point of the isolated product was between 179-180 °C which was closer to 
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the reported melting point of the desired 1,2,4-triazole-thione UNIS00090.  This 
product was therefore taken forward to the next step. 
 
Figure 5.1: IR spectrum of isolated product from reacting imidate 117 with thiosemicarbazide 
5.3.2 Step 2a:  Attempted direct amidation of 1,2,4-triazole-
thione acetoester UNIS00090 
Subsequent sections will describe the difficulties encountered in converting 
acetoester UNIS00090 into the carboxylic acid ready for amide couplings.  During 
that work, some attempts were made to amidate the ester directly instead.  These 
are described in this section. 
As described in Section 4.6, Chapter 4, Price et al. reported the use of 0.25 equiv. 
of DBU as a nucleophilic (Lewis base) catalyst at 40 °C  for direct amidation of 
esters.167 This method was applied to ester UNIS00090 with cyclohexylamine 
(Scheme 5.16).  However, LCMS after 12 and 24 h showed just starting material 
and no sign of the product . In a different attempt, DBU was combined with 1,2,4-
triazole in a bifunctional catalytic, solvent free system (described in Section 4.6, 
Chapter 4).170  However, after 24 h  LCMS again showed only starting material. It 
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was decided then to heat the reaction at 70 oC after adding 0.5 ml of 2-Me-THF. 
Yet, after 24 h of starting heating the LCMS showed just the starting material.  
 
Scheme 5.16: Failed DBU-catalysed amidation of UNIS00090 
In contrast to basic/nucleophilic catalysis, Hiroyuki et al. used lanthanum 
trifluoromethanesulfonate as a Lewis acid catalyst for amidation of esters under 
solvent free conditions at 70 °C; they reported excellent yields for both aliphatic 
and aromatic esters.159 These conditions were applied to triazole-thione acetoester 
UNIS00090 with isopropylamine Scheme 5.17. Care was taken to achieve 
anhydrous conditions heating the catalyst under high vacuum before adding the 
starting material and amine. Again, after 24 h, LCMS showed only starting material 
with no sign of the product (Scheme 5.17).  The reaction was repeated but using 
dry ethanol as a solvent, but again, LCMS after 3 h and 24 h revealed only starting 
material. It was hypothesised that the lanthanum catalyst preferentially coordinates 
to the thione group rather than the carbonyl group it is required to activate since it 
the higher energy level of sulfur orbitals matches better those of lanthanum. 
 
Scheme 5.17: Failed La(OTf)3-catalyzed amidation of UNIS00090 
Moving back to basic catalysis, the use of potassium tert-butoxide (t-BuOK) to 
convert aliphatic and aromatic esters into amides in good to excellent yield has 
also been reported in the literature.192 However, an attempt using 2 equiv. of t-
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BuOK at room temperature for 24 h to convert triazole-thione acetoester 
UNIS00090 into the desired amide 145 again showed only starting material by 
LCMS.   
Ohshima et al. developed the use of NaOMe as a catalyst and showed access to 
a wide variety of functionalised amides through direct amidation of esters.193 They 
also tested the reaction with various solvents and it to proceed in non-polar and 
polar solvents including THF, 1,4-dioxane, hexane, and NMP, but not in acetonitrile 
or alcohols. This method was applied to acetoester UNIS00090 using 1.3 equiv. of 
cyclohexylamine in dry THF at 50 °C (Scheme 5.18).  After 24 h, LCMS showed a 
very small peak corresponding to the [M+H]+ product m/z 241.  Another 5 mol% 
NaOMe  was added but after another 24 h there was no significant change in the 
LCMS UV peak of the product.  
It was hypothesised that NaOMe deprotonated the triazole-thione core proton (pKa 
~ 8.4)194 instead of the amine (pKa ~ 10.6)195 and that the reaction might require 2 
equiv. of NaOMe. so if one equivalent of it deprotonate the triazole proton then the 
other equivalent should be capable to deprotonate the amine after it attack the 
carbonyl group.  Based on this, the reaction was repeated with 2 equiv. of NaOMe. 
However, after 24 h only ~7% conversion (by LC-UV chromatogram) was 
observed. Addition of another 1.3 equiv. of cyclohexylamine and 24 h stirring 
increased this to ~23%. Finally, heating at reflux for 24 h, followed by use of the 
microwave at 110 °C for 1 h improved the apparent LC-UV conversion to ~42%.  
It was decided to stop the reaction by adding saturated NH4Cl as reported,193 
followed by adding 2 M HCl to reach pH~ 5-6 to re-protonate the triazole-thione. 
After extraction with DCM/MeOH (9:1) and flash silica chromatography, the 
product cyclohexylamide UNIS00092 was isolated in just 4% yield and the starting 
material was recovered in 22% yield (Scheme 5.18). The structure of UNIS00092 
was confirmed by  1H-NMR, IR, and LCMS. 
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Scheme 5.18: Synthesis of UNIS00092 using NaOMe-catalysed amidation of UNIS00090 
Since the yield for direct amidation of acetoester UNIS00090 was so low, the 
method was abandoned in favour of hydrolysis to the acid and amide coupling 
(next section). 
5.3.3 Step 2b: Hydrolysis 1,2,4- triazolothione ester 
UNIS00090 
The hydrolysis of 1,2,4-triazole-thione ester UNIS00090 into acid UNIS00091 was 
carried out using LiOH in THF and water (Scheme 5.19), conditions used 
previously, and described in Chapter 4, for the hydrolysis of methyl-1,2,4-triazole 
UNIS00085.196  LCMS showed the disappearance of the staring material and the 
appearance of a new peak which corresponded to the product [M+H]+ m/z 160. 
 
Scheme 5.19: Hydrolysis of 1,2,4-triazole-thione ester UNIS00090 into acid UNIS00091 
The reaction was stopped by adding 2 M HCl to reach pH~2 and extracted with 
DCM/MeOH (9:1). The 1H-NMR (DMSO-d6) of the organic layer showed the 
disappearance of the ethyl group and a broad peak at 12.9 ppm, integrating to one, 
which might correspond to the acid proton. However, the product was isolated in 
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very low yield 10% even after several extractions and the addition of saturated 
NaCl to the aqueous layer. 
An attempt was made to evaporate most of the aqueous layer, filter off the salt and 
then extract the filtrate with DCM/MeOH (9:1) but comparing the mass of the 
isolated product (349 mg) with the theoretical yield (84 mg) indicated the presence 
of high amount of LiCl salt.  This was run through a reverse phase column in order 
to elute the salt first using water before ramping up the ratio of organic solvent. 
Unfortunatly, both the product and the salt eluted at the same time and again the 
mass was higher than the theoretical yield. 
Continuous liquid-liquid extraction is a method to extract very polar compounds 
from aqueous solution using an organic solvent that is heavier than water.197 This 
method was used in an attempt to extract the acid UNIS00091 from the pH~2 
aqueous mixture using DCM.  Although the process was left for 24 h, there was no 
product at all in the organic layer by TLC or LCMS.  
An SCX column was used in another attempt to purify the acid UNIS00091 from 
the salt.  This is a strong cation exchange sorbent which could extract the lithium 
cations from the triazole acid (Scheme 5.20).  The evaporated reaction mixture 
was dissolved in methanol and passed through the SCX column.  After 
evaporation, 10 mg of the eluted product was examined by NMR using an internal 
standard (1mg/ml hexamethyl-cyclotrisiloxane in DMSO-d6, 0.5 ml).198  
Disappointingly, the calculated mass of the acid in the mixture was only 2.07 mg 
out of 10 mg as shown in Figure 5.2. 
Scheme 5.20: LiCl salt removal using an SCX column  
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Figure 5.2: 1H-NMR of purified 1,2,4-triazole-thione acetic acid UNIS00091 and internal standard 
hexamethyl-cyclotrisiloxane 
After repeated failures to purify triazole-thione acetic acid UNIS00091, it was 
decided to try the amide coupling reaction using the impure mixture containing the 
LiCl salt.  
5.3.4 Step 3a: Attempted amide coupling of LiCl-contaminated 
1,2,4-triazole-thione acetic acid 
As described in previous chapters, the amide coupling agent EDC had successfully 
provided the desired amides but in low yields.  This time, to improve the yield, 
HATU was tested in a coupling between cyclohexylamine and the LiCl-
contaminated 1,2,4-triazole-thione acetic acid UNIS00091.184 The reaction was 
started at -30 °C and after LCMS showed starting material only, was warmed to 
RT and stirred overnight. Regardless, LCMS showed only starting material.  
C6H18O3Si3 
-CH2-COOH 
H2O 
residual 
DMSO-d5 
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Following this, several coupling reagents and conditions were tested as shown in 
Table 5.1.183 Unfortunately, in all only starting material was detected by LCMS. It 
was thought that the problem was the presence of the LiCl salt.  
Reagents  Solvents Time Temperature % Yield 
by LCMS 
DCC EtOAc 24 h 60 °C 0 
DCC DMF 24 h 60 °C 0 
DIPEA, TBTU DMF 24 h r.t. 0 
DIPEA, 
HOBT, EDCI 
DMF 48 h r.t. 0 
Table 5.1: Testing of different amide coupling reagents and conditions with LiCl-contaminated 
1,2,4-triazole-thione acetic acid UNIS00091 and cyclohexylamine  
In conclusion, the amide coupling of 1,2,4-triazole-thione acetic acid UNIS00091  
mixture containing LiCl salt contaminant was not successful so it was deemed 
essential to find a method of purifying the acid as will be described in the next 
section. 
5.3.5 Purification of 1,2,4-triazole-thione acid UNIS00091 
using Dowex ion-exchange resin 
It was decided to purify LiCl-contaminated 1,2,4-triazole-thione acetic acid 
UNIS00091 (resulting from hydrolysis using LiOH in THF and water, as described 
in Section 4.7.2) using anion exchange chromatography. It was proposed to use 
Dowex® resin in the hydroxide ion form.  Triazole-thione acetic acid UNIS00091 
would form carboxylate ions which have higher affinity for the resin and so would 
exchange for hydroxide ions and become bound to the resin.  Since neutral 
species and cations do not interact with the resin, the Li cations would be eluted 
at the beginning.  After elution of impurities, the sample ions can then be eluted by 
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introducing an ion with a higher affinity for the resin or a high concentration of an 
ion with equivalent or lower affinity.199  
Thus, Dowex® resin in the chloride ion form was first exchanged with hydroxide 
ions by washing the resin with 20 equiv. of 1 M NaOH followed by adding 4 equiv. 
of deionised water to remove any unexchanged OH anions (Scheme 5.21). Then 
a new LiOH hydrolysis reaction was completed and the entire reaction mixture 
containing 1,2,4-triazole-thione acetic acid was added to the resin. The column 
was first washed with MeOH to elute any neutral impurities and unbound LiCl. This 
was followed by eluting the column with 0.1 M formic acid in MeOH and then with 
0.1 M HCl in MeOH.  Since the product was yellow, it was noticed that once the 
formic acid was added the product began to elute. It was isolated in quantitative 
yield. LCMS showed a peak with a mass spectrum matching a [M-H]- ion at m/z 
158.  1H-NMR using an internal standard (described in Section 5.3.4) revealed the 
absence of any salt by mass and clear N-H peaks of the triazole-thione.  
 
Scheme 5.21: Purification of 1,2,4-triazole-thione acetic acid UNIS00091 using Dowex 1X2 resin 
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5.3.6 Amide coupling of 1,2,4-triazole-thione acetic acid 
UNIS00091 
Many papers report the use of EDC as amide coupling reagent in the presence of 
HOBt and a base such as DIPEA.173,183  With the pure acid UNIS00091 in hand, it 
was decided to try the combination of EDC, HOBt, and DIPEA for the amide 
coupling reaction (Scheme 5.22).  After 3 h, LCMS showed a peak for the desired 
product UNIS00092 and it was in apparent 61% conversion by the UV 
chromatogram.  After 24 h this increased to 81% and the reaction was worked-up 
and purified by flash column chromatography to give the product in 33% yield. The 
low yield of the product was due to loss to the aqueous layer during work-up as 
shown by LCMS. 
 
Scheme 5.22: Preparation of cyclohexylamide UNIS00092 using triazole acetic acid UNIS00091 
and EDC 
Unfortunately, due to time limits, conversion of the triazole-thione into 
methyltrifluoroborate 134 and coupling with a range of aryl halides could not be 
completed. 
5.4 Summary and Conclusion 
The synthesis of analogues of hit triazole-thione UNIS00021 varying at the phenyl 
group using Suzuki-Miyaura cross-coupling of a trifluoroborate precursor could not 
be completed due to time limits.  However, the first three steps on this route were 
established: reaction of imidate 117 with thiosemicarbazide gave the triazole-
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thione ester UNIS00090 in one step in 60% yield. Direct amidation of the ester was 
not possible but it could be hydrolysed to the acid using LiOH in THF/water.  
Purification required significant experimentation and success was achieved using 
ion exchange chromatography with a Dowex resin to give the acid in quantitative 
yield.  Amide coupling of this with cyclohexylamine using EDC in the presence of 
HOBT and DIPEA gave 33% yield of UNIS00092. The low yield was due to loss of 
product in the aqueous layer during extraction and this could be improved in the 
future using a direct reverse phase column chromatography. 
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6. Biochemical Assays of AAG Activity 
and Inhibitor Potency 
6.1 Introduction 
Biochemical assays to test enzyme activity in the absence and presence of 
inhibitors are essential for comparison of inhibitor potencies.  Many sensitive 
enzyme assays have been developed for use with high throuput screening (HTS) 
to enable testing of millions of compounds in a short time.200 However, designing 
a cell-free enzyme assay requires an understanding of the enzyme mechanism of 
action and its initial test conditions such as buffer, salt concentration and pH. 
As discussed in Chapter 1, the AAG enzyme’s mechanism of action is similar to 
other DNA repair enzymes. It gains access to DNA damaged bases, in double 
stranded DNA, by flipping the nucleotide 180° into its active site where it is made 
a better leaving group through hydrogen bonding with the backbone carbonyl 
oxygen of Ala-134.201 This is followed by hydrolysis of the N-glycosidic bond using 
an active site water molecule held in its active site which releases the free 
damaged base into solution and leaves an abasic (apurinic/apyrimidinic) site for 
repair by downstream enzymes.58 Given this information, a biochemical assay for 
AAG activity must use a substrate duplex DNA oligomer containing a damaged 
base which is a substrate for AAG and must provide a means for quantifying either 
the substrate DNA oligomer, the product DNA oligomer containing an abasic site, 
or the product excised free base. 
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6.2 Microplate surface-bound three-component 
fluorescent DNA oligomer assay 
6.2.1 Introduction 
Elliott has developed a microplate-based assay which uses a duplex DNA 
oligonucleotide substrate which is bound covalently to the surface of functionalised 
96-well plates.202 Thermo Scientific use a patented photochemical method for their 
construction of surface-activated ‘NuncTM Immobilizer Amino’ plates which bear an 
electrophilic group that reacts with amines.  The substrate oligonucleotide consists 
of three parts (Figure 6.1): INC01, a single stranded oligomer which is attached to 
the plate via a 5’-amino modification; HX01, which contains an internal 
hypoxanthine (H) residue, to act as a substrate for AAG, and ends at the 3’-end 
with a fluorescein molecule and the 5’-end with a phosphate for ligation to INC01; 
and REP04, which is the complementary strand to ligated INC01 and HX04. 
 
Figure 6.1: DNA oligomer structure used for AAG surface-bound plate assay. Lower case letters 
indicate the presence of phosphorothioate linkages to help protect the complex from non-specfic 
exonucleases. 
After INC01 is bound to the plate, REP04 and HX01 are allowed to anneal with it 
and each other to give a Watson-Crick base-paired complex.  The complex is then 
treated with DNA ligase to covalently bind INC01 to HX01 (Figure 6.2).  The 3’-
fluorescein is now attached to the plate via the INC01-HX01 oligonucleotide.  By 
incubating this with AAG, abasic sites are produced by the enzyme’s excision of 
hypoxanthine. At this point, after a set time, the wells can be emptied and washed 
to remove AAG and any inhibitors being tested; this is a major advantage of this 
assay which should prevent inhibitor interference with fluorescence.  Subsequent 
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treatment of the oligonucleotide with sodium hydroxide solution  (i) generates a 
break in the INC01-HX01 strand, at the alkali-susceptible abasic site only, and; (ii) 
denatures the complex leading to release of fluorescein where a stand break has 
been produced. There are three approaches which may be used to quantify the 
extent of action of AAG on the oligonucleotide complex: (i) direct detection of 
eluted fluorescence; (ii) direct detection of retained fluorescence and; (iii) by 
detection of retained fluorescence with an anti-fluorescence antibody-horseradish 
peroxidase (HRP) conjugate whose action leads to a colour change when its 
substrate 3,3',5,5'-tetramethylbenzidine (TMB) is added. To begin with, eluted 
fluorescence was measured.   
 
Figure 6.2: General procedure for the AAG activity biochemical assay 
Compounds were assessed for inhibitory activity by incubating with a fixed 
concentration of AAG.  It was important that this concentration was one which, 
within the incubation time of the assay, produced an output where inhibition could 
easily be detected, i.e. that this AAG concentration was in the linear range of an 
AAG standard curve.  For this reason, every assay assessing inhibitors included a 
standard curve of AAG activity generated by incubating the substrate 
oligonucleotide with varying concentrations of AAG.  This was done for two further 
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reasons: (i) to check the enzyme was functioning correctly; and (ii) to provide a 
curve equation for the interpolation of absorbance values resuting from inhibitor 
assays to give apparent AAG activities and, thereby, percentage inhibition values.   
Chu used this assay (quantifying eluted fluorescence) to test synthesised lone 
ethenocytidine nucleoside along with three phosphate derivatives but found them 
to be completely inactive (IC50 ˃ 1 mM) against AAG.  He also used this assay to 
test the activity of 49 purchased compounds predicted to be inhibitors from the 
virtual screen using MOE software.  Only UNIS00021 was found to inhibit AAG 
and its IC50 was ~65 μM.10 
6.2.2 Results and Discussion 
6.2.2.1 Failed attempts to reproduce bioassay results 
A reliable biochemical assay for assessment of the activity of the synthesised 
analogues of UNIS00021 was required.  To begin with, reproduction of the original 
assay, used to identify UNIS00021 as an inhibitor and measuring eluted 
fluorescence, was attempted.   
In the first assay, the normal standard curve shown in Figure 6.3 was produced, 
which verified the use of AAG at a concentration of 0.1 U/100 μl for testing the 
inhibitors as inhibition from this point is easily detectable on the approximately 
linear portion of the curve. 
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Figure 6.3: AAG standard curve generated using the surface-bound DNA oligomer assay and 
measuring eluted fluorescence. Values are averages of n=3, error bars show standard deviation. 
On the same plate, several purchased analogues of UNIS00021 were tested at a 
fixed concentration of 0.1 mM and 0.1 U/100 µl AAG.  Although the standard curve 
produced in this experiment was normal, some of the compounds appeared to 
show inhibition while others (UNIS00064, UNIS00065, and UNIS00066) 
apparently increased the eluted fluorescence signal (corresponding to an apparent 
activation of AAG) compared to the blank (no inhibitor) (Figure 6.4). It was 
hypothesised that either AAG was being ‘activated’ by these compounds, an error 
in enzyme concentration with inhibitors had been made or something was 
interfering with the fluorescence values. 
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Figure 6.4: Percentage AAG inhibition at 0.1 mM (calculated from apparent [AAG] obtained by 
interpolation of absorbance values into the AAG standard curve) by purchased analogues of the 
original hit UNIS00021.  Inhibition reactions were performed using 0.1 U AAG/100 µl in 2% 
DMSO-aqueous buffer. Values are averages of 3 technical replicates and error bars indicate the 
standard deviation. * indicates that one absorbance value of the three replicates could not be 
interpolated, due to being above the plateau of the standard curve, so was entered as -150%. 
Initially, it was thought that the well washing protocol used after incubation with 
AAG may not have been sufficient to remove all traces of test compounds and that 
the latter compounds were themselves fluorescent thus increasing the signal in the 
eluate after treatment with sodium hydroxide and showing a corresponding 
apparent ‘activation’ of AAG.  To test this hypothesis, compounds UNIS00064-
UNIS00066 were dissolved at a range of three concentrations in 0.1 M sodium 
hydroxide solution and their fluorescence measured in the same type of plate and 
plate reader.  No compound showed significant fluorescence relative to blank 0.1 
M sodium hydroxide solution so this explanation was eliminated. 
This was followed by several assays in which the inhibitory εC-containing oligomer 
(εC oligo) was tested as a positive control. Also as mentioned previously, it has 
been reported that morin (UNIS00084) can act as an inhibitor against AAG with an 
IC50~2.6 µM using 2.3 nM of AAG in a gel-based excision activity bioassay.62 Since 
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morin is a small organic inhibitor, we examined its potential for use as a positive 
control. Some other compounds were also tested in these assays: UNIS00021 a 
newly purchased batch and synthesised, UNIS00067, UNIS0007, and UNIS0008 
as shown in Table 6.1. The results showed that the bioassay was working well 
based on good standard curves and that εC oligo did inhibit the enzyme in all the 
assays with an IC50~10 nM which was close to that obtained in the previous work 
by Chu using 0.05 U/ 100 µl Aag. However, the candidate inhibitor results were 
not consistent and not reliable even when the same concentration of inhibitors, 
DMSO and AAG were used (e.g. compare Assay 1 with Assay 2, column 2). 
Moreover, morin (UNIS00084) should show 100% inhibition at 100 mM based on 
the result (IC50 = 2.6 µM) from Dixon et al.62 Of greater concern were the large 
negative inhibition values observed in some instances. 
 Assay 1 Assay 2 Assay 3 Assay 4 
[AAG] /U/100 µl 0.1 0.1 0.1 0.1 0.1 0.025 
[Inhibitor] /mM 0.1 0.19 0.1 0.19 0.1 0.1 
% inhibtions  
UNIS00021 
(new purchase) 
10 ± 18 56 ± 2 -26 ± 8 28 ± 14 20 ± 24 11 ± 20 
UNIS00021 
(synthesised) 
19 ± 11 26 ± 4 -37 ± 20 19 ± 12 -3 ± 8 5 ± 13 
UNIS00084 -6 ± 3 31 ± 3 -71 ± 18 -17 ± 37 5 ± 15 2 ± 9 
UNIS00067 3 ± 10 31 ± 7 19 ± 14 2 ± 11 -57 ± 13 -7 ± 13 
UNIS00008 n.d. n.d. n.d. n.d. -34 ± 8 4 ± 14 
UNIS00007 n.d. n.d. n.d. n.d. -20 ± 38 -16 ± 6 
εC-oligo : [AAG],  0.1 0.05 0.1 0.025 
10 nM n.d. 70 ± 10 21 ±  9 57 ± 15 
20 nM n.d. 85 ± 2 57 ± 7 82 ± 8 
40 nM n.d. 89 ± 3 85 ± 1 93 ± 8 
80 nM n.d. 93 ±  2 92 ± 1 99 ± 1 
3 000 nM n.d. 74 ± 16 n.d. n.d. 
10 000 nM 100 ± 0 n.d. n.d. n.d. 
Table 6.1: Comparison of % inhibition values from repeated AAG surface-bound oligomer assays 
showing inconsistent results and anomalous, apparently negative, values.  Values are averages 
of n=3, errors are standard deviations. 
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It was thought that three factors could be responsible for the anomalous results: 
 Use of DMSO as the the solvent to dissolve the compounds:  it was found 
previously by Chu that AAG is sensitive to DMSO and shows lower activity at 
higher concentrations. It was thought that any small change in DMSO amount 
might cause these inconsistent results. Therefore it was thought to try a 
different organic solvent such us DMF to prepare the standard curve and the 
inhibitor dilutions 
 The incubation time of the compounds with the enzyme before addition to the 
substrate oligomer (inhibitor pre-incubation) was insufficient. The incubation 
was done at 0 °C. M. Dixon et. al. incubated inhibitors with AAG for ten minutes 
at room temperature before reaction with the substrate oligomer.62 Therefore, 
it is important to check the effect of the incubation time and temperature.  
 The compounds might not be completely soluble at 100 µM in the glycosylase 
buffer/ 2% DMSO from which the rest of the dilutions were prepared. If so then 
the dilutions might sometimes include precipitate and sometimes not and 
therefore be of differing concentrations.  Consequently, it was important to 
develop a method to measure the kinetic solubility of the test compounds in 2% 
DMSO-glycosylase buffer. 
These possibilities were investigated through the following experiments. 
6.2.2.2 Investigation of the effect of using DMSO as test compound 
solvent 
To check if the inconsistent and negative inhibition of the inhibitors was caused by 
dissolving the inhibitors in DMSO, published inhibitor morin was chosen to be 
tested in the absence of DMSO.  The reason for this was that it possesses five 
hydroxyl groups that makes it more likely to be soluble in water and the published 
aqueous solubility is (>151 µg/ml).203  Also, from the result in Table 6.1 it was clear 
that εC oligo inhibited AAG either in DMSO or buffer only, so it could be used as a 
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positive control. In this assay all the dilutions were kept in ice and then AAG 
enzyme was added to them to give 0.025 U/100 µl . The result shown in Figure 
6.5 B revealed that the εC oligo worked well even without DMSO. However, the 
result of the different concentrations of morin did not give gradual inhibition and 
the highest inhibition was 42% at 0.0125 mM (Figure 6.5 C). Interestingly, it was 
noticed in this assay that the apparent AAG inhibition values did not show 
overactivity of AAG indicating that, in the previous assays, this may have been due 
to a systematic error in dilutions for the AAG standard curve leading to more 
inhibitory DMSO being present than planned. 
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Figure 6.5: AAG standard curve generated using the surface-bound oligonucleotide assay. % 
Inhibition values were calculated from apparent [AAG] obtained by interpolation of absorbance 
values into the AAG standard curve.  For inhibitor testing, 0.025 U/100 µl AAG in aqueous buffer 
was used.  Values are averages of n=3-4, all dilutions were kept in ice, error bars show standard 
deviation.  
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Changing the solvent of the inhibitors from DMSO to a different one was one of the 
suggested solutions. DMF is another polar solvent with low volatility so it was 
tested in the assay in place of DMSO. Figure 6.6 shows that DMF was not as good 
a solvent for this assay since the standard curve shape was abnormal, UNIS00084 
showed, at low concentrations, apparent AAG activity greater than that in the 
absence of inhibitors (illustrated as negative % inhibiton) in some of its dilutions 
and even the εC oligo did not inhibit AAG.  From these two bioassays it could be 
concluded that this assay was very solvent sensitive. However, all of the 
synthesised UNIS00021 analogues were not water soluble and an organic solvent 
was required to prepare the stock solution of these inhibitors. It was decided to 
continue using glycosylase buffer/ 2% DMSO but to try to ensure no variability in 
DMSO concentration was produced. 
0 . 0 0 0 . 0 5 0 . 1 0 0 . 1 5 0 . 2 0
1 6 0 0 0 0
1 8 0 0 0 0
2 0 0 0 0 0
2 2 0 0 0 0
[ A A G ]
( U  /  1 0 0  u L )
F
lu
o
r
e
s
c
e
n
c
e
 (
e
lu
t
e
d
)
(
p
r
o
c
e
d
u
r
e
 d
e
f
in
e
d
 u
n
it
)
 
0 . 1 1 1 0 1 0 0 1 0 0 0
- 4 0
- 2 0
0
2 0
4 0
6 0
l o g  [ M o r i n ]  ( u M )
%
 i
n
h
ib
it
io
n
 
Figure 6.6: AAG standard curve and UNIS00084 (morin) inhibition curve generated using the 
surface-bound DNA oligonucleotide, % inhibition was calculated from apparent [AAG] obtained by 
interpolation of absorbance values into the AAG standard curve. 0.05 U/100 µl AAG in 2% DMF-
aqueous buffer was used with the inhibitor, values are averages of n=4, all dilutions were kept in 
ice, error bars show standard deviation.  
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6.2.2.3 Investigation of the effect of pre-incubation time of inhibitors with 
AAG enzyme 
In all the previous assays the test compound dilutions were pre-incubated with 
AAG on ice before adding them into the reaction plate with substrate DNA oligomer 
bound. It was decided to check the effect of applying this pre-incubation at room 
temperature as reported by M. Dixon et. al..62 For this, an assay was designed to 
check the effect of the pre-incubation of AAG dilutions at room temperature on the 
standard curve. These pre-incubations were done for five, ten, and twenty minutes 
in a water bath at 30 °C and on ice for 10 min. Interestingly, there was no significant 
difference between any of the standard curves. 
This experiment was followed by testing the effect of incubating the AAG enzyme 
with UNIS00021, UNIS00067, and morin at room temperature for ten minutes  
using 0.025 U/100 µl of AAG and 0.1 mM of the inhibitors in 2% DMSO-glycosylase 
buffer. The result was promising since UNIS00021, both synthesised and newly 
purchased, gave the same inhibition results (70 and 73% respectively). In this 
assay morin was also  tested in both  2% and 1% DMSO-glycosylase buffer and it 
seemed that with higher DMSO concentration the inhibition decreased (from 75% 
to 56%). UNIS00067 also showed 97% inhibition. 
Based on this successful assay, the same conditions were applied to generate an 
IC50 curve for morin ( 2% DMSO-glycosylase buffer, and 10 min pre-incubation 
with AAG at room temperature). Unfortunately, as shown in Figure 6.7, the two 
highest concentrations (0.2 and 0.1 mM) were less effective than lower 
concentrations and the standard deviations were large compared to those of the 
εC olilgo positive control, which incidentally inhibited AAG completely at 20 nM.
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Figure 6.7: AAG standard curve and UNIS00084 (morin) inhibition curve generated using the 
surface-bound duplex oligonucleotide,% inhibition was calculated from apparent [AAG] obtained 
by interpolation of absorbance values into the AAG standard curve. Using 0.1 U/100 µl AAG in 
2% DMSO-aqueous buffer, values are averages of n=4, all dilutions were pre-incubated with AAG 
at r.t. for ten minutes before incubation at 37 ͦC with the substrate oligomer, error bars show 
standard deviation.  
The same assay was applied to UNIS00021 to generate an IC50 curve but the 
results were similar to those with morin lower concentrations appearing to inhibit 
AAG more than higher concentrations. Also, the standard deviations were large. 
Nevertheless, given the original success, it was decided to pre-incubate inhibitors 
with AAG at room temperatue for 10 min in all subsequent experiments.  Attention 
next turned to the solubility of UNIS00021 and morin as a cause for the anomalous 
IC50 curves. 
6.2.2.4 Development of a solubility assay 
Introduction 
The last factor to be checked for causing reproducibility problems in the bioassay 
was the solubility of the test compounds. Since the above results showed a higher 
inhibition results with lower concentrations of the tested inhibitors compared to the 
higher concentrations, it was thought that this might be due to poor solubility  
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In addition, solubility is an important physicochemical property which affects the 
absorption of oral drugs so early determination in the drug discovery process is 
important.204  
Thermodynamic solubility can be measured by mixing the compound with the 
appropriate solvent and shaking it for at least 24 h to ensure equilibrium is reached. 
The mixture can then be filtered and the concentration of the dissolved compound 
determined by a suitable analytical method.205  However this method is not ideal 
for this project because the different dilutions of the inhibitors in 2% DMSO-
glycosylase buffer are used directly in the bioassay without leaving time to 
equilibrate with the solvent.  An assessment of kinetic solubility would therefore be 
preferred. 
Kinetic solubility can be measured using laser nephelometry in which precipitated 
compound can be detected by measuring the intensity of scattered light when light 
is applied to the suspension.203,205 Solubility has been measured using this method 
by preparing a stepwise dilution of a fine suspension and then the concentration 
at which turbidity just disappeared is determined using UV spectrophotometry.206 
More recently, Bevan and Lloyd measured the kinetic solubility of several drugs 
using laser nephelometry in microtiter plates.203 They prepared their dilutions from 
10 mM DMSO stock solution of the drug into an aqueous PBS buffer at constant 
5% DMSO to lessen the gradual increase in DMSO and detected the concentration 
at which precipitate formed and scattered light as the solubility. Based on this 
literature a method was developed to measure the solubility of some of the 
synthesised compounds using a Zetasizer Nano instrument which can quantify 
light scattering (mean count rate) as well as providing the ability to measure 
particle size over a wide range of concentrations using Dynamic Light Scattering 
(DLS).  
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Measuring the solubility of the inhibitors 
Bevan and Lloyd used 5% DMSO in PBS as the solvent for all the compounds so 
initially, the method was tested on two of their reported compounds which included 
prednison and morin hydrate. The highest concentration for each of them was 
prepared from 100 mM % DMSO stock solution added to 5% DMSO in PBS which 
then was diluted several times in 5% DMSO in PBS. Light scattering of each 
solution was measured using the Zetasizer Nano instrument as mean count rate. 
The mean count rate was then divided by the % transmission which is read from 
the attenuator index table in the manual as the instrument automatically adjusted 
this to optimise detection.207 On a plot of light scattering against concentration, the 
intersection between the precipitate concentrations and the dissolved 
concentrations would be equivalent to the point of compound solubility.  The result 
of the prednisone solubility was 91.50 µg/ml (0.30 mM) which is comparable to that 
found by Boven (> 179 µg/ml) (from DMSO solution by HPLC) but the mean count 
rate/% transmission of the lower concentration did not give the expected result 
where there should be almost no scattering. The same procedure was applied to 
morin hydrate but this time the two lines intersected at a point and the solubility 
was found to be 88 µg/ml which was also comparable to that found by Boven (>151 
µg/ml).  
Unfortunately, it was not possible to measure the solubility at 0 oC, which would 
match plate setup in the bioassay, because of the condensation that formed in the 
cell. However, to improve the result and to avoid any precipitation it was decided 
to prepare each dilution of the inhibitor by making separate stock solutions at 
decreasing concentrations in 100% DMSO and then diluting them to 2% DMSO-
glycosylase buffer to resemble the bioassay setup conditions. This was applied to 
test the solubility of morin hydrate in bioassay conditions and the results are shown 
in Figure 6.8.  Solubility was found to be 1.2 mM (366 µg/ml). 
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Figure 6.8: Solubility curve of UNIS00084 (morin) using 2% DMSO-glycosylase buffer as solvent, 
values are averages of n=3 
The same method was applied to measure the solubilities of UNIS00021 and 
UNIS00067 and these were found to be 0.1 mM (32 µg/ml) and 0.4 mM (116 
µg/ml), respectively.  
In conclusion, theoretically solubility should not be a problem with morin since all 
dilutions in previous bioassays were prepared from 0.2 mM in 2% DMSO-
glycosylase buffer – well below its determined solubility of 1.2 mM. However, for 
UNIS00021, solubility (0.1 mM) is lower than that of the starting dilution (0.2 mM).  
To address this, the following assays were designed to test whether the use of a 
lower concentration stock solution of the inhibitor would give more consistent 
results. 
-500000
0
500000
1000000
1500000
2000000
2500000
3000000
3500000
0 0.5 1 1.5 2 2.5
Concentration (mM)
Morin hydrate solubility curve
M
e
a
n
 c
o
u
n
t 
ra
te
/ 
tr
a
n
s
m
is
s
io
n
 
 154 
Addressing solubility through modification of dilution sequence in the 
bioassay 
In a parallel work with the solubility assay the surface-bound DNA oligomer 
bioassay was repeated by preparing morin dilutions from two different stock 
solutions: 10 mM (100% DMSO) to prepare final plate 2% DMSO/glycosylase 
buffer dilutions of 0.1 and 0.05 mM; and 5 mM (100% DMSO) to prepare final plate 
2% DMSO/glycosylase buffer dilutions of 0.05, 0.025, 0.0125 and 0.0031 mM..  
This was done so that any precipitation problems would become apparent from the 
higher concentration stock solution results compared to the lower.  The results are 
shown in the Figure 6.9. The dilutions prepared from the 5 mM stock solution 
showed high inhibition starting from 74% and there was a gradual decrease in AAG 
activity as the morin concentration increased (Figure 6.9 B).  The curve showed 
the IC50 to be 10 µM which was close to that reported by Dixon et al. (2.6 µM).62  
Yet the same two dilutions (0.1, and 0.5 mM) that were prepared from the 10 mM 
showed just slight inhibition (Figure 6.9 C). This result did not match the solubility 
result which showed that morin should be completely soluble at 100 mM in 2% 
DMSO and thus starting from a different stock solution should not affect the 
outcome of the bioassay. 
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Figure 6.9: AAG standard curve (A), UNIS00084 (morin) inhibition curve (B) and bar chart 
showing effect of diluting inhibitor from different DMSO stock concentrations (C) generated using 
the surface-bound duplex oligonucleotide, % inhibition was calculated from apparent [AAG] 
obtained by interpolation of absorbance values into the AAG standard curve. Using 0.1 U/100 µl 
AAG in 2% DMSO-aqueous buffer, values are averages of n=3, all dilutions were pre-incubated 
with AAG at r.t. for ten minutes, error bars show standard  
A further anomalous result was obtained when the bioassay of morin was repeated 
following exactly the same conditions, starting from the 5 mM (100% DMSO) stock 
solution and using 0.1 U/100 µl of AAG: No IC50 curve was obtained and some of 
the dilutions showed negative inhibition of the enzyme. Similarly, preparing 
UNIS00021 dilutions in glycosylase buffer/ 2% DMSO from a 5 mM (100% DMSO) 
stock solution and using 0.1 U/100 µl of AAG also did not give an IC50  curve and 
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there was a higher % inhibition with the lower concentrations compared to the 
higher concentrations.  
In an alternative method to reduce the likelihood of compound precipitation during 
dilution from stock solution, it was thought to prepare all the dilutions of the inhibitor 
in 4% DMSO-glycosylase before adding them to an equal volume of the AAG 
enzyme dilution, prepared in glycosylase buffer only, to obtain a final concentration 
in 2% DMSO-glycosylase buffer. UNIS00021 was used for this assay. As in the 
previous experiment, 10 and 5 mM (100% DMSO) stock solutions were prepared 
and used to make 0.4 and 0.2 μM solutions in glycosylase buffer/ 4% DMSO so 
any effect of precipitation would be limited to individual dilutions only.  All lower 
dilutions between 50 µM and 0.25 µM were prepared from a 2.5 mM (100% DMSO) 
stock solution.  The dilutions were mixed with AAG to give UNIS00021 in 
glycosylase buffer/ 2% DMSO and 0.1 U/100 μl of AAG. Unfortunately, there was 
no improvement in the consistency of the activity of each dilution (Figure 6.10) 
with the two highest concentrations giving equal inhibitions and the third highest 
showing a negative inhibition.  
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Figure 6.10: UNIS00021 inhibition curve from AAG assay using the surface-bound DNA 
oligonucleotide, % inhibition was calculated from apparent [AAG] obtained by interpolation of 
absorbance values into the AAG standard curve. 0.1 U/100 µl AAG in 2% DMSO-aqueous buffer 
was used with inhibitors, values are averages of n=4, all dilutions were pre-incubated with AAG at 
r.t. for ten minutes, error bars show standard deviation. 
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Overall, it was decided that factors other than solubility and precipitation were 
causing inconsistent and irreproducible bioassay results. 
6.2.2.5 Checking the possibility of inhibitors interfering with fluorescence  
Some purchased analogues of UNIS00021 had already been tested for 
fluorescence (Section 6.2.2.1) and shown not to fluoresce thus eliminating the 
possibility of residual compounds affecting bioassay results.  However, it was 
subsequently thought that there might be an interaction between the inhibitors and 
fluorescein, after their action on AAG, which quenches the fluorescence to an 
extent depending on how much compound remained on the plate. 
To test for fluorescence quenching, an assay was designed to use just free (not 
surface-bound) DNA-fluorescein complex (HX01/REP04) and mimic the alkali–
mediated DNA-fluorescein release step without the need to do the ligation step or 
the AAG treatment. The concentration of the HX01/REP04 was chosen according 
to the fluorescence reading that gave an ‘eluted fluorescence signal’ which is 
corresponded to approximately 50% AAG inhibition and that was found to be 50 
nM as shown in Figure 6.11.  HX01/REP04 was mixed with morin and UNIS00021 
at several concentrations in alkaline denaturation buffer then incubated at 37 °C 
for 2 h to mimic the final step of the assay.  Fluorescence was then measured in 
the plate reader and the results are shown in  Figure 6.11. It was clear that there 
was no effect of UNIS00021 on fluorescence since the same fluorescence level 
was detected for each concentration. Also, there was no quenching of 
fluorescence by morin but morin was itself fluorescent and increased fluorescence 
corresponding to its concentration.  
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Figure 6.11: Measured fluorescence from different concentrations of fluorescent oligo complex 
(left) and the effect of the presence of inhibitors on fluorescence (right). All dilutions in 100% 
alkaline denaturation buffer (0.1 xSSC, 0.1 M NaOH), [HX01/REP04]=50 nM, values are 
averages of n=3, error bars show standard deviation. 
6.2.3 Summary of surface-bound 3-component fluorescent 
DNA oligomer bioassay 
In summary, although considerable effort was made to explain anomalous results 
from this bioassay and improve it, IC50 curves remained inconsistent and 
irreproducible.   Furthermore, apparent overactivity of AAG was observed with 
some dilutions of (even published) inhibitors.  At this point it was decided to try a 
different microplate-based assay which was giving consistently good results on 
another project investigating DNA repair enzyme activities. It also used a duplex 
DNA oligonucleotide substrate bound covalently to the surface of functionalised 
96-well plates but consisted of only 2 components due to the inclusion of a hairpin 
loop.  The fluorescein molecule was also held closer to the plate. In parallel work, 
a third bioassay was designed to use LCMS to assess AAG activity by quantifing 
the excised base in solution.  These will be described in the following sections.  
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6.3 Microplate surface-bound hairpin loop fluorescent 
DNA oligomer assay  
Given the ongoing problems with the 3-component fluorescent DNA oligomer 
assay, it was decided to try a slightly different experimental method, which had 
already been used successfully by another student investigating DNA repair 
enzyme activities. In this assay, in place of the linear double stranded 
oligonucleotide complex, a  hairpin oligonucleotide structure is immobilised to the 
microplate wells. Construction of the hairpin loop is achived by coupling single 
stranded oligonucleotide HX02 to the surface of the wells and then hybiridizing and 
ligating oligonucleotide Loop01 to it (Figure 6.12). 
In addition to this change, a more sensitive fluorescein detection method was 
employed, again also discovered in parallel work.  This used antifluorescein-horse 
radish peroxidase (HRP) conjugate colorimetric detection system whereby the 
antibody conjugate binds to remaining fluorescein on the plate and the conjugated 
HRP enzyme converts an added substrate 3,3',5,5'-tetramethylbenzidine (TMB) to 
a product which is blue in colour.  This amplifies the signal originally resulting from 
retained fluorescein-linked oligomer. 
Initial experiments were performed to determine appropriate concentrations of the 
oligonucleotides to use in the assay. The desired AAG standard curves were 
successfully obtained and a concentration of 0.1 pmol/well oligonucleotide HX02 
was selected for subsequent experiments. 
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Figure 6.12: The hairpin loop oligomer structure used for AAG surface-bound oligomer assay. 
HX01+Loop01 is the substrate designed to assess AAG activity; yellow highlight-fluorescein 
moiety;; blue highlight-hairpin loop.202  
Next, an experiment was designed to test the effects of some of the candidate 
compounds on AAG activity, using a final microplate concentration of 0.05 mM of 
each compound and 0.05 U/100 µl AAG.  The compounds tested both synthesised 
and purchased UNIS00021. The standard curve obtained with serial dilutions of 
AAG was as expected and 0.05 U/100 μl AAG was at an appropriate position on 
the linear portion of the curve to allow inhibition to be quantified.  However, both 
synthesised and purchased UNIS00021 and some other inhibitors again showed 
apparent overactivity of AAG with large error bars (Figure 6.13).  
 
 
 161 
0 .0 0 .2 0 .4
0 .0
0 .5
1 .0
1 .5
[A A G ]
(U  / 1 0 0  u L )
A
b
s
o
r
b
a
n
c
e
(p
r
o
c
e
d
u
r
e
 d
e
fi
n
e
d
 u
n
it
)
 
5
6
5
7
5
8
5
9
6
0
6
1
6
2
6
3
6
4
*
6
4
6
5
6
6
6
7
6
8
6
9
7
0
7
1
7
2
7
3
7
4
2
1
*
2
1
0
7
0
8
- 5 0
0
5 0
C o m p o u n d  b e g in n in g  U N IS 0 0 0 ..
%
 i
n
h
ib
it
io
n
 
Figure 6.13: AAG standard curve generated using the surface-bound duplex oligonucleotide 
(Loop01) assay and measuring absorbance (left). % Inhibition values from candidate inhibitors 
(calculated from apparent AAG activity obtained by interpolation of absorbance values into the 
AAG standard curve).  Inhibition reactions were performed using 0.05 U AAG/100 µl reaction in 
2% DMSO-aqueous buffer. Values shown indicate averages of n=3 and error bars indicate 
standard deviation. *Synthesised UNIS00021 
This assay was repeated twice using 0.1 mM of each candidtate inhibitor and again 
the level of inhibition of the inhibitors were not the same in all the assays with also  
apparent overactivity of AAG with some of the inhibtiors.  
Further assays suggested that  UNIS00021 at 0.1 mM only marginally inhibited 
AAG, while purchased UNIS00021 showed 37% inhibition (Figure 6.14). 
Hypothesising that an impurity could be responsible for the apparent activity of the 
purchased UNIS00021, the purity of the same samples was analysed using LCMS. 
The result showed that the synthesised version was pure and there was a very 
small impurity peak in the purchased one with a mass of 659 m/z in the positive 
mode corresponding to the mass of the disulfide dimer of UNIS00021. However, it 
was not possible to isolate it given the small sample size. Hence an effort was 
made to synthesise the disulfide dimer of UNIS00021 but it was unsuccessful.  
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Figure 6.14: AAG standard curve generated using the surface-bound duplex oligonucleotide 
(Loop01) assay and measuring absorbance (left): % Inhibition values (right, calculated from 
apparent [AAG] obtained by interpolation of absorbance values into the AAG standard curve) of 
purchased analogues of the original hit UNIS00021.  Using 0.1 U/100 µl AAG in 2% DMSO-
aqueous buffer, values are averages of n=4, error bars show standard deviation. * Synthesised 
UNIS00021 
In most AAG activity assays described in the literature, bovine serum albumin 
(BSA) is included as one of the components of the buffer. Elliott had not found this 
necessary for the surface-bound assays202 but O’Brien et al. found that low 
concentrations of AAG enzyme are susceptible to inactivation within minutes to 
hours under the standard reaction conditions. However, they found that this 
problem could be overcome by adding BSA (0.1 mg/ml) or ovalbumin (0.1 mg/ml) 
which can stabilise even very low concentrations of AAG (~1 nM) for more than 24 
h at 37 °C.34  It was hypothesised that AAG being unstable and its stability affected 
by changes in the solution, such as the concentration of candidate inhibitors, could 
have been leading to the inconsistencies between bioassays.   
An assay was designed to check the effect of BSA on stabilising the AAG enzyme 
and whether its incorporation would lead to more consistent standard curves and 
consistent inhibitor IC50 curves. The BSA concentration used in most of the 
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literature is 100 ug/ml so this was used in the hairpin loop bioassay alongside an 
assay without BSA on the same plate.62 UNIS00021, morin and εC oligo were 
tested in this assay2017-05-23- Aag Hairpin loop Colorimetric Assay - BSA coat 
test PROTOCOL morin+UNIS00021 (1). The colour development of the standard 
curve and so the absorbance readings were better when BSA was included 
(Figure 6.15 A). The signal difference between the Aag concentration used with 
the inhibitors (0.1 U/100 ul)  and the 0 U/100 µl was very small with no BSA (0.09) 
which can not give an indication of the inhibitors’ effect. Yet, the difference in in the 
absorbance signals when BSA was included was 0.33 which was enough to show 
inhibition.  Interestingly, repeating this assay to check the consistency of the 
standard curves gave approximately the same curves. The εC oligo curve showed 
an IC50~ 5 nM (Figure 6.15 B) which was close to that reported, and both 
UNIS00021 and morin showed increases in inhibition with concentration but the 
curves were shallow and showed negative inhibition at low concentrations and that 
was more negative in the assay with BSA (Figure 6.15 C and D).  
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Figure 6.15:  The effect of adding 0.1 mg/100 ul BSA into the AAG glycosylase buffer on the 
standard curve and inhibition curves ([AAG] = 0.1 U/100 µl, values of average n=3, all [AAG] 
dilutions were pre-incubated with AAG at r.t. for 10 min before incubation at 37 ͦC with the 
substrate oligomer. Error bars show standard deviation. 
It was also thought to coat the plate with 0.1 mg/100 µl BSA as an extra step after 
loading of the first oligomer and either before hybridisation or after for 1 h or 
overnight. This was mentioned in the Thermo Scientific NuncTM Immobilizer Amino 
instruction protocol as an additional recommendation to quench the remaining 
reactive groups on the plate surface. This step was tested keeping also 0.1 mg/100 
µl BSA in the glycosylase buffer. The results are shown in Figure 6.16 and reveal 
little difference between including the BSA coating step and not.  Interestingly, in 
these assays, εC oligo showed good inhibition curves with IC50 again ~5 nM, but 
UNIS00021 showed no inhibition  and only a small amount of negative inhibition 
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at the start of the curve.  Morin only began to show inhibition at very high 
concentration (200 µM) and also still showed negative inhibition at lower 
concentrations. 
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Figure 6.16:  The effect of adding 0.1 mg/100 µl BSA into the AAG glycosylase buffer on the 
standard curve and coating the plate with 0.1 mg/100 µl BSA . [AAG] = 0-0.4 U/100 µl, values of 
average n=3, all [Aag] dilutions were pre-incubated with Aag at r.t. for ten minutes before 
incubation at 37 ͦC. error bars show standard deviation 
In summary, the presence of BSA in the assay buffer was found to make standard 
curves more robust but negative inhibition was still observed at low concentrations 
of candidate inhibitors.  It was also looking more likely that UNIS00021 was not a 
real, specific inhibitor of AAG. 
 166 
6.4 A free substrate oligomer assay using LCMS  
Liquid chromatography coupled with single stage and tandem mass spectrometers 
(LCMS) is increasingly used in pharamaceutical research and development. This 
is due to its high-throuput determinations of drug concentrations in biological 
samples.208-210 
It was thought that designing an LCMS-based assay would permit the use of label-
free, non-bound substrate DNA oilgomer would dramatically simplify the assay and 
could solve the problems of inconsistent and irreproducible inhibitor curves 
encountered with the surface-bound fluorescein-linked DNA oligomer assays.   
In this assay, AAG enzyme would be added to a solution of a free substrate oligo 
containing the damaged base hypoxanthine (Hx).  On incubation at 37 °C, AAG 
should excise the Hx into solution and heating the plate to 65 °C after a set time 
should denature AAG and halt the reaction.  Excised Hx could be quantifid using 
a Q-Exactive Plus Orbitrap Mass Spectrometer combined with UltiMate™ 3000 
LC. 
In order to design this assay the following points needed  to be studied: 
1. Optimisation of an LC method and column to seperate the buffer 
components, DNA oligomers, AAG enzyme and inhibitors from Hx and an 
internal standard. This is important to avoid ion suppression which might 
cause a low signal for the target components peaks. This should be followed 
by reducing the period of time to run each sample to minimize the time 
required to run a whole 96-wel plate based assay. For this, a shorter LC 
column should be used to maintain sensitivity.  
2. The limit of detection (LOD) of hypoxanthine by the instrument to inform the 
concentration of substrate oligomer and AAG that should be used to give a 
detectable signal at a fraction of AAG’s full activity in order to detect the 
action of inhibitors. 
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3. Find the best internal standard that can be added to the assay samples that 
does not affect AAG’s activity itself.  The presence of internal standard in the 
calibration curve and the unknown samples of the assay is important since 
there will be 96 samples running overnight in which variations in the 
sensitivity of the instrument could alter the peak sizes of detected ions. This 
should be normalized by considering the ratio of peaks for Hx and the 
internal standard at constant concentration.  The internal standard should 
have a molecular weight and structure that is close to the target analyte in 
an attempt to match ionization and detection levels. 
6.4.1 Development of an LC Method 
One property which affects the separation of sample components by LC is their 
pKa (along with the pH of the mobile phase) since ions should have a lower affinity 
for the reverse phase than neutral molecules and hence a shorter retention time.  
The pKa values of proposed sample components of the LCMS bioassay are shown 
in Figure 6.17 and represent an aim to select those which would be ionized while 
Hx remained neutral. Tris(2-carboxyethyl)phosphine (TCEP) is a reported 
alternative, odorless reducing agent to β-mercaptoethanol and is stable in acidic 
and basic solutions.211 Although, no literature reported its use in the AAG assays, 
it was decided to check its use here since it would be easily ionized compared to 
β-mercaptoethanol.  
During LC method development, it was found that the main buffer component used 
previously, Tris, remained on the column for a long time, giving a long-tailing peak 
on the chromatogram which overlapped other peaks.  Interestingly, a buffering 
compound 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) has also 
been reported for use in AAG assay buffer and it was found to elute with a sharper 
peak shape.62  
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Figure 6.17: Glycosylase buffer components  
Several attempts were made to separate the buffer components and hypoxanthine 
using a Phenomenex Onyx Monolithic C18 (100 mm × 2 mm) column, different LC 
solvents (MeCN and MeOH) and aqueous buffers, such as formic acid 0.1% 
(pH~2.7) or ammonium acetate 10 mM (pH~3.8-5.8) and normal LC water, and 
different LC gradients. However, all these attempts failed to separate them and 
they were eluted vey quickly from the column along with the hypoxanthine.  
It was decided to change the column to the Hyperclone ODS (C18) 150 mm x4.6 
mm column containing 5 µm silica. Intrestingly, this column showed a slight 
separation. This was followed by several attempts to find the best separation 
conditions using a 7 minute run. These conditions included changing the gradient 
of the solvents, buffers, flow rate and the mode of electrospray (positive or negative 
mode). The best conditions found for seperation was to use the mobile phase 
acetonitrile in aqueous ammonium acetate using the positive mode of the MS and 
flow rate of 1 ml / min.  The gradient was as follows:  0-1 min, 5% MeCN, 1-7 mins, 
5-100% MeCN, 7-8 mins, 5% MeCN (Table 6.2 and Figure 6.18). 
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Component MW 
Retention time 
/min 
Hypoxanthine 136.12 2.10 
TCEP 250.19 1.25 
HEPES 238.1 1.60 
EDTA 292.24 1.28 
Tris 121.14 1.35 
β-mercaptoerhanol  78.13 1.83 
UNIS00021 330.45 5.30 
Table 6.2: Retention time of glycosylase buffer components by LCMS using MeCN in ammonium 
acetate (pH 7); 0-1 min, 5% MeCN, 1-7 mins, 5-100% MeCN, 7-8 mins, 5% MeCN 
Since the retention time of β-mercaptoethanol was very close to hypoxanthine it 
was decided to substitute it for TCEP. As discussed above, tris showed a long, 
trailing peak so was substituted for HEPES.  
 
Figure 6.18: Chromatogram with the retention time of the glycosylase buffer components using 
the Q-Exactive Plus Orbitrap Mass Spectrometer 
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These conditions were used to determine the limit of detection for hypoxanthine 
(LOD) in this instrument. Several dilutions of hypoxanthine were tested (25 - 0.382 
nM). Unfortunately, the results showed that the LOD of the hypoxanthine was only 
25 nM. a lower LOD was required so an affordable concentration of substrate 
oligomer and AAG enzyme could be used in the assay.  
One way to increase the sensitivity to hypoxanthine was to use a smaller column 
and shorter run time with a lower flow rate to give taller peaks.  
On advice from the Phenomenex company a new column, Luna Omega PS-was 
tested. It has a positively charged surface in between the C18 chains wich would 
help to repel the hypoxanthine’s delta-positive nitrogen functional groups helping 
to minimise tailing and give a better peak shape.  
Therefore, this column was used to check first its ability to separate the 
components. Again, many attempts were made to optimise conditions as shown in 
Table 6.2. Entry 6 showed the best separation in the shortest time. 
A new assessment of the LOD using these conditions and several dilutions of 
hypoxanthine (195 - 0.76 nM) prepared in 2% DMSO / 20 mM HEPES (pH 7.8) / 5 
mM EDTA / 5 µM TCEP / 100 mM KCl as the new AAG glycosylase buffer. In this 
test 12 nM of caffeine was added as the internal standard which showed a retention 
time at 4.3 minute. This gave the calibration curve shown in Figure 6.19 which 
could be used to determine the LOD of hypoxanthine by calculating the standard 
deviation, multiplying it by 3 and adding the result to the apparent concentration 
derived from (the noise of) a blank sample.  The LOD was determined in this way 
to be 6 nM. Unfortunately, the chromatogram did not show a defined peak for the 
12 nM caffeine although it was detectable when run at 50 nM.  
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Conditions Component 
Retention 
time 
1.ESI Negative, MeCN in water: 0-2 min, 0%; 2-5 min, 0-100%, 5-7 
min, 0% EDTA 0.43 
 TCEP 0.47 
 HEPES 0.67 
 Hypoxanthine 0.93 
 UNIS00021 4.75 
2.ESI Positive, MeCN in ammonium bicarbonate (pH 8): 0-2 min, 0%; 
2-5 min, 0-100%, 5-7 min, 0% EDTA 0.43 
 TCEP 0.48 
 HEPES 0.68 
 Hypoxanthine 0.89 
 UNIS00021 4.68 
3.ESI Positive, MeCN in water, 1% formic acid: 0-2 min, 0%; 2-5 min, 
0-100%, 5-7 min, 0% EDTA 0.42 
 TCEP 0.79 
 HEPES 0.65 
 Hypoxanthine 0.96 
 UNIS00021 4.72 
4.ESI Positive, MeCN in ammonium acetate (pH 7): 0-2 min, 0%; 2-5 
min, 0-100%, 5-7 min, 0% EDTA 0.43 
 TCEP 0.43 
 HEPES 0.72 
 Hypoxanthine 1.03 
 UNIS00021 4.78 
5.ESI Positive, MeCN in ammonium acetate (pH 7): 0-2 min, 0%; 2-5 
min, 0-100%, 5-7 min, 0% (Q-Exactive Plus Orbitrap Mass 
Spectrometer) EDTA 0.24 
 TCEP 0.25 
 HEPES 0.39 
 Hypoxanthine 0.92 
 UNIS00021 4.6 
6.ESI Positive, MeCN in ammonium acetate (pH 7): 0-1 min, 0%; 1-3 
min, 0-100%, 3-4 min, 100-0%, 4-5 min, 0% (Q-Exactive Plus 
Orbitrap Mass Spectrometer) EDTA 0.24 
 TCEP 0.25 
 HEPES 0.4 
 Hypoxanthine 0.86 
 UNIS00021 2.1 
Table 6.3: Retention times of glycosylase buffer components by LCMS using Luna Omega PS 
column 
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Figure 6.19: Calibration curve of several dilutions of hypoxanthine detected by the Q-Exactive 
Plus Orbitrap Mass Spectrometer, all dilutions were in 2% DMSO in HEPES, values are averages 
of n=3 
Several compounds of similar structure to hypoxanthine were tested for use as 
internal standard (Figure 6.20). Theobromine (180.164 g/mol) was found to have 
a retention time of 3.30 min using the same condition in Table 6.3 entry 5 so it was 
used in the first LCMS-bioassay.  
 
Figure 6.20: Different compounds tested as internal standard 
6.4.2 Design of the LCMS-based bioassay 
After developing an LCMS method to separate proposed new components of an 
AAG assay buffer system from hypoxanthine, the new buffer of 20 mM HEPES, 5 
mM EDTA, 5 uM TCEP and 100 mM KCl were tested in the former bioassay to 
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generate a standard curve which was usually reproducible.  The new HEPES-
based buffer showed a comparable standard curve to the original tris buffer. 
The next step was to design a simple substrate DNA oligomer. The shortest used 
with AAG in an assay (32P-labelled, gel-based) and reported in the literature is a 
25-mer so a 25-mer equivalent of the oligomer used in the surface-bound assay 
was used to decrease costs and hypoxanthine was incorporated as the damaged 
base (Figure 6.21). 
 
Figure 6.21: 25-mer DNA oligomer designed for use as substrate in the LCMS assay 
Since the LOD of the hypoxanthine was 6 nM, the AAG enzyme and substrate 
oligomer concentrations used needed to be calculated so that the 6 nM would be 
a fraction (or high % inhibition) of the maximum produced by AAG in the specified 
time at the fixed concentration of AAG used to test inhibitors.  The chosen fraction 
was 3% maximum AAG activity which would correspond to release of 
hypoxanthine at 200 nM concentration for 100% AAG activity.  According to AAG 
manufacturer’s specifications, one unit (U) of the enzyme was defined as the 
amount of enzyme required to release 1 pmol of hypoxanthine per hour assuming 
there is excess substrate.  To reduce expense, a reaction volume of 50 µl and an 
incubation time of 2 h was chosen thus requiring 5 U of AAG (10 U/100 µl) to 
produce a 200 nM hypoxanthine solution.  An excess of substrate oligomer was 
required for this not to be a limiting factor and this excess was chosen to be 5-fold 
which was 1 µM.  
After 2 h of incubation, the reaction would be quenched by 15 minutes incubation 
at 65 oC to deactivate the enzyme.62   It was decided to add the internal standard, 
theobromine into the buffer to be one of the components during all steps. This was 
to decrease the pipetting error since the reaction volume was very small. However, 
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theobromine had not been tested against the AAG enzyme and so several dilutions 
of it were also made up for testing of its effect on AAG activity.  
6.4.3 Results of the LCMS-based assay 
The first experiment was to generate the AAG standard curve so AAG 
concentrations either side of the fixed 10 U/100 µl chosen for use with inhibitors 
(0-40 U/ 100 µl). Standard curves were tested with and without BSA and a 
calibration curve of hypoxanthine vs theobromine was included in every LCMS run.  
Standard curves were generated successfully as shown in Figure 6.22. The 
concentration of BSA prepared was accidentally 10-fold too dilute (10 µg/ml) so 
the standard curves almost look the same. Surprisingly, despite the calculations of 
how much AAG to use to release 200 nM hypoxanthine at 10 U/100 µl, this 
concentration actually produced almost 900 nM hypoxanthine.  Hence it was 
reduced to 1.25 U/100 µl in subsequent assays. 
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Figure 6.22: Standard curves generated using free substrate oilgomer and the Q-Exactive Plus 
Orbitrap Mass Spectrometer, all dilutions were in 2% DMSO-glycosylase buffer with or without 
BSA, 50 nM theobromine, values of average n=3, all dilutions were pre-incubated with AAG at r.t. 
for ten minutes before incubation at 37 °C with the substrate oligomer. LC-MS conditions: 
acetonitrile in 10 mM ammonium acetate (pH 6.9) 0-1 min: 0%, 1-3 min: 0-100%, 3-4 min: 100%, 
4 min: 100-0%, 4-5 min: 0%.  Error bars show standard deviation. 
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However, the extracted ion chromatograms of theobromine showed high levels of 
noise (Figure 6.23) which gave high standard deviations. Therefore, it was 
decided to increase its concentation in the buffer to 300 nM since it did not show 
any inhibition result against AAG in this assay up to 2.5 µM.  
 
Figure 6.23: The chromotgram of 50 nM theobromine obtained from Q-Exactive Plus Orbitrap 
Mass Spectrometer 
The next two assays were planned to test inhibitors εC oligo, UNIS00021, 
UNIS00067 and morin using 300 nM of theobromine and 1.25 U/100 µl AAG with 
the inhibitors dilutions. Unfortunately, in these two attempts there were a dramatic 
reduction in peak areas and that was clear in the calibration curves as shown in 
Figure 6.24.  
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Figure 6.24: Calibration curves from three LCMS- based assays using Q-Exactive Plus Orbitrap 
Mass Spectrometer. All dilutions were in 2% DMSO-glycosylase buffer, values of average n=3. 
LC-MS condition: acetonitrile in 10 mM ammonium acetate (pH 6.9) 0-1 min: 0%, 1-3 min: 0-
100%, 3-4 min: 100%, 4 min: 100-0%, 4-5 min: 0%.   
This could be due to a reduction in the cone temperature (inlet temperature) of the 
MS instrument compared to the last experiment (300 oC). Another factor could be 
contamination of the cone and this was hypothesised to be due to the high 
concentration of buffer components passing into the mass spectrometer. 
Therefore, it was deemed necessary to use the divert valve, which can be 
programmed to switch at specified run times, after the LC to direct everthing but 
hypoxanthine and internal standard to waste. A summary of the divert valve 
schedule and assay component concentrations and retention times is shown in 
Table 6.4.  Based on this data the KCl, TCEP, EDTA and HEPES were eluted 
earlier than the analyte and theobromine, and the DNA,  BSA, and UNIS00021 
were eluted much later than the analyte and theobromine so the divert valve 
timings were proposed as shown in Table 6.4. 
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Component 
Concn 
(uM) 
MW Concn 
RT 
(min)* 
Proposed 
divert schedule 
KCl 100000 74.5 7.45 mg/mL 0.2 
0.0-0.7 to waste 
0.7-1.1 to MS 
1.1-1.7 to waste 
1.7-2.0 to MS 
2.0-5.0 to waste 
 
HEPES 20000 238.30 4.77 mg/mL 0.2 - 0.6 
TCEP 5000 286.65 1.43 mg/mL 0.2 - 0.3 
Hypoxanthine 1 136.11 0.14 ug/mL 0.8 - 1.0 
BSA  66399.00 100.00 ug/mL 3.3 - 3.6 
DNA 25-mer 1 7839.10 7.84 ug/mL 2.8 - 3.2 
Theobromine 
(int. std.) 
0.3 180.16 54.05 ng/mL 1.8 - 2.0 
Inhibitors (e.g. 
UNIS00021) 
200 290.39 58.08 ug/mL 2.1 
*acetonitrile in 10 mM ammonium acetate (pH 6.9) 0-1 min: 0%, 1-3 min: 0-100%, 3-4 
min: 100%, 4 min: 100-0%, 4-5 min: 0%. 
Table 6.4: Concentrations and retention times of the buffer and assay components using the 
LCMS 
Using this method ten samples of just the buffer components and 1 uM of the DNA 
oilgo were tested and no contamination of the MS instrument was detected. 
However, the extracted ion chromatogram of theobromine still showed lots of 
noise. Therefore, it was decided to search for a different internal standard which 
should be eluted close and after the hypoxanthine. Two interesting compounds 
were considered to check their retention time: mercaptopurine (pKa= 7.71) and 3-
methylxanthine (pKa= 2.3) (Table 6.5). Mercaptopurine was chosen since it eluted 
earlier and would allow a single switch of the divert valve to MS. 
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Compound 
  
Retention time 
(min) 
1.46 2.85 
Table 6.5: The retention time of other internal standard, LC-MS condition: LC-MS condition: 
acetonitrile in 10 mM ammonium acetate (pH 6.9) 0-1 min: 0%, 1-3 min: 0-100%, 3-4 min: 100%, 
4 min: 100-0%, 4-5 min: 0%. 
Using this method the last assay was repeated using the same conditions. The 
standard curve was successful but the calibration curve was poor. Closer 
inspection of the chromatograms showed some hypoxanthine extracted ion 
chromatogram peaks to be bimodal as shown in Figure 6.25 indicating carryover 
of hypoxanthine and that was more noticeable in the last replicate of the calibration 
curve. This caused incorrect integration of the hypoxanthine peaks.   
 
Figure 6.25: The chromatogram of the hypoxanthine bimodal peak and accurate mass spectrum 
proving it is hypoxanthine. 
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It was first thought that the hypoxanthine was trapped in the MS after switching to 
the waste. However, that should not be correct because the hypoxanthine 
chromatogram peak was normal in the standard curve and also with the inhibitors 
results. Subsequently it was hypothesised that the internal standard, 
mercaptopurine was hydrolysing into hypoxanthine since it was the last compound 
to enter the MS before the divert valve switched to waste. Residual mercaptopurine 
might sit in electrospray chamber at high temperature and be hydrolysed to 
hypoxanthine which is then detected when flow returns to the MS on subsequent 
run and divert valve switch to MS. This problem could be solved by running the 
last 1.5 minutes of the run (which should be pure MeCN then pure aqueous mobile 
phase) to MS to wash the electrospray chamber. 
Interestingly, this time the result in all the runs showed the hypoxanthine as a single 
peak and there was no sign of the bimodal peak, indicating that all the internal 
standard residues had been washed off before the next run as shown in Figure 
6.26. Also, the standard curve was much better compared to the previous LCMS 
assay standard curves (Figure 6.27 A). 
 
Figure 6.26:  The total ion count and extracted ion chromatogram peaks of hypoxanthine and 
mercaptopurine obtained from LCMS-Orbitrap 
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Another concern about the result of this assay was that there was no inhibition by 
any candidate inhibitors, even the εC oligo and, strangely, the assay showed that 
hypoxanthine was produced by 1.25 U/100 uL AAG in the presence of inhibitors to 
a greater extent than the 1.25 U/100 uL point on the standard curve. It was 
hypothesised  that inhibitors stabilise AAG against denaturation during heat 
treatment reaction quench at 65 oC and a higher temperature was needed to 
denature the enzyme in the presence of inhibitors. 
Therefore, this assay was repeated but the enzyme was deactivated at 80 °C for 
15 minutes.    This time the hypoxanthine produced by 1.25 U AAG/100 µl in the 
presence of the ethenocytidine and UNIS00021 was not greater than that 
produced by the 1.25 U/100 µl point on the standard curve, indicating that the 
enzyme was completely deactivated. Yet both inhibitors showed about the same 
amount of hypoxanthine production which did not decrease with inhibitor 
concentration Figure 6.27 B and C). It was hypothesised that this could be due to 
the high amount of both enzyme and substrate used compared to inhibitor. The 
IC50 of the εC oligo in the surface-bound fluorescein-linked oligomer assay was 
about 5 nM using 0.05-0.1 U/ 100 µl of AAG and 0.1 pmol/ 100 ul (1 nM) substrate 
oligomer. The amount of the enzyme used in LCMS was 1.25 U/ 50 µl, which is 
50-25 times more concentrated, and the substrate was 1 µM which is 1000-fold 
higher than 0.1 pmol/ well (assuming that is all coupled to the plate and forms 
complete ligation complex). Correlating this to the εC oligo concentration of 320 
nM, the highest concentation used in both assays, it was around 320-fold excess 
over substrate in the surface-bound assay whereas in the LCMS-assay it was in 
only 0.32-fold excess. Combining  this with the 50-fold increase in the enzyme 
concentration in the LCMS assay meant that the inhibitor was at a concentration 
far lower than that required to show inhibition. 
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Figure 6.27: AAG standard curve (A) using the free substrate oilgo and the Q-Exactive Plus 
Orbitrap Mass Spectrometer;  inhibition curves for εC oligomer (B) and UNIS00021 (C).  All 
dilutions were in 2% DMSO-glycosylase buffer containing 0.1 mg/100 ul BSA, values are 
averages of n=3, error bars show standard deviation. 
Unfortunately, time constraints prevented any further research into optimising the 
LCMS-based assay. 
6.5 Conclusion: Artifactual inhibition and aggregation 
Three assays were investigated for the assessment of the potency of candidate 
inhibitors of AAG.  Although all could be used to generate an appropriate standard 
curve for increasing AAG concentrations and the surface-bound hairpin loop 
oligomer assay generated correct inhibition curves for εC oligo, the curves for 
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UNIS00021 and morin were inconsistent and irreproducible.  Such characteristics 
of a candidate inhibitor can be attributed to non-specific inhibition of AAG by 
aggregation.212,213 Shoichet reported that many drug-like organic molecules that 
passed Lipinski rules aggregate into colloid-like particles in aqueous media at 
micromolar and submicromolar concentrations.212 These types of inhibitors can 
sequester protien targets and inhibit them in a non-specific manner. He found that 
these types of inhibitors were reversible by dilution and they can inhibit multiple 
enzymes.  Also, Shoichet mentioned that increasing the amount of the target 
enzyme or adding large amounts of BSA diminished the potency of these 
compounds. This was noticed in our results in the  AAG hairpin loop assay in which 
there were almost no inhibition with all the dilutions in the presence of BSA. 
Shoichet proved their hypothesis by measuring the particle size of aqueous 
mixtures of these inhibitors using DLS and transmission electron microscopy. They 
found that the particles were larger than the target enzymes by up to two orders of 
magnitude, being hundreds of nanometers in diameter DLS. The aggregation 
reduces the concentration of monomer and leads to false potencies especially if 
the actual monomer concentration is much less than the total compound 
concentration.213 Shoichet concluded that these type of compounds were non-
competitive, their inhibition was time-dependent with steep dose-response curves, 
high sensitivity to enzyme concentration and to detergent. Interestingly, one of his 
reported compounds was morin which might explain its inhibition behaviour against 
the AAG enzyme in the Dixon paper but not in the assays reported here.62,212 This 
could also be the case for UNIS00021.  In the future, to prove this, assay conditions 
should be found which show these molecules to have inhibition curves and then 
the assay should be repeated in the presence of a detergent to examine whether 
all inhibitory activity is lost, as would be the case if inhibition was through non-
specific aggregation. 
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7. Conclusion and Future Work  
The research described in this thesis involved the design and development of 
synthetic routes to small molecule candidate AAG inhibitors. These were based on 
a hit triazole-thione-based compound UNIS00021 that had been shown to have an 
IC50 of ~68 µM against AAG in a biochemical assay. 
In summary, a robust synthetic method to vary the alkyl group of the amide in 
UNIS00021 has been developed. The key step was cyclisation of a 
thiosemicarbazide and it was found that the most successful conditions were to 
heat it at reflux in 1 M aqueous NaHCO3 because then it cyclised into the desired 
triazole-thione acetic acid in 86% yield. Out of this synthesis five different novel 
amide analogues of the hit cmopund have been synthesised successfully using 
amide coupling reactions: iPr (UNIS00067, 50%), Me(UNIS00068, 47%), 
(cyclopropyl (UNIS00069, 52%), N-Methyl-N-cyclohexyl (UNIS00070, 40%) and 
also the hit compound UNIS00021 (20%). Also, the equivalent primary amide 
(UNIS00074) was made (50%) by reacting the corresponding 1,2,4-triazole-thione 
nitrlie with TFA-H2SO4 at RT.  
To synthesise analogues of UNIS00021 with a free amine in place of the amide 
and with variation in the length of the alkyl linkage group a robust  synthetic method 
was developed. Similarly, this was achieved by synthesising the corresponding 
thiosemicarbazides, after protecting the amine using a Boc group, and cyclising 
them in 1 M NaHCO3 at reflux. Removing the Boc group to provide the free amine 
was a challenge in this synthesis and it was solved using HCl/EtOAc (1:1). Out of 
this synthesis novel cyclohexyl (UNIS00077, UNIS00082) and isopropyl amines 
(UNIS00078, UNIS00083), each with two lengths of linkage, and methyl amine 
triazole thione with n=1 linkage (UNIS00079) were produced using reductive 
amination of the free primary amines. 
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A one-pot synthesis was also developed to access an analogue of UNIS00021 
bearing a C5-methyl group instead of thiol/thione. The key step in this synthesis 
was to cyclodehydrate the intermediate acyl amidrazone, synthesised by activating 
benzyl acetylamide and reacting it with hydrazide acetoester, to give a triazole 
acetoester which was then hydrolysed to the acid using LiOH in THF/water. This 
was then used to produce the isopropyl amide UNIS00089 in 60% yield in an amide 
coupling reaction. 
A synthesis of analogues of UNIS00021 varying at the phenyl group was designed 
to use Suzuki-Miyaura cross-coupling of a trifluoroborate precursor but it was not 
completed due to time limits and only the first three steps of this route were 
established successfully. The triazole-thione ester was synthesised in one step by 
reacting thiosemicarbazide with an imidate.  This was followed by hydrolysis into 
the acid using LiOH in THF/water. This could be then used to synthesis the 
cyclohexylamide triazole-thione.  
To test the activity of these synthesised compounds and other purchased 
analogues of the original hit UNIS00021 against the AAG enzyme, two types of 
AAG bioassay using a surface-bound fluorescein-linked duplex DNA 
oligonucleotide substrate were investigated and optimisation of a novel LCMS-
based assay was also begun. The two types of AAG surface-bound oligomer 
bioassays revealed that the hit UNIS00021 is most likely not a specific inhibitor of 
AAG and this could also be the case for published inhibitor morin.  No inhibition 
was observed by the analogues of UNIS00021.  It is hypothesised that the original 
UNIS00021 inhibition result was artifactual and due to aggregation.  Despite this, 
during assay optimisation, it was concluded that adding BSA into the AAG buffer 
gives a more robust bioassay and the enzyme linked imunosorbent colorimetric 
detection method is more sensitive than the eluted fluorescence detection method. 
However, dilutions involving inhibitors often showed negative inhibition and there 
was still inconsistent curves with morin and UNIS00021 and both might be due to 
aggregation effects. In future, the free substrate oligomer assay using LCMS could 
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be improved and used in future screens of novel candidate inhibitors based on 
new virtual screens or substrate based design.  To fully establish whether 
UNIS00021 and morin are aggregators, assay conditions should be found which 
show them as inhibitors and this should be repeated in the presence of surfactant 
to break up any aggregates.  This might require resort to replication of the 32P-
radiolabelled oligomer gel-based assay reported in the literature which showed 
morin to be an inhibitor.   
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8. Experimental Procedures 
8.1 General Procedures 
All reactions were carried out under nitrogen atmosphere in glassware dried under 
high vacuum by a heat-gun unless otherwise stated. 
Reagents and solvents 
Reagents and solvents for reactions were reagent grade and were used without 
further purification unless otherwise specified.  
Chromatography 
Flash column chromatography was carried out using silica gel 40-60u 60A.Thin 
layer chromatography (TLC) was performed using precoated aluminum backed 
plates (silica gel 60 F254) and visualised by UV radiation at 254 nm, or by staining 
with potassium permanganate solution (K2CO3 (13.3 g), KMnO4 (2 g), water (200 
mL), NaOH solution (10% w/v, 1.7 mL, added last)). 
IR spectroscopy 
Infra-red (IR) spectra were recorded in the range 600-4000 cm-1 using an Agilent 
Clary 640 FTIR spectrometer with MKII Golden Gate Single Reflection ATR 
System or as a thin film between sodium chloride plates. 
Gas chromatography mass spectrometry (GC-MS) 
GC-MS was carried out on an Agilent 7890A-5975C with an electron ionisation (EI) 
detector. Column length was 30 m, injection volume was 2 µL, temperature was 
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50 °C for 3 minutes followed by an increase of 10 °C per minute to 250 °C and 
held for 2 minutes. 
Mass Spectrometry (MS) 
LCMS was carried out on a Waters 2695 LC coupled to a Waters 2487 Dual λ 
Absorbance Detector and a Micromass Quattro Ultima Triple Quadrupole Mass 
Spectrometer using electrospray ionisation (positive or negative mode).  LC 
conditions were as follows: inj. vol. 10 μL, column Phenomenex Onyx Monolithic 
C18 (100 mm × 3 mm), column temp. 30 °C, flow rate 1 mL min-1, mobile phase 
(positive mode) MeCN (containing 0.1% formic acid) in water (containing 0.1% 
formic acid), mobile phase (negative mode) MeCN in water, gradient 0-0.4 min, 
5%; 0.4-2 min, 5-20%; 2-3.5 min, 20-100%; 3.5-5.5 min, 100%; 5.5-6 min, 100-5%; 
6-7 min, 5%..  
GCMS was carried out on an Agilent 7890A GC system connected to an Agilent 
5975C inert XL EI/CI with Triple-Axis Detectors and the conditions were as follows: 
inj. Vol. 1μL, inj. Temp. 250 ºC, column Zebron ZB-5MS (30 m × 0.25 mm), oven 
temperature gradient 0-3 min, 50 ºC; 3-23 min, 50-250 ºC (10 ºC ramp per minute); 
23-35 min, 250 ºC.   
High-resolution mass spectrometry (HRMS) was performed at the Institute of 
Cancer Research, Sutton, UK on a Waters QTOF Premier with electrospray 
ionisation.   
Nuclear Magnetic Resonance Spectroscopy (NMR) 
1H- and 13C-NMR spectra were recorded using a Bruker 500MHz spectrometer at 
500 MHz for 1H-NMR and 125 MHz for 13C-NMR. 1H-NMR spectra were referenced 
either to TMS at 0 ppm or to residual protonated solvent: 2.50 ppm for DMSO-d6, 
3.31 ppm for CD3OD and 7.26 for CDCl3. 13C-NMR spectra were referenced to 
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deuterated solvent peaks:  39.0 ppm for DMSO-d6, 77.16 for CDCl3 and 49.00 for 
CD3OD. The data is given as follows: chemical shift (δ) in ppm, integration, 
multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; p, pentet; m, multipliet), 
coupling constant(s) (J in Hz accurate to 0.5 Hz), assignment.  
8.2 Experimental Detail 
2-Cyanoacetohydrazide (29) 
 
To a mixture of methyl cyanoacetate (1.00 g, 10.0 mmol) and hydrazine hydrate 
(0.51 g, 10.1 mmol)  was added ethanol  (10 ml). The mixture was heated at reflux 
for 1.5 h and then evaporated to dryness. The resulting white powder was 
recrystallized from ethanol to give the title compound as white crystals as a mixture 
of atropisomers (0.79g, 79%); m.p. = 95-97 °C; IR (cm-1)  3346 (N-H), 3281, 3188 
(N-H2), 3029, 2978, 2928, 2260 (CN), 1685 (C=O), 1619, 1527, 1467, 1389, 1342, 
1255, 1101, 1007, 956, 912, 738; δH (500 MHz; DMSO-d6) 9.28, (0.9H, s, N-H), 
8.79 (0.1H, s, N-Hatrop.), 4.50 (0.2H, s, NH2 atrop.), 4.35(1.8H, s, NH2), 3.83 (0.2H, 
s, 2-C atrop.), 3.53 (1.8H, s, 2-C); δC (126 MHz; DMSO-d6) 167.36 (1-C), 161.76 
(1-Catrop.), 116.71 (3-C), 116.16 (3-Catrop.), 24.0 (2-C).Refrence: sigmaaldrich NMR 
database. 
N-[(Benzylcarbamothioyl)amino]-2-cyanoacetamide (25) 
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Cyanoacetohydrazide (29)(520 mg, 5.20 mmol) and benzyl isothiocyanate (938 
mg, 6.30 mmol) were dissolved in ethanol (10 ml) was heated at reflux for 1.5 
hours.  The reaction mixture was left to cool and asolid product precipitated.  This 
was filtered off and recrystallized from ethanol to give the title compound as a white 
solid (1 g, 83%); m. p. 167-168 °C; IR (cm-1)  3348 (N-H), 3240, 3124, 3029 (CH 
arom.), 2265 (CN), 1699 (C=O),1223, 1172 (S=C); δH  (500 MHz; DMSO-d6) 10.17 
(1H,-br s, NH-CO-), 9.50 (1H, -br s, NH-NH-CS-), 8.63 (1H, br s, -NH-CH2Ph), 
7.31 (2H, br t, J 7.2 Hz, 3',5'-H), 7.26 (2H, d, J 7.2 Hz, 2',6'-H), 7.22 (1H, t, J 7.2 
Hz, 4'-H), 4.74 (2H, d, J 5.9 Hz, CH2-NH-), 3.66 (2H, s, CH2-CN); δC (126 MHz; 
DMSO-d6) 181.9 (C=S), 162.5 (C=O), 139.1 (1’-C), 128.1 (3',5'-C), 126.9 (2',6'-C), 
126.7 (4'-C), 115.71 (CN), 46.64 (PhCH2-NH-), 24.36 (-CH2-CN); LCMS m/z (ESI-
)  247 ([M-H]-,100%, 206 (11%), 180 (39%), 495 (7%); Elemental analysis; 
calculated: C, 53.21; H, 4.87; N, 22.56; found: C, 53.21; H, 4.84; N, 22.48. 
2-(4-Benzyl-5-sulfanyl-1H-1,2,4-triazol-3-yl)acetonitrile (UNIS00073) 
 
Method 1 
A mixture of 4-benzyl-1-cyanoacetylthiosemicarbazide 25 (500 mg, 2 mmol), 
hydrazine hydrate (104 mg, 2 mmol, 0.1 ml) and ethanol (20 ml) was stirred at RT 
for 48 h. The solution was then acidified with hydrochloric acid until the mixture 
was  pH 5 (pH paper) and then extracted with DCM (3 × 7 mL). Flash silica column 
chromatography, gradient elution (DCM in ethylacetate ethylacetate gave the title 
compound as a yellow solid powder (140 mg, 28%) m.p. = 186 °C ; IR (cm-1)  ;3096, 
3049, (C-H arom.), 2265 (CN), 1583, 1496, 1456 (CH aliph.), 1356, 1307 (C=S), 
766; LCMS m/z (ESI-)  229 ([M-H]-,100%, 138 (2%), 155 (5%), 197 (21%), 481 
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(15%); δH  (500 MHz; DMSO-d6) 7.36 (2H, broad triplet, J 7.5 Hz, 3',5'-H), 7.33-
7.28 (3H, m, 2’, 4', 6’-H), 5.24 (2H, s, -CH2-Ph), 4.22 (2H, s, -CH2-CN); δC  (126 
MHz; DMSO-d6) 168. 1 (5-C), 144.5 (3-C), 134.9 (1'-C), 128.8 (3',5'-C), 128.0 (4'-
C), 127.2 (2',6'-C), 114.5 (-CN), 45.9 (-CH2-Ph), 15.9 (-CH2-CN) 
Method 2 
 4-Benzyl-1-cyanoacetylthiosemicarbazides (500 mg, 2.01 mmol) was dissolved in 
1M NaHCO3 (20.16 ml) and the reaction mixture was heated at 60 °C for 24 hours. 
After cooling, 2 M HCl was added until the mixture was pH 5. The white precipitate 
was extracted with ethylacetate, and then dried to give the title compound (270 
mg, 80%). 1H NMR agreed with that described above. 
2-(4-Benzyl-5-sulfanylidene-4,5-dihydro-1H-1,2,4-triazol-3-yl)acetic acid 
(UNIS00064) 
 
Method 1 
4-Benzyl-1-cyanoacetylthiosemicarbazide (25) (500 mg, 2.01 mmol) was 
dissolved in 2 M NaOH (6.7 ml) and the reaction mixture was heated at reflux for 
4 hours. After cooling, cold water was added to the solution and 2 M HCl was 
added until the mixture was pH 3 (pH paper). The acidified solution was then 
extracted with DCM/MeOH [9:1] (3 × 7 mL). The organic layer was dried over 
MgSO4, filtered and evaporated to give the title compound as a white solid powder 
(76 mg, 15%) m.p. = 187 °C ; IR(cm-1)  3283 (O-H), 2971, 2943, 2885, 2833, 2631 
, 1822, 1712 (C=O), 1578, 1492, 1455 (C=C), 1421, 1348 (C=S), 1158, 1121, 
1075, 1028, 946, 868, 835, 715, 690, 657; δH (500 MHz; DMSO-d6) 13.88 (1H, s, 
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-COOH), 12.96 (1H, s,-NH), 7.33 (2H, br t, J 7.5 Hz, 3',5'-H), 7.29 (1H,d, J 7.5 Hz, 
4'-H), 7.27 (2H,d , J 7.5 Hz, 2',6'-H), 5.23 (2H, s, -CH2-Ph), 3.68 (2H, -CH2-COOH); 
δC (126 MHz; DMSO-d6) 168.7 (5-C), 167.7 (-COOH), 147.65 (3-C),  135.71 (1'-
C), 128.7 (3',5'-C), 127.9 (4'-C), 127.2 (2',6'-C), 46.1 (-CH2-Ph), 32.0 (-CH2-
COOH); LCMS m/z (ESI-) 204 ([M-H]- (100%), 205 (75%), 460(32%), 431(28%), 
460 (32%),172 (25%),113 (10%). 
Method 2 
4-Benzyl-1-cyanoacetylthiosemicarbazide (25) (200 mg, 0.81 mmol) was 
dissolved in aqueous NaHCO3 (1 M, 8.0 ml) and the reaction mixture was heated 
at reflux for 14 hours. After cooling, 2 M HCl was added until the mixture was pH 
3. The acidified solution was then extracted with DCM/MeOH [9:1] (3 × 7 mL). The 
organic layer was dried over MgSO4, filtered and concentrated to give the title 
compound as a white solid powder (160 mg, 86%); 1H NMR agreed with that 
described above. 
2-(4-Benzyl-5-sulfanyl-1H-1,2,4-triazol-3-yl)-N-(propan-2-yl)acetamide 
(UNIS00067) 
 
To dry DCM (7.3 ml) under nitrogen, was added 2-(4-benzyl-5-sulfanylidene-4,5-
dihydro-1H-1,2,4-triazol-3-yl)acetic acid (UNIS00064)(100 mg, 0.401 mmol), 
isopropylamine (28 mg, 0.48 mmol), and EDC (130 mg, 0.677 mmol). The mixture 
was stirred for 26 h at RT. Dilute HCl (0.1 M) was added until the mixture was  pH 
5 (pH paper) and it was then extracted with DCM (3 × 7 mL). The combined organic 
layers were dried over MgSO4, filtered and evaporated. Flash silica column 
chromatography, gradient elution (DCM/ethylacetate [8:2], [7:3], [1:1]) gave the 
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title compound as a white solid (33 mg, 28%); m.p. = 187 °C (sharp); Rf 
(DCM/ethylacetate [8:2] 0.6; IR (cm-1) 3287 (N-H), 3091, 3038, 2929, 2851, 2762, 
2429, 2359, 2224, 1627 (C=O), 1566 (C=N), 1504, 1439 (C=C), 1348(C=S), 1161, 
1079, 941, 891, 769, 721; δH (500 MHz; CD3OD) 7.33 (2H, t, J 7.1 Hz, 3',5'-H), 
7.31 (1H, t, J 7.1 Hz,4'-H), 7.25 (2H,d, J 7.1 Hz, 2',6'-H), 5.34 (2H, s,  -CH2Ph), 
3.87 (1H, septet, J 6.7 Hz,-CHMe2), 3.46 (2H, s, -CH2CO-), 1.10 (6H, d, J 6.7 Hz, 
-CHMe2); δC (126 MHz; CD3OD) 169.6 (-CO-), 167.2 (-C=S), 149.5 (-C-CH2), 136.5 
(1'-C), 129.9 (2',6'-C), 129.1(4'-C), 128.2(3',5'-C), 47.9 (-CH2Ph), 43.0 (-CHMe2), 
34.1 (-CH2CO-), 22.4 (-CHMe2); m/z (ESI) 289 ([M-H]-, 37%), 204 (100%), 172 
(11%), 112 (49%). 
2-(4-Benzyl-5-sulfanyl-1H-1,2,4-triazol-3-yl)-N-cyclopropylacetamide  
(UNIS00069) 
 
To dry DCM (14.6 ml) under nitrogen, was added 2-(4-benzyl-5-sulfanylidene-4,5-
dihydro-1H-1,2,4-triazol-3-yl)acetic acid (UNIS00064) (200 mg, 0.802 mmol), 
cyclopropylamine (55 mg, 0.962 mmol), and EDC (259 mg, 0.677 mmol). The 
mixture was stirred for 24 h at RT. Dilute HCl (0.1 M) was added until the mixture 
was pH 5 and it was extracted with DCM/MeOH [9:1] (3 × 10 mL). The combined 
organic layers were dried over MgSO4, filtered and evaporated. Flash silica column 
chromatography, gradient elution (DCM/ethylacetate [8:2], [7:3], [1:1]) gave the 
title compound as a white powder solid (120 mg, 52%); m.p. = 170 °C ; Rf 
(DCM/ethylacetate [7:3] 0.3; IR (cm-1) 3292 (N-H, stretch), 2929, 2906 (C-H, 
stretch), 1642 (C=O, stretch), 1537(C=C), 1350 (C=S) ; δH (500 MHz; CD3OD) 0.43 
(2H,m, J 6.90Hz,2"-H), 0.677 (2H, m, J 6.90 Hz, 3"-H), 2.61 (1H,m, ,1"-H), 3.50 
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(2H, s, -CH2-CO-), 5.34 (2H, s, -CH2-Ph), 7.25 (2H, br d, J 7.6 Hz, 2',6'-H), 7.34 
(2H, m, , 3',5'-H), 7.30 (1H,m, 4'-H); δC (126 MHz; CD3OD) 6.34 (2"-C), 6.34 (3"-
C), 23.52 (1"-C), 169.62 (-CO-), 33.90 (-CH2-CO-), 149.33 (3-C), 169.78 (5-C), 
136.48 (1'-C), 128.27 (2',6'-C), 129.93 (3',5'-C), 129.16 (4'-C); LCMS m/z (ESI-)  
204 (100%), 287 [M-H]- (56%), 597 (13%), 112 (49%). HRMS (ESI) found: [M+H]+, 
289.1115. C14H16N4OS requires [M+H]+,  289.1045 
2-(4-Benzyl-5-sulfanyl-1H-1,2,4-triazol-3-yl)-N-methylacetamide  
(UNIS00068) 
 
To dry DCM (14.60 ml) under nitrogen, was added 2-(4-benzyl-5-sulfanylidene-
4,5-dihydro-1H-1,2,4-triazol-3-yl)acetic acid acid (UNIS00064)(200 mg, 0.802 
mmol), methylamine (31 mg, 0.96 mmol), and EDC (259 mg, 0.677 mmol). The 
mixture was stirred for 28 h at RT. Dilute HCl [0.1M] was added until the mixture 
was pH 5  and it was extracted with DCM/MeOH [9:1] (3 × 10 mL). The combined 
organic layers were dried over MgSO4, filtered and evaporated. Flash silica column 
chromatography, gradient elution (DCM/ethylacetate [8:2], [7:3], [1:1]) gave the 
title compound as a yellow powder (98 mg, 47%); m.p. = 155  °C; Rf 
(DCM/ethylacetate [7:3] 0.26; IR (cm-1)  1642 (C=O, stretch), 1484(C=C), 1363 
(C=S), 2924, 2852 (C-H, stretch), 3266 (N-H, stretch);δH (500 MHz; CD3OD) 
7.32(2H, m, 3',5'-H), 7.29 (1H, m, 4'-H), 7.25 (2H,d, J 7.5 Hz, 2',6'-H), 5.34 (2H, s, 
-CH2-Ph), 3.49 (2H, s, -CH2-CO-) 2.61 (3H, s, CH3-NH-);  , δC   (126 MHz; CD3OD) 
169.7 (5-C), 168. 7 (-CO-), 149.3 (3-C),   129.9 (3',5'-C), 129.1 (4'-C), 136.5 (1'-C),  
128.3 (2',6'-C), 47.9 (-CH2-Ph), 34.0 (-CH2-CO-), 26.5 (CH3-NH-); LCMS m/z (ESI-
)  (204 (100%), 261 [M-H]-(82%), 545 (6%), 112 (4%). HRMS (ESI) found: [M+H]+, 
263.0964. C21H14N4OS requires [M+H]+,  263.0888. 
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2-(4-Benzyl-5-sulfanyl-1H-1,2,4-triazol-3-yl)-N-cyclohexyl-N-
methylacetamide (UNIS00070) 
  
To dry DCM (0.055 M, 14.60 ml) under nitrogen, was added 2-(4-benzyl-5-sulfanyl-
4H-1,2,4-triazol-3-yl)acetic acid (UNIS00064)(200 mg, 0.802 mmol), methyl 
cyclohexylamine  (113 mg, 0.962 mmol), and EDC (259 mg, 0.677 mmol). The 
mixture was stirred for 29 h at RT. Dilute HCl (0.1 M) was added until the mixture 
was pH 5  and it was extracted with DCM/MeOH [9:1] (3 × 10 mL). The combined 
organic layers were dried over MgSO4, filtered and evaporated. Flash silica column 
chromatography, gradient elution (DCM/ethylacetate [8:2], [7:3], [1:1]) gave the 
title compound as a ~1:1 mixture of atropisomers as a white powder (80 mg, 40%); 
m.p. = 183 °C; Rf (DCM/ethylacetate [7:3] 0.3; IR (cm-1)  1642 (C=O, stretch), 1453 
(C=C), 1353 (C=S), 2922, 2853 (C-H, stretch); δH (500 MHz; CDCl3) 7.27-7.20 (5H, 
m, Ar-H), 5.35 (1H, s, -CH2-Ph), 5.34 (1H, s, -CH2-Ph), 4.33 (0.5H, m, 1”-H), 3.68 
(0.5H, -CH2-CO-),3.54 (0.5H, -CH2-CO-),3.33 (0.5H, m, 1”-H), 2.77 (1.5H, s, -
CH3), 2.68 (1.5H, s, -CH3), 1.74 (2H, m, Cy), 1.57 (3H, m, Cy), 1.41 (1H, qd, J 12.5, 
3.1 Hz, Cy), 1.31 (2H, m, Cy), 1.21-1.12 (1H, m, Cy),  1.00 (1H, m, Cy); δC (126 
MHz; CD3OD) 168.7 (5-C), 165.3 (-CO-), 148.6 (3-C), 148.5 (3-C), 134.96 (1'-C), 
134.99 (1'-C), 129.00 (3',5'-C), 128.98 (3',5'-C), 128.29 (4'-C), 128.27 (4'-C), 
127.61 (2',6'-C), 127.57 (2',6'-C), 57.2 (1"-C), 53.2 (1"-C), 47.5 (-CH2Ph), 47.4 (-
CH2Ph),  46.15 (-CH2-Ph), 33.1 (-CH2-CO-), 32.5 (-CH2-CO-), 30.8 (Cy) , 29.9 
(Cy), 29.9 (-CH3), 29.8 (Cy), 27.7 (-CH3), 25.1 (Cy), 25.47 (Cy), 25.51 (Cy), 25.55 
(Cy); LCMS m/z (ESI-)  343 ([M-H]-, 100%), 252 (18%), 702 (18%). HRMS (ESI) 
found: [M+H]+, 345.1793. C18H24N4OS requires [M+H]+,  345.1671. 
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2-(4-Benzyl-5-sulfanyl-1H-1,2,4-triazol-3-yl)-N-cyclohexylacetamide 
(UNIS00021) 
 
To dry DCM (4.6 ml) under nitrogen, was added 2-(4-benzyl-5-sulfanyl-1H-1,2,4-
triazol-3-yl)acetic acid (UNIS00064)(200 mg, 0.802 mmol), cyclohexylamine  (95 
mg, 0.96 mmol), and EDC (259 mg, 0.677 mmol). The mixture was stirred for 21 h 
at RT. Dilute HCl (0.1 M) was added until the mixture was pH 5 and it  was 
extracted with DCM/MeOH [9:1] (3 × 10 mL). The combined organic layers were 
dried over MgSO4, filtered and evaporated. Flash silica column chromatography, 
gradient elution (DCM/ethylacetate [8:2], [7:3], [1:1]) gave the title compound (40 
mg, 20%); m.p. = 211 °C; Rf (DCM/ethylacetate) [7:3] 0.3; IR (cm-1)  3280 (N-H, 
stretch), 2932, 2853 (C-H, stretch), 1643 (C=O, stretch), 1444 (C=C), 1349 (C=S);  
δH (500 MHz; CD3OD) 7.33(2H, t, J 7.2 Hz, 3',5'-H), 7.30 (1H, t, J 7.2 Hz, 4'-H), 
7.24 (2H, d, J 7.2 Hz,2',6'-H), 5.34 (2H, s, -CH2-Ph),3.54 (1H, tt, J 10.7, 3.8 Hz,1"-
H), 3.46 (2H,s, -CH2-CO-), 1.72 (2H, m, Cy), 1.62 (1H, m,Cy), 1.37-1.28 (2H, m, 
Cy), 1.23-1.12 (3H, m, Cy), 1.18, 1.80 (2H, m, Cy), ,; δC   (126 MHz; CD3OD) 169.7 
(5-C),  167.2 (-CO-), 149.6 (3-C), 136.5 (1'-C), 129.9 (3',5'-C), 129.1 (4'-C) , 128.2 
(2',6'-C), 50.26 (1" -C), 47.9 (-CH2-Ph), 34.1 (-CH2-CO-), 33.6 (2",6"-C), 26.6 (4"-
C), 26.0 (3",5"-C); LCMS, m/z (ESI-)  (204 (100%), 329 [M-H]-, 50%), 681(30%), 
113 (4%). HRMS (ESI) found: [M+H]+, 331.1583. C17H22N4OS requires [M+H]+, 
331.1514. 
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2-(4-Benzyl-5-sulfanyl-1H-1,2,4-triazol-3-yl)-N,N-dimethylacetamide 
(UNIS00071) 
 
To dry DCM (10.9 ml) under nitrogen, was added 2-(4-benzyl-5-sulfanyl-1H-1,2,4-
triazol-3-yl)acetic acid (UNIS00064)(150 mg, 0.60 mmol), dimethylamine (0.08 mg, 
0.72 mmol), and EDC (194.38 mg, 1.01 mmol). The mixture was stirred for 21 h at 
RT and then heated at 42 °C for 3 h. Dilute HCl (0.1M) was added until the mixture 
was pH 5  and it was extracted with DCM/MeOH [9:1] (3 × 10 mL). The combined 
organic layers were dried over MgSO4, filtered and evaporated. Flash silica column 
chromatography, gradient elution (DCM/ethylacetate [8:2], [7:3], [1:1]) gave the 
title compound as a white powder (39 mg, 26%); m.p. = 110  °C; Rf 
(DCM/ethylacetate [7:3] 0.26; IR (cm-1)  2935, 2853 (C-H, stretch), 1627 (C=O, 
stretch), 1453(C=C), 1353 (C=S); δH (500 MHz; CD3OD) 7.35 (2H, t, J 7.4 Hz, 3',5'-
H), 7.31 (1H, t, J 7.4 Hz, 4'-H), 7.25 (2H, d, J 7.4 Hz, 2',6'-H), 5.30 (2H, s, -CH2-
Ph), 3.65 (2H , s, -CH2-CO-), 2.91 (3H, s, -N-CH3), 2.86 (3H, s, -N-CH3);  δC   (126 
MHz; CD3OD) 169.6 (5-C), 168.2 (-CO-),  149.6 (3-C), 136.4 (1'-C), 129.9 (3',5'-
C), 129.2 (4'-C), 128.5 (2',6'-C), 48.1 (-CH2-Ph), 37.8 (-N-CH3), 35.9 (-N-CH3), 32.6 
(-CH2-CO-); LCMS m/z (ESI-)  275 ([M-H]-, 100%), 184 (31%), 243 (10%). HRMS 
(ESI) found: [M+H]+, 277.1121. C13H16N4OS requires [M+H]+,  277.1045. 
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2-(4-Benzyl-5-sulfanyl-1H-1,2,4-triazol-3-yl)-2-(diethylamino)acetamide 
(UNIS00072) 
 
N,N-Diethylhydroxylamine (77 mg, 0.87 mmol) was added to a mixture of 2-(4-
benzyl-5-sulfanyl-1H-1,2,4-triazol-3-yl)acetonitrile (UNIS00073) (200 mg, 0.87 
mmol) and water (2.6 ml). The reaction was heated at reflux for 2 h 45 minutes. 
Dilute HCl 0.1 M was added until the mixture was pH 3 and it was extracted with 
DCM/MeOH [9:1] (3 × 10 mL). The combined organic layers were dried over 
MgSO4, filtered and evaporated.  Flash silica column chromatography, gradient 
elution (DCM/ethylacetate [8:2], [7:3], [1:1]) gave the title compound as a white 
powder (20 mg, 10%); m.p. = 150  °C; Rf (DCM/ethylacetate [7:3] 0.29; IR (cm-1)  
3329 (N-H), 2923, 2875 (C-H, stretch), 1680 (C=O, stretch), 1495 (C=C),  1342 
(C=S); δH (500 MHz; CD3OD) 7.35 (2H, t, J 7.4 Hz, 3',5'-H), 7.30 (1H, t, J 7.4 Hz, 
4'-H), 7.28 (2H, d, J 7.4Hz, 2',6'-H), 5.75 (1H, d, 15.4 Hz, -CH2-Ph), 5.05 (1H, 
d,15.4 Hz, -CH2-Ph), 4.44 (1H, s, -CH-CO-), 2.68-2.55 (4H, m, -CH2-CH3), 0.77 
(6H, t, J 7.3 Hz, -CH2-CH3);  δC  (126 MHz; CD3OD) 173.2 (5-C), 169.6 (-CO-), 
151.0 (3-C), 136.9 (1'-C), 130.0 (3',5'-C), 129.2 (4'-C), 128.3 (2',6'-C), 62.5 (-CH-
CO-), 47.9 (-CH2-Ph), 46.4 (-CH2-CH3), 13.8 (-CH2-CH3); LCMS m/z (ESI-)  318 
(275 (100%), 246 (51%), 217 (21%), [M-H]-, 11%). HRMS (ESI) found: [M+H]+, 
320.1534. C15H21N5OS requires [M+H]+,  320.1467. 
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2-(4-Benzyl-5-sulfanyl-1H-1,2,4-triazol-3-yl)acetamide (UNIS00074) 
 
A solution of 2-(4-benzyl-5-sulfanyl-4H-1,2,4-triazol-3-yl)acetonitrile UNIS00073 
(100 mg, 0.43 mmol) in a mixture of TFA (2 mL) and H2SO4 (1 mL) was stirred at 
RT for 2 h. The reaction mixture was then poured into ice-cold water purified using 
reverse-phase flash silica column chromatography, gradient elution (MeCN/water 
[5:95 %], [15:85%], [20:80%], [100:0%]) and then water was evaporated using a 
lyophiliser. This gave the title compound as a white powder (54 mg, 50%); Rf 
(DCM/ethylacetate [3:7] 0.8; IR (cm-1)  3366 (N-H), 2950, 2927 (C-H, stretch), 1660 
(C=O, stretch), 1452 (C=C), 1343 (C=S); δH (500 MHz; CD3OD) 7.36 (2H, t, J 7.5 
Hz, 3',5'-H), 7.32 (1H, t, J 7.5 Hz, 4'-H), 7.28 (2H, d, J 7.5 Hz, 2',6'-H), 5.35 (2H, s, 
-CH2-Ph),3.52 (2H, s, -CH2-CO-) ;  δC (126 MHz; CD3OD) 170.9 (5-C), 169.6 
(-CO-),  149.40 (3-C), 136.5 (1'-C), 130.0 (3',5'-C), 129.2 (4'-C), 128.4 (2',6'-C), 
48.0 (-CH2-Ph), 33.6 (-CH2-CO-); LCMS, m/z (ESI) 204 (100%), 247 [M-H]-, 72%), 
517 (55%), 113 (31%), 172 (19%). 
β-Alanine Methyl Ester (46) 
  
Thionyl chloride (9 g, 78.60 mmol) was added dropwise to a suspension of β-
alanine (5 g, 56 mmol) in (42 ml) methanol at 0 °C.  The reaction was stirred at 0 
°C for 24 h and then concentrated using a rotary evaporator. The residual oil was 
triturated with cold ether and β-alanine methyl ester precipitated as a white powder 
(6.90 g, 88%); m. p. = RT; IR (cm-1)  2940 (N-H2), 1660 (C=O), 1597, 1523, 1392, 
1344, 1213, 1001, 891, 797; δH (500 MHz; CD3OD) 8.20 (2H, NH2), 3.73 (3H, Me), 
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3.37 (2H, q, J 6.60 Hz, 3-H), 2.94 (2H, t, J 6.60 Hz, 2-H); δC  )(126 MHz; CD3OD) 
171.75 (-CO-), 52.39 (-OMe), 35.78 (3-C), 31.24 (2-C); m/z (GC-MS, EI) 143 
(10%), 129 (5%), 103 (M+, 15%), 85 (18%), 70 (15%). 
N-(tert-Butoxycarbonyl)-β-alanine methyl ester (48) 
 
To a solution of β-alanine methyl ester hydrochloride (5 g, 35.8 mmol) in 108 ml 
methanol cooled in an ice bath was added triethylamine (15 ml) with vigorous 
stirring. Di-tert-butyl dicarbonate was then added to the mixture in portions (12 g, 
53.7 mmol) and the reaction was stirred for 12 h. The mixture was concentrated to 
half its volume under reduced pressure, and triethylammonium hydrochloride was 
filtered from solution. The filtrate was diluted with chloroform (17 ml), and the 
mixture was washed with water (17 ml), and then with 10% w/w aqueous citric acid 
(17 ml). The organic layer was evaporated to give N-(tert-butoxycarbonyl)-β-
alanine methyl ester as a transparent oil (4.80 g, 96%), IR (cm-1); 3372 (N-H), 1700 
(-C=O), 1693 (tBu-O-CO-), 1515, 1366, 1392, 1248, 1150 (-C-O-Me) , 1076; δH 
(300 MHz; CDCl3) 5.05 (1H, s, -NH-), 3.71 (3H, s, -OMe), 3.42 (2H, q, J 6.30 Hz, 
3-C), 2.54 (2H, t, J 6.35 Hz, 2-C), 1.45 (9H, s, -(Me)3); δC (300 MHz; CDCl3) 173.1 
(1-C), 155.9 (-CO-NH-), 79.5 (-C-(Me)3), 51.9 (-OMe), 36.2 (3-C), 34.6 (2-C), 28.5 
(-(Me)3); m/z (GC-MS, EI)147 ([M-tBu+H] , 50%), 130 ([M-tBuO] , 38%), 116 
(46%), 98 (30%), 57 (tBu , 100%). 
N-Boc-β-alanine hydrazide (50) 
  
To N-Boc-β-alanine methyl ester (2 g, 9.84 mmol) in 3 ml MeOH was added 
hydrazine hydrate (1.89 ml, 38.8 mmol) and the mixture was heated at reflux for 
16 h. The mixture was evaporated and redissolved in chloroform (10 ml) and then 
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washed with water (10 ml). The mixture was dried over MgSO4 and evaporated to 
dryness to give the title compound as a white solid (1.3 g, 67%); m. p. = 125 ºC; 
IR(cm-1) 3283 (N-H2), 1688 (-CO-OMe), 1632 (tBu-O-CO-) 1520, 1364, 1280, 
1247, 1163, 1013, 970, 939, 872; δH (500 MHz; DMSO) 8.90 (1H, s, NH-NH2), 6.7 
(1H, s, Boc-NH-), 4.20 (2H, s, -NH2), 3.12 (2H, q, J 7.16 Hz, -NH-CH2-), 2.15 (2H, 
t, J 7.16, -CH2-CO-), 1.36 (9H, s, -(Me)3); δC (126 MHz; DMSO-d6) 170.2 (-CO-
NH-NH2), 155.9 (tBu-O-CO-), 78.1 (-C-(Me)3), 37.2 (-NH-CH2-), 34.4 (-CH2-CO-), 
28.71 (-C-(Me)3); m/z (GC-MS, EI) 147 ([M-tBu+H] , 15%), 130 ([M-tBuO] , 
50%), 103 ([M-Boc], 91%), 74 (42%), 57 (tBu , 100%)    
tert-Butyl N-(2-([(benzylcarbamothioyl)amino]carbamoyl)ethyl)carbamate 
(52) 
 
N-Boc-β-alanine hydrazide 50 (400 mg, 1.20 mmol) and benzyl isothiocyanate 
(353 mg, 2.36 mmol) were dissolved in ethanol (3.90 ml) and heated at reflux for 
2 h.  The reaction mixture was left to cool and then evaporated to give a white solid 
product. Flash silica column chromatography, gradient elution (DCM/ethylacetate 
[8:3], [1:1], [3:7]) gave the title compound as a white powder solid (642 mg, 92%); 
m.p. = 145 ºC; IR (cm-1)  3272 (N-H), 3182, 2993 (CH arom.), 1700 (-CO-OMe), 
1548 (tBu-O-CO-) 1365, 1287, 1228 (S=C), 1162; δH  (500 MHz; DMSO-d6) 9.78 
(1H, s, NH-CO-), 9.24 (1H, s, NH-NH-CS-), 8.40 (1H, s, -NH-CH2Ph), 6.79 (1H,s, 
-NH-Boc), 7.29 (2H, m, 3',5'-H), 7.28 (2H, m, 2',6'-H), 7.22 (1H, t, J 7.2 Hz, 4'-H), 
4.72 (2H, d, J 6.4 Hz, CH2-Ph), 3.16 (2H, q, J 7.16 Hz, -NH-CH2-), 2.30 (2H, t, J 
7.16, -CH2-CO-), 1.36 (9H, s, -(Me)3); δC (126 MHz; DMSO-d6) 182 (C=S), 170 (-
CO-NH-NH2), 156 (tBu-O-CO-), 139.8 (1’-C), 128.5 (3',5'-C), 127.28 (2',6'-C), 
127.22(4'-C), 78.9 (-C-(Me)3), 47.09 (-CH2-Ph), 37.2 (Boc-NH-CH2-), 34.4 (-CH2-
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CO-), 28.71 (-C-(Me)3); LCMS m/z (ESI-)  351 ([M-H]- (30%), 277(100%), 243 
(35%), 234 (60%), 128 (20%). 
tert-Butyl-N-[2-(4-benzyl-5-sulfanyl-1H-1,2,4-triazol-3-yl)ethyl]carbamate 
(UNIS00075) 
 
tert-Butyl-N-(2-([(benzylcarbamothioyl)amino]carbamoyl)ethyl)carbamate (52) 
(200 mg, 0.57 mmol) was dissolved in 1 M NaHCO3 (5.70 ml) and MeOH (2.5 ml) 
and the reaction mixture was heated at 60 oC for 24 h. After cooling, 2 M HCl was 
added until the mixture was pH 6. The white precipitate was extracted with 
ethylacetate, and then dried to give the title compound (150 mg, 79%); m.p. = 160 
°C; IR (cm-1) 3263 (-NH-Boc) 3116, 2970, 2925 (C-H arom.), 1666 (tBu-O-CO-), 
1502, 1454, 1399 (CH aliph.),1356 (C=S), 1167, 1140, 721; δH  (500 MHz; (CDCl3) 
11.88 (1H, s, 1H),  7.27 (2H, m, 3',5'-H), 7.23-7.25 (3H, m, 2’, 4', 6’-H), 5.24 (2H, 
s, -CH2-Ph), 5.00 (1H, br s, Boc-NH-), 3.39 (2H, q, 6.8 Hz, Boc-NH-CH2-), 2.61 
(2H, t, 6.22 Hz, Boc-NH-CH2-CH2-), 1.35 (9H, s, -(Me)3); δC  (126 MHz; (CDCl3) 
168.1 (5-C), 155.8 (tBu-O-CO-), 151.3 (3-C), 134.5 (1'-C), 129.1 (3',5'-C), 128.4 
(2',6'-C), 127.5 (4'-C), 79.9 (-C-(Me)3), 47.1 (-CH2-Ph), 36.6 (Boc-NH-CH2-), 28.3 
(-(Me)3), 26.8 (Boc-NH-CH2-CH2-); LCMS m/z (ESI-) 333.3 ([M-H]- (9%), 259.1 
(100%), 168 (18%). 
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3-(2-Aminoethyl)-4-benzyl-4,5-dihydro-1H-1,2,4-triazole-5-thione 
(UNIS00076) 
 
Tert-butyl-N-[2-(4-benzyl-5-sulfanyl-1H-1,2,4-triazol-3-yl)ethyl]carbamate (100 
mg, 0.30 mmol) were dissolved in 6 ml of  1M of (HCl/EtOAc) (1:1) and heated at 
reflux for 1 h. The mixture was evaporated to form a yellow solid product (70 mg, 
86%) m.p. = 220 °C ; IR(cm-1) 3028 (-NH2), 2930, 2753 (C-H arom.), 1578, 1473 
(C=C), (CH aliph.),1346 (C=S), 1250, 1173 (CH aliph.); δH  (500 MHz; (CD3OD) 
7.30-7.38 (5H, m, 2',3',4',5',6’-H), 5.34 (2H, s, -CH2-Ph), 3.25 (2H, t, 6.4 Hz, NH2-
CH2-), 2.91(2H, t, 6.44 Hz, NH2-CH2-CH2-); δC  (126 MHz; (CD3OD) 168.8 (5-C), 
149.4(3-C), 135.1 (1'-C), 128.7 (3',5'-C), 127.9 (4'-C), 127.1 (2',6'-C), 46.2 (-CH2-
Ph), 35.3 (NH2-CH2-), 23.4 (NH2-CH2-CH2-); LCMS m/z (ESI-)  (233 ([M-H]- 
(100%), 203.9 (30%), 174.7 (28%). 
4-Benzyl-3-[2-(cyclohexylamino)ethyl]-4,5-dihydro-1H-1,2,4-triazole-5-thione 
(UNIS00077) 
 
Acetic acid (0.031 ml) and sodium triacetoxyborohydride (114 mg, 0.54 mmol) 
were added to a mixture of the 3-(2-aminoethyl)-4-benzyl-4,5-dihydro-1H-1,2,4-
triazole-5-thione (100 mg, 0.37 mmol) and cyclohexanon (36.31 mg, 0.37 mmol) 
in DCM (2.89 ml). The mixture were stirred at RT for 24 h. The mixture were 
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concentrated by evaporating most of the solvent and then saturated NaHCO3 was 
added until the mixture was pH 7 and it was extracted with DCM/MeOH [9:1] (3 × 
10 mL). The combined organic layers were dried over MgSO4, filtered and 
evaporated. Flash silica column chromatography, gradient elution (DCM/MeOH 
[8:2], [1:1], [2:8]) gave the title compound (60 mg, 63%); m.p. = 147°C; Rf 
(DCM/MeOH) [9:1] 0.3; IR (cm-1)  3228 (N-H), 2865, 2851 (C-H, stretch), 1575, 
1456 (C=C), 1364 (C=S), 1109, 903, 696;  δH (500 MHz; CD3OD) 7.31(2H, m, 3',5'-
H), 7.32 (1H, m, 4'-H), 7.35 (2H, m,2',6'-H), 5.34 (2H, s, -CH2-Ph), 3.08 (2H, t, 6.9 
Hz, -NH-CH2-), 2.83 (2H, t, 6.9 Hz, -NH-CH2-CH2-), 2.70 (1H, tt, J 10.7 Hz,1"-H), 
1.91 (2H, m, Cy), 1.78 (2H, m,Cy), 1.65 (1H, m, Cy), 1.32-1.24 (2H, m, Cy), 1.21-
1.13 (3H, m, Cy), 1.65 (1H, m, Cy); δC   (126 MHz; CD3OD) 169.4 (5-C), 151.6 (3-
C), 136.8(1'-C), 130.0 (3',5'-C), 129.2 (4'-C) , 128.4 (2',6'-C), 58.1 (1" -C), 47.5 (-
CH2-Ph), 42.3 (-NH-CH2-),  31.8 (2",6"-C), 26.4 (4"-C), 25.6 (3",5"-C), 25.30 (-NH-
CH2-CH2-); LCMS m/z (ESI-)  (653(5%), 315 [M-H]-, 100%), 265 (5%).  
4-Benzyl-3-(2-[(propan-2-yl)amino]ethyl)-4,5-dihydro-1H-1,2,4-triazole-5-
thione (UNIS00078) 
 
Acetic acid (0.031 ml) and sodium triacetoxyborohydride (114.4 mg, 0.54 mmol) 
were added to a mixture of 3-(2-aminoethyl)-4-benzyl-4,5-dihydro-1H-1,2,4-
triazole-5-thione (100 mg, 0.37 mmol) and acetone (21 mg, 0.37 mmol) in DCM 
(2.89 ml). The mixture were stirred at RT for 24 h. The mixture were concentrated 
by evaporating most of the solvent and then saturated NaHCO3 was added until 
the mixture was pH 7 and it was extracted with DCM/MeOH [9:1] (3 × 10 mL). The 
combined organic layers were dried over MgSO4, filtered and evaporated. Flash 
silica column chromatography, gradient elution (DCM/MeOH [8:2], [1:1], [2:8]) 
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gave the title compound (60 mg, 59%); m.p. = 144 °C; Rf (DCM/MeOH) [9:1] 0.43 
IR (cm-1) 3233 (N-H), 2968, 2852, 2720, 2476 (C-H, stretch), 1624, 1575, 1421 
(C=C), 1350 (C=S), 1286, 1013, 896, 722; δH (500 MHz; CD3OD) 7.02 (2H, m, 
2',6'-H), 7.32-7.30 (3H, m, 3',5',4'-H), 5.34 (2H, -CH2Ph), 2.99 (2H, t, 6.9 Hz, -NH-
CH2-), 2.96 (1H, m,-CHMe2), 2.79 (2H, t, 6.9 Hz, -NH-CH2-CH2-), 1.11 (6H, d, J 
6.5 Hz, -CHMe2); δC  (126 MHz; CD3OD) 169.4 (-C=S), 151.6 (3-C), 136.8 (1'-C), 
130.0 (2',6'-C), 129.2 (4'-C), 128.3 (3',4'-C), 50.5 (-CHMe2), 47.6 (-CH2Ph), 42.9 (-
NH-CH2-), 25 (-NH-CH2-CH2-), 21.0 (-CHMe2); LCMS m/z (ESI-)  (573.5 (5%), 275 
[M-H]-, 100%), 260.9 (2%).  
4-Benzyl-3-[2-(methylamino)ethyl]-4,5-dihydro-1H-1,2,4-triazole-5-thione 
(UNIS00079) 
 
Dimethyl sulphate (69 mg, 0.55 mmol) was added to a mixture of 3-(2-aminoethyl)-
4-benzyl-4,5-dihydro-1H-1,2,4-triazole-5-thione (100 mg, 0.37 mmol) and 1 M 
NaHCO3 (0.3 ml) and HFIP (0.4 ml). The mixture were stirred at RT for 5 h. 2M 
HCl was added into the mixture until the mixture was pH 2 and it was extracted 
with DCM three times and then 1M NaHCO3 was added into the aqueous layer 
until the mixture was pH 8. The aqueous layer was extracted with DCM/MeOH 
[9:1] (3 × 10 mL). The combined organic layer was then purified using Reverse-
phase flash silica column chromatography, gradient elution (water in 0.1% formic 
acid/MeCN in 0.1% formic acid [5:95 %], [15:85%], [20:80%], [100:0%]) which then 
gave the title compound as a transperent sticky solution (70 mg, 78%). m.p. = 
80°C; IR (cm-1) 3311 (N-H), 2932, 2868 (C-H, stretch), 3311 (N-H), 1360 (C=S), 
1274, 1154, 959; δH (500 MHz; CD3OD) 8.40(1H, 1-H), 7.38 (2H, t, , J 7.20 Hz, 
3',5'-H), 7.33 (1H, J 7.20 Hz, 4'-H), 7.16 (2H, d, J 7.20 Hz, 2',6'-H), 5.23 (2H, -
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CH2Ph), 3.36 (2H, t, 6.4 Hz, -NH-CH2-), 3.06 (2H, t, 6.4 Hz, -NH-CH2-CH2-), 2.64 
(3H, -CH3); δC   (126 MHz; CD3OD) 168.5 (-C=S), 154.6 (3-C), 135.9 (1'-C), 130.2 
(3',5'-C), 129.50 (4'-C), 127.8 (2',6'-C), 48.1 (-CH2Ph), 37.4 (-NH-CH2-), 24.1 (-NH-
CH2-CH2-), 15.8 (-CH3); LCMS m/z (ESI+)  (129.8 (15%), 219.9 (10%), 249 [M-H]+, 
100%), 271 (20%).  
N-(tert-Butoxycarbonyl)glycine hydrazide (47) 
 
To N-(tert-Butoxycarbonyl)glycine methyl ester (2 g, 10.60 mmol) in 3 ml MeOH 
was added hydrazine hydrate (2.0 ml, 41.65 mmol) and the mixture was refluxed 
for 16 h. The mixture was evaporated and redissolved in (10 ml) chloroform and 
then washed with (10 ml) water. The mixture was dried over magnesium sulphate 
and evaporated to dryness to give title compound as a white solid (1.3 g, 67%); m. 
p.= 99 ºC ;IR(cm-1) 3288(N-H2), 1701 (-CO-OMe), 1657 (tBu-O-CO-) 1542, 1366, 
1251, 1248, 1053, 941, 675; δH (500 MHz; DMSO) 9.01 (1H, s, NH-NH2), 6.84 (1H, 
t, J 6.35 Hz, Boc-NH-), 4.19 (2H, s, -NH2), 3.48 (2H, d, J 6.28 Hz, -NH-CH2-), 1.33 
(9H, s, -(Me)3); δC (126 MHz; DMSO) 169.5(-CO-NH-NH2), 156.3(tBu-O-CO-), 78.9 
(-C-(Me)3), 42.2 (-NH-CH2-), 28.5 (-C-(Me)3); m/z (GC-MS, EI) 133([M-tBu+H] , 
51%), 116 ([M-tBuO] , 48%), 89 ([M-Boc], 75%), 74 (25%), 57 (tBu , 100%)    
tert-Butyl N-(([(benzylcarbamothioyl)amino]carbamoyl)methyl)carbamate 
(51) 
 
N-Boc-β-glycine hydrazide (1.200 g, 6.34 mmol) and benzyl isothiocyanate (114 
g, 7.61 mmol) were dissolved in ethanol (12.68 ml) was heated at reflux for 2 hours.  
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The reaction mixture was left to cool and the mixture was evaporated to form a 
white solid product. Flash silica column chromatography, gradient elution 
(DCM/ethylacetate [8:3], [1:1], [3:7]) gave the title compound as a white powder 
solid (642 g, 92%); m. p.=90 ºC; Rf (DCM/EtOAc) [6:4] 0.27 ;IR(cm-1)  3385 (N-H), 
3175, 3062, 2983 (CH arom.), 1700 (-CO-OMe), 1570(tBu-O-CO-) 1451, 1219 
(S=C), 1168, 967; δH  (500 MHz; DMSO-d6) 9.93(1H, s, NH-CO-), 9.42 (1H, s, NH-
NH-CS-), 8.31 (1H, s, -NH-CH2Ph), 7.29 (2H, m, 3',5'-H), 7.27 (2H, m, 2',6'-H), 
7.21 (1H, m, 4'-H), 4.73 (2H, d, J 6.4 Hz, CH2-Ph), 3.61 (2H, d, J 5.68 Hz, -CH2-
CO-), 1.34 (9H, s, -(Me)3); δC (126 MHz; DMSO-d6) 181 (C=S), 168 (-CO-NH-
NH2), 155.5 (tBu-O-CO-), 138.5 (1’-C), 127.5 (3',5'-C), 126.32 (2',6'-C), 126.32 (4'-
C), 78.1 (-C-(Me)3), 46.2 (-CH2-Ph), 41.5 (-CH2-CO-), 27.6 (-C-(Me)3); LCMS  m/z 
(ESI-)  697.5 [M2Na]- (20%), 337 ([M-H]- (29%), 263 (100%), 162 (4%), 114 (5%). 
tert-butylN-[(4-benzyl-5-sulfanylidene-4,5-dihydro-1H-1,2,4-triazol-3-
yl)methyl]carbamate (UNIS00080) 
 
tert-butyl N-(([(benzylcarbamothioyl)amino]carbamoyl)methyl)carbamate (1.17 g, 
3.46 mmol) were dissolved in 1M NaHCO3 (34.68 ml)  and (15 ml) MeOH and the 
reaction mixture was heated at 60 0C for 24 hours. After cooling, (2 M) HCl was 
added until the mixture was pH 6. The white precipitate was extracted with 
ethylacetate, and then dried to give the titled compound (887 mg, 80%) m.p. = 198 
°C; IR(cm-1) 3291 (-NH-Boc) 3046, 2929, 2768 (C-H arom.), 1650 (tBu-O-CO-), 
1537, 1442, 1428 (CH aliph.),1350 (C=S), 1289, 1031, 779; δH  (500 MHz; (DMSO) 
13.73 (1H, s, 1H), 7.39 (1H, s, Boc-NH-),   7.34 (2H, t, J 7.6 Hz, 3',5'-H), 7.29 (1H, 
d, J 7.15 Hz, 4'-H), 7.25 (2H, d, J 7.15 Hz, 2',6'-H), 5.23 (2H, s, -CH2-Ph), 4.1 (2H, 
d, 5.7 Hz, Boc-NH-CH2-),  1.31 (9H, s, -(Me)3); δC  (126 MHz; (DMSO) 167.7 (5-
 207 
C), 155.8 (tBu-O-CO-), 150.2 (3-C), 135.6 (1'-C), 128.5 (3',5'-C), 127.5 (2',6'-C), 
126.9 (4'-C), 78.43 (-C-(Me)3), 45.6 (-CH2-Ph), 35.4 (Boc-NH-CH2-), 28.0 (-(Me)3); 
LCMS m/z (ESI-)  (319.1, [M-H]- (20%), 244.9 (100%), 232.8 (4%), 154.7 (5%). 
[(4-Benzyl-5-sulfanylidene-4,5-dihydro-1H-1,2,4-triazol-3-
yl)methyl](chloro)aminyl (UNIS00081) 
 
tert-butyl-N-[(4-benzyl-5-sulfanylidene-4,5-dihydro-1H-1,2,4-triazol-3-
yl)methyl]carbamate (540 mg, 1.69 mmol) was dissolved in 34 ml of 1 M HCl in 
EtOAc) (1:1) and heated at reflux for 1 h. The mixture was evaporated to form a 
yellow solid product (400 mg, 92%) m.p. = 200 °C ; IR(cm-1) 3022 (-NH2), 2910, 
2751 (C-H arom.), 1574, 1470 (C=C), 1343(C=S), 1272, 1146, 983, 737; δH  (500 
MHz; (DMSO-d6) 14.14 ((1H, s, 1H), 8.75 (3H, s, -NH2.HCl),  7.38 (2H, t, J 7.6 Hz, 
3',5'-H), 7.34 (1H, d, J 7.15 Hz, 4'-H), 7.29 (2H, d, J 7.15 Hz, 2',6'-H), 5.33 (2H, s, 
-CH2-Ph), 4.1 (2H, s, -NH2-CH2-); δC  (126 MHz; (DMSO-d6) 168.1 (5-C), 146.8(3-
C), 135.0 (1'-C), 128.8 (3',5'-C), 128.0 (4'-C), 127.1 (2',6'-C), 45.6 (-CH2-Ph), 33.6 
(NH2-CH2-); LCMS m/z (ESI-)  (218.9 ([M-H]- (100%), 186.9 (10%), 174.7 (8%), 
127.7 (15%). 
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4-Benzyl-3-[(cyclohexylamino)methyl]-4,5-dihydro-1H-1,2,4-triazole-5-thione 
(UNIS00082) 
 
Acetic acid (0.031 ml) and sodium triacetoxyborohydride (114 mg, 0.54 mmol) 
were added to a mixture of the [(4-benzyl-5-sulfanylidene-4,5-dihydro-1H-1,2,4-
triazol-3-yl)methyl](chloro)aminyl (100 mg, 0.37 mmol) and cyclohexanone (36.31 
mg, 0.37 mmol) in DCM (2.89 ml). The mixture was stirred at RT for 24 h. The 
mixture were concentrated by evaporating most of the solvent and then saturated 
NaHCO3was added until the mixture was pH 7 and it was extracted with 
DCM/MeOH [9:1] (3 × 10 mL). The combined organic layers were dried over 
MgSO4, filtered and evaporated. Flash silica column chromatography, gradient 
elution (DCM/MeOH [8:2], [1:1], [2:8]) gave the title compound (70 mg, 59%); m.p. 
= 166°C; Rf (DCM/MeOH) [9:1] 0.28; IR (cm-1)  3190 (N-H), 2919, 2851 (C-H, 
stretch), 1514, 1447 (C=C), 1366 (C=S), 1298, 1252, 1097, 932, 730;  δH (500 
MHz; CD3OD) 7.36 (2H, m, 3',5'-H), 7.32-7.30 (3H, m, 2',6',4'-H), 5.41 (2H, s, -
CH2-Ph), 3.68 (2H, s, -NH-CH2-), 2.27 (1H, tt, J 10.7 Hz,1"-H), 1.67 (4H, m, Cy), 
1.15 (3H, m, Cy), 0.96 (2H, m, Cy); δC   (126 MHz; CD3OD) 169.7 (5-C), 152.6 (3-
C), 137.1(1'-C), 130.0 (3',5'-C), 129.2 (4'-C) , 128.2 (2',6'-C), 56.9 (1" -C), 47.4 (-
CH2-Ph), 41.8 (-NH-CH2-),  33.5 (2",6"-C), 27.0 (4"-C), 25.9 (3",5"-C); LCMS  m/z 
(ESI-)  (625(20%), 301 [M-H]-, 100%), 269 (5%).  
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4-Benzyl-3-([(propan-2-yl)amino]methyl)-4,5-dihydro-1H-1,2,4-triazole-5-
thione (UNIS00083) 
 
Acetic acid (0.033 ml) and sodium triacetoxyborohydride (114.4 mg, 0.54 mmol) 
were added to a mixture of the [(4-benzyl-5-sulfanylidene-4,5-dihydro-1H-1,2,4-
triazol-3-yl)methyl](chloro)aminyl (100 mg, 0.37 mmol) and acetone (21 mg, 0.37 
mmol) in DCM (2.89 ml). The mixture were stirred at RT for 24 h. The mixture was 
concentrated by evaporating most of the solvent and then saturated NaHCO3 was 
added until the mixture was pH 7 and it was extracted with DCM/MeOH [9:1] (3 × 
10 mL). The combined organic layers were dried over MgSO4, filtered and 
evaporated. Flash silica column chromatography, gradient elution (DCM/MeOH 
[8:2], [1:1], [2:8]) gave the title compound (60 mg, 58%); m.p. =144 °C; Rf 
(DCM/MeOH) [9:1] 0.32 IR (cm-1) 3195 (N-H), 2966, 2918, 2862 (C-H, stretch), 
1582, 1512, 1447 (C=C), 1362 (C=S), 1302, 1298, 1255, 1160, 1012, 920, 728; δH 
(500 MHz; CD3OD) 7.35 (2H, m, 2',6'-H), 7.31-7.29 (3H, m, 3',5',4'-H), 5.40 (2H, -
CH2Ph), 3.64 (2H, s, -NH-CH2-), 2.65 (1H, m,-CHMe2), 0.96 (6H, d, J 6.3 Hz, -
CHMe2); δC  (126 MHz; CD3OD) 169.7 (-C=S), 152.4 (3-C), 137.0 (1'-C), 130.0 
(2',6'-C), 129.2 (4'-C), 128.3 (3',4'-C), 48.4 (-CHMe2), 47.5 (-CH2Ph), 42.3 (-NH-
CH2-), 22.2 (-CHMe2); LCMS m/z (ESI+)  (263 [M+H]+, 100%), 222 (5%), 203.9 
(80%), 174.9 (5%).  
Ethyl 3-ethoxy-3-iminopropanoate (117) 
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acetyl chloride (839 mmol, 59.7 ml) was added dropwise into dry ethanol (49.6 ml) 
at 0 °C. Ethyl cyanoacetate (88.40 mmol) was then added. The reaction was stirred 
at 22 °C for 20 h and then concentrated and triturated with diethyl ether to give a 
white powder salt (8.4 g, 70%). m.p. = 86°C; IR (cm-1) 2865, 2851 (C-H, stretch), 
1740 (C=NH, stretch), 1662 (C=O);  δH (500 MHz; CDCl3) 12.71 (1H, HCl), 11.98 
(1H, NH), 4.70 (2H, q, J 7.13 Hz, 2-H), 4.21 (2H, q, J 7.13 Hz, 6-H), 3.87 (2H, s, 4-
H), 1.48 (3H, t, J 7.13 Hz, 1-H), 1.27 (3H, t, J 7.13 Hz, 7-H); δC   (126 MHz; CDCl3) 
172.2 (5-C), 164.4 (3-C), 71.8(2-C), 62.7 (6-C), 39.3 (4-C) , 14.1 (1-C), 13.6 (7 -
C); LCMS m/z (ESI+)  (160 [M+H]+, 100%), 146 (80%), 115 (40%).  
 
Methyl 3-[(Z)-(1,3-dimethoxy-3-oxopropylidene)amino]-3-iminopropanoate 
(115) 
 
acetyl chloride (478 mmol, 34 ml) was added dropwise into dry methanol (28 ml) 
at 0 °C. Methyl cyanoacetate (50.5 mmol, 4 ml) was then added. The reaction was 
stirred at 0 °C for 20 h and then concentrated and triturated to give a white sticky 
powder (2.4 g, 28%). m.p. = 120 °C; IR (cm-1) 3115 (N-H), 3000, 2804 (C-H, 
stretch), 1719 (C=NH, stretch), 1655 (C=O), 1395, 1205;  δH (500 MHz; DMSO-
d6) 3.63 (6H, s, -COOMe), 3.59 (3 H, s,  -N=C-OMe), 3.51 (2H, s, -CH2-C=NH), 
3.20 (2H, s, -N=C-CH2-COOMe); δC  (126 MHz; DMSO-d6) 168 (-N=C-OMe), 
167.2 (-C=NH), 167.0 (-CO-CH2-C=NH), 167.0 (-CO-OMe), 52.2 (-COOMe),  
51.75 (-N=C-OMe), 42.2 (–N=C-CH2-COOMe), 41 (-CH2-C=NH); LCMS m/z 
(ESI+)  (208 (100%), 213 (50%),231 [M+H]+, 5%), 260 (5%), 265 (30%).  
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Methyl 3-methoxy-3-iminopropanoate (111) 
 
Acetyl chloride (240mmol, 17 ml) was added dropwisedry methanol (14 ml) at 0 
°C. Methyl cyanoacetate (25 mmol, 2 ml) was then added. The reaction was stirred 
at 22 oC for 4 h and then concentrated and triturated with diethyl ether to give a 
white powder (3.2 g, 75%); m.p. = RT; IR (cm-1) 2788, 2735 (C-H, stretch),1732 
(C=NH, stretch), 1664 (C=O);  δH (500 MHz; CDCl3) 12.82 (1H, HCl), 12.1 (1H, 
NH), 4.34 (3H, s, 1-H), 3.93 (2H, s, 3-H), 3.76 (3H, s, 5-H); δC  (126 MHz; CDCl3) 
173.3 (2-C), 164.8 (4-C), 61.6 (5-C), 62.7 (6-C), 53.4 (1-C) , 38.9 (3-C); LCMS  m/z 
(ESI+)  (132 [M-H]+, 100%), 167 (10%), 204 (15%), 263 (20%).  
Methyl 2-[N'-(3-methoxy-3-oxopropanoyl)hydrazinecarbonyl]acetate (104) 
 
Malonyl chloride (3.66 mmol, 0.4 ml) was added dropwise at 0 °C to a hydrazine 
(7.32 mmol) in water (19.3 ml). The reaction was stirred at 0 °C for 2 h and then 
extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over 
MgSO4, filtered and evaporated. Flash silica column chromatography, gradient 
elution (DCM/MeOH [9:1]) gave the title compound as white crystal (200 mg, 41%); 
m.p. =118 °C , IR (cm-1)  3186 (NH), 1738, 1583 (C=O), (C=O-NH) δH (500 MHz; 
CD3OD) 3.71 (6H, s, MeO-), 3.38 (4H, s, -CH2-COOMe); δC  (126 MHz; CD3OD) 
169.1(-CO-NH-), 166.8 (-COOMe), 52.8 (MeO-); LCMS  m/z (ESI+)  (101(5%), 233 
[M-H]+, (3%), 255 (100%).  
  
 212 
Ethoxycarbonylacetohydrazide (106) 
 
Hydrazine hydrate (7.48 mmol) was added at RT to a solution of diethyl malonate 
(2 g, 12.48 mmol) in ethanol (0.9 ml). The mixture was stored overnight, and 
malonohydrazide (240 mg) was separated by filtration. The filtrate was triturated 
with diethylether. Evaporation of the filtrate left a partly white crystalline residue 
(410 mg, 40%), m.p. = 59 oC , IR (cm-1)  3296, 3048 (NH2, NH), 1725, 1637 (C=O), 
δH (500 MHz;DMSO-d6) 9.18 (1H, s, NH), 4.06 (2H, q, J= 7.1, -CH2-CH3), 3.14 
(2H, s, -CH2), 1.17 (3H, t, J= 7.1, -CH3); δC   (126 MHz; DMSO-d6) 168.2 (-NH-
CO), 165 (-COOEt), 41.1 (-CH2-CH3), 14.5 (CH3).  
Malonohydrazide (107) 
 
White powder (240 mg), IR (cm-1)  3295, 3100 (NH2, NH), 1640 (C=O), δH (500 
MHz;DMSO-d6) 9.05 (2H, s, NH), 4.22 (4H, s(broad), -NH2), 2.39 (2H, s, -CH2-); 
δC  (126 MHz;DMSO-d6) 166 (-CO-), 40 (-CH2-) 
Methyl 2-(benzylcarbamoyl)acetate (123) 
 
Methyl malonyl chloride (2 g, 14.64 mmol) was added drop wise over 30 minutes 
into a mixture of benzyl amine (1.57 g, 14.64 mmol), triethylamine (1.63 g,16 
mmol), DCM (49 ml). The reaction mixture was stirred for 4 h at rt. The 
triethylamine salt was then filtered and DCM (40 ml) was added into the filtrate. 
The filtrate was washed with saturated ammonium chloride and brine. The mixture 
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then was concentrated. Flash silica column chromatography, gradient elution 
(DCM /EtOAc (8/2) gave the title compound as a white solid powder (1.20 g, 34%). 
m.p. = 65°C; IR (cm-1) 3285.7 (N-H, stretch), 1742.8 (NH-C=O, stretch), 1633 
(CH2-C=O);  δH (500 MHz; CDCl3) 7.30-7.28(3H, d, J 7.57 Hz, 3',4',5'-H), 7.35-7.32 
(2H, t, J 7.57 Hz, 2',6'-H), 4.49 (2H, d, J 5.55 Hz, -CH2-Ph), 3.74 (3H, s, CH3), 3.38 
(2H, s, -CO-CH2-); δC  (126 MHz; CDCl3) 170 (NH-CO-), 164.6 (1-C), 137.8 (1'-C), 
128.8 (2',6'-C), 127.7-127.5 (3',4',5'-C), 43.62 (-CH2-Ph), 52.5 (CH3) , 40.8 (2-C); 
LCMS  m/z (ESI+)  (230(95%), 227 (25%), 208 (5%, [M+H]+). 
Ethyl 2-(4-benzyl-5-methyl-4H-1,2,4-triazol-3-yl)acetate (UNIS00085) 
 
Oxalylchloride (2.60 g, 20.5 mmol) was added to a solution of N-benzylacetamide 
(3 g, 20.5 mmol) and 2,6-lutidine (4.40 g, 41 mmol) in DCM (102 ml) at 0 °C which 
caused heavy gas [CAUTION: carbon monoxide] evolution. The mixture was 
stirred for 40 min, and ethoxycarbonylacetohydrazide (3 g, 20.5 mmol) was added. 
The reaction mixture was stirred for 3 h at RT. The volatiles were then removed 
under reduced pressure. The residue was dissolved in toluene/MeCN (100/50 ml) 
and refluxed for 24 h. After cooling to 0 °C, the precipitate was filtered and the 
filtrate was collected. The solvent was evaporated from the filtrate to give an oily 
sticky crude product. Flash silica column chromatography, gradient elution (DCM 
/EtOAc/MeOH (8/1.5/0.5)) gave the title compound as a white solid powder (2.64 
g, 50%). m.p. = 60 °C ; IR (cm-1)  3370 (C-H arom.), 1733.4 (C=O), 1534, 1440, 
1162 (CH aliph.); δH  (500 MHz; DMSO-d6) 7.36 (2H, t, J 7.0 Hz, 3',5'-H), 7.30 (1H, 
t, J 7.0 Hz, 4'-H), 7.0 (2H, d, J 7.0 Hz, 2',6'-H), 5.21 (2H, s, -CH2-Ph), 3.96 (2H, q, 
J 7.0 Hz, -CH2-CH3) 3.89 (2H, s, -CH2-COOEt), 2.23 (3H, s, CH3-C=N-), 1.10 (3H, 
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t, J 7.0 Hz, -CH2-CH3); δC  (126 MHz; DMSO-d6) 168. 6 (-CO-), 152.1 (5-C), 149 
(3-C), 136.1 (1'-C),  129.2 (3',5'-C), 128.2 (4'-C), 127 (2',6'-C), 61.4 (-CH2-CH3), 
46.6 (-CH2-Ph), 31.5 (-CH2-COOEt), 14.3 (-CH2-CH3), 11.1 (CH3-C=N-); LCMS  
m/z (ESI+) 282 (20%),  260 ([M+H]+,100%, 208 (18%), 143 (100%); Elemental 
analysis; calculated: C, 64.85; H, 6.61; N, 16.20; found: C, 60.27; H, 6.80; N, 16.01. 
2-(4-Benzyl-5-methyl-4H-1,2,4-triazol-3-yl)acetic acid (103) 
 
Method 1 
LiOH (146 mg, 3.47 mmol) was added to a mixture of ethyl 2-(4-benzyl-5-methyl-
4H-1,2,4-triazol-3-yl)acetate (300 mg, 1.15 mmol), THF (7 ml) and water (3 ml) and 
the reaction mixture was stirred for 2 h 30 at RT. 2 M HCl was added to the solution 
until the mixture was pH 2 (pH paper). The acidified solution was then extracted 
with DCM/MeOH [9:1] (3 × 7 mL). The organic layer was dried over MgSO4, filtered 
and evaporated to give the title compound as an oil (55 mg, 18%), IR (cm-1)  1703 
(C=O),1533, 1334, 712 (CH aliph.); δH  (500 MHz; DMSO-d6) 7.36 (2H, t, J 7.0 Hz, 
3',5'-H), 7.30 (1H, t, J 7.0 Hz, 4'-H), 7.0 (2H, d, J 7.0 Hz, 2',6'-H), 5.21 (2H, s, -CH2-
Ph), 3.85 (2H, s, -CH2-COOH), 2.25 (3H, s, CH3-C=N-), δC  (126 MHz; DMSO-d6) 
169.7 (-CO-), 151.4 (5-C), 149.2 (3-C), 135.6 (1'-C),  128.7 (3',5'-C), 127.6 (4'-C), 
126.5 (2',6'-C), 46.1 (-CH2-Ph), 31.3 (-CH2-COOH), 10.6 (CH3-C=N-); LCMS  m/z 
(ESI+)  276 70%), 250 (25%), 232 ([M+H]+ (22%), 186 (15%), 106 (8%). 
Method 2 
LiOH (48.6 mg, 1.16 mmol) was added to a mixture of ethyl 2-(4-benzyl-5-methyl-
4H-1,2,4-triazol-3-yl)acetate (100 mg, 0.39 mmol), THF (2 ml) and water (1 ml) and 
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the reaction mixture was heated at 90  ͦ C for  22 h. 1 M NaHCO3 was added to the 
solution until the mixture was pH 2 (pH paper). The solution was then extracted 
with DCM/MeOH [9:1] (3 × 7 mL). The organic layer was dried over MgSO4, filtered 
and evaporated to give the title compound as an oil (55 mg, 38%) 
Method 3 
LiOH (146 mg, 3.47 mmol) was added to a mixture of ethyl 2-(4-benzyl-5-methyl-
4H-1,2,4-triazol-3-yl)acetate (300 mg, 1.16 mmol), THF (7.2 ml) and water (3 ml) 
and the reaction mixture was stirred for  2 and a half hours at RT The mixture was 
purified using a resin (Dowex 1 x 2 chloride form)  column that was prepared to 
have hydroxide ions. The column was eluted first with (formic acid in methanol pH~ 
3) followed by (0.1 M HCl in MeOH). The collected fraction was evaporated using 
using a lyophiliser to give the title compound as an oil (267 mg, 100%).  
4-Benzyl-3,5-dimethyl-4H-1,2,4-triazole (UNIS00086) 
 
LiOH (859 mg, 20.5 mmol) was added to a mixture of ethyl 2-(4-benzyl-5-methyl-
4H-1,2,4-triazol-3-yl)acetate (1.70 g, 6.55 mmol), THF (42.6 ml) and water (17.7 
ml) and the reaction mixture was stirred for  24 h at rt. (2 M) HCl was added to the 
solution until the mixture was pH 2 (pH paper). Saturated NaCl was added to the 
acidified solution and was then extracted with DCM/MeOH [9:1] (3 × 7 mL). The 
organic layer was dried over MgSO4, filtered and evaporated to give an oil (acid 
103) Leaving this oily product at RT for around 22 h gave the title compound as an 
oil (437 mg, 34%), IR (cm-1)  3336 (C-H strech.), 1534, 1440, 1162 (CH aliph.); δH  
(500 MHz; DMSO-d6) 7.37 (2H, t, J 7.0 Hz, 3',5'-H), 7.31 (1H, t, J 7.0 Hz, 4'-H), 
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7.0 (2H, d, J 7.0 Hz, 2',6'-H), 5.21 (2H, s, -CH2-Ph), 2.31 (6H, s, CH3-C=N-); δC  
(126 MHz; DMSO-d6) 151.3 (3,5-C), 135.4 (1'-C), 128.9 (3',5'-C), 127.9 (4'-C), 
126.6 (2',6'-C), 46.6 (-CH2-Ph), 10.4 (CH3-C=N-); LCMS  m/z (ESI+) 210 (22%),  
188 ([M+H]+,22%), 132 (20%), 106 (50%). 
Methyl 2-(4-benzyl-5-methyl-4H-1,2,4-triazol-3-yl)acetate (UNIS00087) 
 
To dry DCM (15 ml) under nitrogen, was added 2-(4-benzyl-5-methyl-4H-1,2,4-
triazol-3-yl)acetic acid  (200 mg, 0.86 mmol), isopropylamine  (61 mg, 1.03 mmol), 
and EDC (78 mg, 1.45 mmol). The mixture was stirred for 22 h at RT. 1 M NaHCO3 
was added until the mixture was pH 5 and it was extracted with DCM/MeOH [9:1] 
(3 × 10 mL). The combined organic layers were dried over MgSO4, filtered and 
evaporated. Preparative silica TLC, (DCM/EtOAc/MeOH [6:3.5:0.5]) gave the title 
compound as an oil (30 mg, 15%); IR (cm-1)  3368 (C-H arom.), 1700 (C=O), 1530, 
1435, 1173 (CH aliph.); δH  (500 MHz; (CDCl3) 7.35-7.28 (3H, m, 3',4',5'-H), 6.96 
(2H, d, J 6.79 Hz,2',6'-H), 5.11 (2H, s, -CH2-Ph), 3.76 (2H,s, -CH2-CO-), 3.62 (3H, 
-CO-CH3), 2.23 (3H, s, CH3-C=N-); δC  (126 MHz; (CDCl3) 168.49 (-CO-), 152.70 
(5-C), 148.72 (3-C), 134.70 (1'-C),  129.34 (3',5'-C), 128.52 (4'-C), 126.14 (2',6'-
C), 52.67 (-COO-CH3), 47.18 (-CH2-Ph), 31.76 (-CH2-COOMe), 11.19 (CH3-C=N-
); LCMS m/z (ESI+) 106 (30%),  132 (20%), 246 ([M+H]+,15%, 268 (100%), 295 
(30%). 
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2-(4-Benzyl-5-methyl-4H-1,2,4-triazol-3-yl)-N-cyclohexylacetamide 
(UNIS00088) 
 
To dry DCM (4.30 ml) under nitrogen, was added 2-(4-benzyl-5-methyl-4H-1,2,4-
triazol-3-yl)acetic acid (55 mg, 0.237 mmol), cyclohexylamine  (28 mg, 0.033 
mmol), and EDC (78 mg, 0.4 mmol). The mixture was stirred for 24 h at RT. 1 M 
NaHCO3 was added until the mixture was pH 5 and it  was extracted with 
DCM/MeOH [9:1] (3 × 10 mL). The combined organic layers were dried over 
MgSO4, filtered and evaporated. Preparative silica TLC (DCM/EtOAc/MeOH 
[6:3.5:0.5]) gave the title compound as white powder (37 mg, 50%); m.p. =  230 
°C; Rf (DCM/EtOAc/MeOH [6:3.5:0.5] 0.8 ; IR (cm-1)  3385, 3241 (N-H, stretch), 
2934 (CH3), 1650 (C=O, stretch), 1444 (C=C), 1352 (C=S), ;  δH (500 MHz; CDCl3) 
7.36-7.30(3H, m, 3',4',5'-H), 7.13 (1H, b, -CO-NH-), 6.96 (2H, d, J 6.79 Hz,2',6'-H), 
5.17 (2H, s, -CH2-Ph),3.70 (1H, tt, J 8.31, 3.90 Hz,1"-H), 3.60 (2H,s, -CH2-CO-), 
2.39 (3H, s, CH3-C=N-), 1.8 (2H, m, Cy), 1.62 (5H, m,Cy), 1.58 (1H, m, Cy), 1.36-
1.29 (2H, m, Cy), 1.20, 1.13 (3H, m, Cy); δC   (126 MHz; CDCl3) 165.2 (-CO-),  
152.4 (5-C), 150.3 (3-C), 134.3(1'-C), 129.4 (3',5'-C), 128.5 (4'-C) , 126.1 (2',6'-C), 
48.8 (1" -C), 47.0 (-CH2-Ph), 33.6 (-CH2-CO-), 32.8 (2",6"-C), 25.5 (4"-C), 24.8 
(3",5"-C), 11.1 (CH3-C=N-); LCMS m/z (ESI-)  (313 [M-H]-, (100%)), 231(80%), 214 
(70%), 186 (60%).  
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2-(4-Benzyl-5-methyl-4H-1,2,4-triazol-3-yl)-isopropylacetamide (UNIS00089) 
 
Method 1 
To dry DCM (14.62 ml) under nitrogen, was added 2-(4-benzyl-5-methyl-4H-1,2,4-
triazol-3-yl)acetic acid  (186 mg, 0.80 mmol) and isopropylamine  (57 mg, 0.96 
mmol), followed by EDC (260 mg, 1.35 mmol). The mixture was stirred for 24 h at 
RT. 1 M NaHCO3 was added until the mixture was pH 7 and it was extracted with 
DCM/MeOH [9:1] (3 × 10 mL). The combined organic layers were dried over 
MgSO4, filtered and evaporated. Flash silica column chromatography (DCM 
/EtOAc/MeOH (6/3/1)) gave the title compound as a white powder (4 mg, 2%); m.p. 
=174 °C; IR (cm-1)  3244 (N-H, stretch), 2972 (CH3), 1643 (C=O, stretch), 1532, 
1443, 1173; δH (500 MHz; DMSO-d6)) 8.09 (1H, d, J 7.31 Hz, -CO-NH-), 7.36-7.27 
(3H, m, 3',4',5'-H), 7.05 (2H, d, J 7.3 Hz, 2',6'-H), 5.23 (2H, s, -CH2-Ph), 3.76 (1H, 
sextet, J 6.8 Hz, -CH-Me2), 3.57 (2H,s, -CH2-CO-), 2.17 (3H, s, CH3-C=N-), 1.01 
(6H, d, J 6.6 Hz, -Me2); δC   (126 MHz; DMSO-d6) 166.2 (-CO-), 151.8 (5-C), 150.5 
(3-C), 136.3 (1'-C), 129.2 (3',5'-C), 128.12 (4'-C), 127 (2',6'-C), 46.5 (-CH2-Ph), 
41.2 (-CH-Me2), 32.7 (-CH2-CO-), 22.6 (-Me2), 11.1 (CH3-C=N-); LCMS  m/z (ESI+)  
(123 (10%), 186 (65%), 214 (80%), 273 [M-H]+, (100%)), 295 (90%). 
Method 2 
To isopropyl amine (25 mg, 0.42 mmol) under nitrogen, was added a solution of 2-
(4-benzyl-5-methyl-4H-1,2,4-triazol-3-yl)acetic acid (80 mg, 0.35 mmol) in DMF 
(0.58 ml) followed by a soltion of a mixture of  EDCI (106 mg, 0.55 mmol), HOBT 
(51 mg, 0.38 mmol) in DMF (0.61 ml). Finally DIPEA (89 mg, 0.69 mmol) was 
added dropwise to the mixture. The mixture was stirred for 35 h at RT. The DMF 
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was evaporated and the mixture was purified using reverse-phase flash column 
chromatography, gradient elution (MeCN (1% formic acid)/water (1% formic acid) 
[5:95 %], [15:85%], [20:80%], [100:0%]) and then water was evaporated using a 
lyophiliser to gave the title compound as a white powder (56 mg, 59%).  
Ethyl 2-[(carbamothioylamino)carbamoyl]acetate (133) 
 
Method 1 
Thiosemicarbazide (121 mg, 1.33 mmol) was dissolved in dry MeCN (2 ml) under 
nitrogen. Ethyl-3-chloro-3-oxopropanoate (200 mg, 1.33 mmol) was added 
dropwise at 0 °C to the mixture. The mixture was then heated to reflux for 2 h. It 
was then filtered and the precipitate was collected and recrystallized using ethanol 
to give white crystals  (63 mg, 23%), m.p. = 165 oC, IR (cm-1)  3327, 3129 (NH2, 
NH), 1695, 1652 (C=O), δH (500 MHz; DMSO-d6) 10.1 (1H, s, -CO-NH-), 9.36 (1H, 
s, -CO-NH-NH-), 7.97 (1H, s, -CS-NH2), 7.35 (1H, s, -CS-NH2),  4.09 (2H, q, J= 
7.1, -CH2-CH3), 3.28 (2H, s, -CO-CH2), 1.19 (3H, t, J= 7.1, -CH3); δC  (126 
MHz;DMSO-d6) 182.3 (-CS-), 168.1 (-CO-NH-), 165.2 (-COOEt), 61.2(-CH2-CH3), 
14.5 (CH3), LCMS Rt 0.7, no corresponding molecular ion could be detected. 
Method 2 
Thiosemicarbazide (605 mg, 6.64 mmol) was dissolved in dry MeCN (11 ml) and 
pyridine (525 mg, 6.64 mmol) was added. Ethyl-3-chloro-3-oxopropanoate (1 g, 
6.64 mmol) was added dropwise to the mixture at 0 °C. The mixture was then 
heated at reflux for 2 h. The mixture was filtered and the solid was collected and 
recrystallized using ethanol to give white crystals (184 mg, 13%). 
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Ethyl 2-(5-sulfanylidene-1,4-dihydro-1,2,4-triazol-3-yl)acetate (UNIS00090) 
 
Dry EtOH (4 ml) was added into ethyl 3-ethoxy-3-iminopropanoate (200 mg, 1.02 
mmol) under nitrogen followed by the addition of Et3N (103 mg, 0.4 m,1.02 mmol). 
Thiosemicarbazide (93 mg, 1.02 mmol) was added to the mixture at 0 °C and the 
miture was stirred at RT for 2 h. The mixture was then heated at reflux for 24 h. 
After cooling to 0 °C, the precipitate was filtered and the filtrate was collected. The 
solvent was evaporated from the filtrate to give a yellow powder. Flash silica 
column chromatography (DCM /EtOAc (7:3) gave the title compound as a yellow 
powder (112 mg, 60%). m.p. = 179-180 °C ; IR (cm-1) 1738 (C=O),1593, 1469; δH  
(500 MHz; DMSO-d6) 13.38 (1H, s, 1-H), 13.21 (1H, s, 4-H), 4.27 (2H, q, J 7.14 
Hz, -CH2-CH3), 3.74 (2H, s, -CH2-COOEt), 1.20 (3H, t, J 7.14 Hz, -CH2-CH3); δC  
(126 MHz; DMSO-d6) 168. 6 (5-C), 166.8 (-CO-), 146.7 (3-C), 61.6 (-CH2-CH3), 
31.9 (-CH2-COOEt), 14.4 (-CH2-CH3); LCMS m/z (ESI+) 262 (40%),  234 (20%), 
188 ([M+H]+,35%, 156 (20%), 142 (40%), 132 (80%), 114 (100%). Elemental 
analysis; calculated: C, 38.49; H, 4.85; N, 22.45; found: C, 38.53; H, 4.99; N, 15.98. 
2-(5-Sulfanylidene-4,5-dihydro-1H-1,2,4-triazol-3-yl)aceticacid (UNIS00091) 
 
Method 1 
LiOH (66.7 mg, 1.59 mmol) was added to a mixture of ethyl 2-(5-sulfanylidene-1,4-
dihydro-1,2,4-triazol-3-yl)acetate (100 mg, 0.53 mmol), THF (3.31 ml) and water 
(1 ml) and the reaction mixture was stirred for 24 h at RT. 2 M HCl was added to 
the solution until the mixture was pH 2 (pH paper). The acidified solution was then 
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extracted with DCM/MeOH [9:1] (3 × 7 mL). The organic layer was dried over 
MgSO4, filtered and evaporated to give the title compound as a yellow powder (10 
mg, 11%), m.p. = 178 °C ; IR (cm-1) 3119 (N-H, stretch), 1743 (C=O),159, 1473, 
1429 (C=S), 1227, 989; δH  (500 MHz; DMSO-d6) 13.38 (1H, s, 1-H), 13.21 (1H, 
s, 4-H), 12.92 (1H, s, -COOH), 3.63 (2H, s, -CH2-COOH); δC (126 MHz; DMSO-
d6) 169. 6 (5-C), 166.8 (-CO-), 147.2 (3-C), 32.2(-CH2-COOH); LCMS  m/z (ESI-) 
114 (100%), 158 ([M+H]-, 5%, 180 (5%), 317 (5%), 339 (7%). 
Method 2 
LiOH (67 mg, 1.59 mmol) was added to a mixture of ethyl 2-(5-sulfanylidene-1,4-
dihydro-1,2,4-triazol-3-yl)acetate (100 mg, 0.53 mmol),THF (3.31 ml) and water (1 
ml) and the reaction mixture was stirred for 1 hour at RT. The mixture was purified 
using a resin (Dowex 1 x 2 chloride form) column that was prepared to have 
hydroxide ions. The column was eluted first with formic acid in methanol pH~ 3 
followed by 0.1 M HCl in MeOH. The collected fraction was evaporated using a 
lyophiliser to give the title compound as a yellow powder (90 mg, 100%).  
N-Cyclohexyl-2-(5-sulfanylidene-4,5-dihydro-1H-1,2,4-triazol-3-yl)acetamide 
(UNIS00092) 
 
Ethyl 2-(5-sulfanylidene-1,4-dihydro-1,2,4-triazol-3-yl)acetate (100 mg) was added 
into a mixture of NaOMe (57.70 mg, 1.06 mmol), cyclohexylamine (137 mg, 1.38 
mmol) in THF (2 ml). The reaction mixture was stirred for  24 h at 50 °C. Saturated 
NH4Cl was added to the solution, followed by 2 M HCl until the mixture was pH 2 
(pH paper). The acidified solution was then extracted with DCM/MeOH [9:1] (3 × 7 
mL). The organic layer was dried over MgSO4, filtered and evaporated. Flash silica 
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column chromatography (DCM /EtOAc (6:4)) gave the title compound as a white 
powder (5 mg, 3%). m.p. = 230 °C ; IR (cm-1) 3304 (N-H, stretch), 2929, 2852 (C-
H, stretch), 1652 (C=O, stretch), 1548, 1350 (C=S), 1334, 1038, 810;  δH  (500 
MHz; CD3OD ) 5.48 (2H,s, -CH2-CO-), 3.64 (1H, tt, J 10.7, 3.8 Hz,1-H), 1.87 (2H, 
m, Cy), 1.75 (2H, m,Cy), 1.63 (1H, m, Cy), 1.39-1.16 (5H, m, Cy); δC (126 MHz; 
CD3OD ) 167.87 (5-C), 167.68 (-CO-), 149.37 (3-C), 54.80 (1 -C), 50.14 (-CH2-CO-
), 33.64 (2,6-C), 26.61 (4-C), 26 (3,5-C); LCMS  m/z (ESI-) 125 (78%), 174 (45%), 
207 (60%), 239 [M-H]-, (20%). 
8.3 AAG Inhibitor biochemical assay  
General 
All surface-bound substrate DNA oligomer bioassays for testing the potency of 
inhibitors against AAG were carried out in 96-well Thermo Scientific Nunc 
Immobilizer Amino plates (Thermo Fisher Scientific, Loughborough, UK).  Each 
plate used for testing inhibitors included a simple standard curve assay, where the 
AAG enzyme was tested in the absence of inhibitors, at varying concentrations, 
for its natural activity and to verify the a concentration of AAG was being used with 
inhibitors that was on a linear point of the standard curve and thus would provide 
a discernable readout.  
Materials and buffers 
Oligonucleotides were purchased from Integrated DNA Technolgies, Leuven, 
Belgium and were supplied lyophilized and they were resuspended in ultrapure 
(milliQ) water to a concentration of 1 mM then diluted to 10 uM solutions in the 
appropriate buffer.  T4 DNA Ligase was purchased from Promega (Southampton, 
UK). It was supplied in the following storage buffer: 10mM Tris-HCl (pH 7.4), 50mM 
KCl, 1mM DTT, 0.1mM EDTA and 50% glycerol. AAG enzyme (10,000 U/mL), in 
which U represents unit of the enzyme and is defined as the amount of enzyme 
 223 
that catalyses the conversion of 1 μmol of substrate per minute, was supplied by 
New England Biolabs, Hitchin, UK. This enzyme was supplied in the following 
storage buffer: 10 mM Tris-HCl, 100 mM KCl, 1 mM DTT, 0.1 mM EDTA, 50% 
Glycerol, 0.5% Tween® 20, 0.5% NP-40. The goat anti-fluorescein horseradish 
peroxidase conjugate was from Abcam, Cambridge, UK. It was supplied at a 
concentration of 1 mg/ml in a buffer consisting of 0.42% Potassium phosphate, 
0.87% Sodium chloride, 1% BSA (pH 7.2) containing  0.1% Gentamicin sulphate. 
It was diluted 10-fold into PBST containing 1% w/v BSA and stored as single use 
aliquots at -20°C.  3,3’,5,5’-Tetramethylbenzidine (TMB) peroxidase substrate and 
peroxidase substrate solution B from were purchased from Insight Biotechnology 
Ltd (Wembley, UK). 
Bicarbonate buffer was prepared from 0.18 g of NaHCO3 and 0.04 g of Na2CO3 in 
50 ml milliQ water (pH= 9.6). Phosphate buffered saline with 0.1% v/v Tween® 20  
(PBST) was prepared from 1 ml of Tween® 20 (Sigma-Aldrich) in 1 L of miliQ water 
that had 10 tablets of PBS (Sigma-Aldrich) dissolved in it. AAG glycosylase buffer 
was made from 4 ml of 1 M Tris (Sigma-Aldrich) (pH 7.8), 20 ml of 1 M of KCl, 4 
ml of 0.25 M ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich) (pH 8), 400 
µl of 500 mM of egtazic acid (EGTA) (Sigma-Aldrich) and 69.6 μl of β-
mercptoethanol (Sigma-Aldrich) in 171.5 ml of miliQ water. T4 ligase buffer 
comprised 6 ml of 1 M Tris (pH 7.8), 6 ml of 1 M NaCl, and 2 ml of 1 M of MgCl2 in 
186 ml of miliQ water. T4 DNA Ligase solution was prepared by dissolving 4 ul of 
3U/ul T4 DNA ligase in 12 ml buffer freshly prepared by adding 120 μl of 1 M DTT 
(Sigma-Aldrich) and 24 μl of 0.5 M ATP (Sigma-Aldrich) to hybridisation buffer (30 
ml of 20 X SSC buffer (Sigma-Aldrich), 1 ml of 500 mM EDTA, and 100 ul of  
Tween® 20  in 68.9 ml miliQ water). Alkaline denaturation buffer comprised 10 ml 
of 5 M of NaOH and 2.5 ml of 20 X SSC buffer in 487.5 ml miliQ water, AAG buffer 
for LCMS comprised 8 ml of 0.5 M HEPES (Sigma-Aldrich) (pH 7.8), 20 ml of 1 M 
of KCl, 4 ml of 0.25 M EDTA (Sigma-Aldrich) (pH 8), and 250 mg of TCEP (Sigma-
Aldrich) in 168 ml miliQ water. 
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Representative procedure of AAG surface-bound fluorescein-linked duplex 
DNA oligonucleotide substrate built from three smaller oligonucleotides: 
INC01, HX01 and REP04 
The oligonucleotide complex used for the assay consisted of three 
oligonucleotides referred to as INC01 (sequence from 5’ to 3’: [OH] CTA CAC CAC 
ATA CAC-NH2), HX01 ([P] AAC ACH GTC CAC TCA CCT ACT CG [Fluorescein]) 
and REP04 (lower case letters represent phosphorothioate-linked nucleotides:  ga 
TGT GGT GTA TGT GTT GTG TCA GGT GAG TGG ATG A gc). 2.5 pmol/100 µl 
of INC01 was prepared in Bicarbonate buffer (pH 8.5) and added to the surface-
activated plate and incubated at RT for 2 h or at 4 °C overnight. The liquid was 
decanted from the wells and the plate was washed (3 × 100 µl/well) with PBST. 
The oligonucleotide HX01 and REP04 were hybridised previously to form the 
duplex and prepared at a concentration of 10 uM. For the hybridisation and ligation 
of this duplex with INC01, 30 ul of 10 uM HX01/REP04 duplex was diluted into 12 
ml of T4 DNA Ligase solution, to give a 2.5 pmol/100 ul of pre-hybridized complex.  
100 µl of this was added to each well. The plate was sealed and incubated at 30 
°C for 2 h. The liquid was decanted from the wells and the wells were washed with 
PBST (3 × 100 µl/well). Increasing concentrations of AAG enzyme from 0 U/well 
to 0.1 U/well were prepared by diluting the stock solution of the AAG enzyme into 
2% DMSO in glycosylase buffer or just glycosylase buffer (depending on the 
experiment) and all dilutions were kept in ice or at RT (depending on the 
experiment). These solutions were then added into the wells (100 µl/well) and the 
plate was incubated at 37 °C for 1-2 h. The liquid was decanted from the wells and 
the wells were then washed with PBST (3 × 100 µl/well). 125 µl of alkaline 
denaturation buffer was added to each well and the plates were sealed and 
incubated at 75 °C for 30 minutes. 100 ul of the solution in each well was 
transferred to the corresponding well on a standard black plate and a further 100 
µl of NaOH solution was added to each well which was then also transferred into 
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the black plate to give 225 µl in each black plate well. The eluted fluorescence 
signals were detected using plate reader. 
Representative procedure of AAG surface-bound fluorescein-linked hairpin 
loop DNA oligonucleotide substrate built from oligonucleotides HX02 and 
Loop01 
The synthetic oligonucleotide used in this assay bore a 3’-NH2 group, a 5’- 
fluorescein moiety, a hairpin loop, and an internal hypoxanthine as the ‘damaged 
base’ AAG substrate.  It was prepared in situ by hybridisation between the two 
oligonucleotides named HX02 and Loop01 whose sequences (from 5’ to 3’) are as 
follows: 
HX02: [P] CAC GAA HCA ACT CAG CAA CTC C tt [Amc7T]-NH2  
Loop01: [Fluorescein] tt GGA GTT GCT GAG TTG ATT CGT GAG CAC CAA CCG 
GTG CT [OH] 
A 1 nM solution of oligonucleotide HX02 was prepared in bicarbonate buffer 
(pH~9.6) and was added to the Nunc Immobilizer Amino plate (0.1 pmol, 100 
µl/well) which was incubated 2 h at RT or at 4 °C overnight. The liquid was then 
decanted from the wells and the plate was washed with PBST (3 × 100 µl/well). A 
solution of oligonucleotide Loop01 was prepared by diluting 10 uM stock solution 
into the hybridisation buffer to give 1 nM. This solution was then added into the 
wells (100 µl/well) and the plate was heated to 95 °C and then slowly cooled to RT 
to promote annealing of the DNA strands. The liquid was decanted from the wells 
and the plate was then washed with PBST (3 × 100 µl/well). T4 DNA ligase (3 U/µl, 
2.6 ul) solution was then added into the wells (100 µl/well). The plate was 
incubated at 37 °C for 1 h. The liquid was decanted from the wells and the plate 
was then washed with PBST (3 × 100 µl/well). Increasing concentrations of AAG 
enzyme from 0 U/well to 0.1 U/well were prepared by diluting the stock solution of 
the AAG enzyme into 0 or 2% DMSO in glycosylase buffer (depending on 
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experiment) and all dilutions were kept in ice or RT (depending on experiment). 
These solutions were then added to the wells (100 µl/well) and the plate was 
incubated at 37 °C after adding the enzyme for 1 h. The liquid was decanted from 
the wells and the wells were then washed with PBST (3 × 100 µl/well). 125 µl of 
alkaline denaturation buffer was added to each well and the plates were sealed 
and incubated at 75 °C for 30 minutes. The liquid was decanted from the wells and 
the plate was then washed with PBST (3 × 100 µl/well). 1% v/v BSA in PBST was 
prepared by dissolving 100 mg BSA in 10 ml PBST. To this was added 10 ul of 
1:10 diluted goat anti-fluorescein HRP conjugate.  This solution was then added 
into the wells (100 µl/well) and the plate was incubated at RT for 1 h.  The liquid 
was decanted and the plate was then washed with PBST (3 × 100 µl/well). To each 
well was added a mixture of an equal volume of (TMB) peroxidase substrate and 
peroxidase substrate solution B (100 µl/well). After the development of sufficient 
colour (as judged by gradual decrease in blue colour with increasing AAG enzyme 
concentration in the well) the reaction was stopped by adding phosphoric acid 
(concentration, volume) to give a yellow colour.  Absorbance at 450 nm was then 
read in the plate reader.  
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